

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068054 A2

(51) International Patent Classification⁷: A61B

(21) International Application Number: PCT/US03/04688

(22) International Filing Date: 13 February 2003 (13.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/357,031 13 February 2002 (13.02.2002) US

(71) Applicants (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). THE SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JAZAERI, Amir, A. [US/US]; 823 Pizer Street, Houston, TX 77009 (US). BOYD, Jeffrey [US/US]; 41 Beechdale Road, Dobbs Ferry, NY 10522 (US). LIU, Edison, T. [US/US]; 12 Cuscadan Walk #23-01, Singapore 249694 (US).

(74) Agent: NOONAN, William, D.; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/068054 A2

(54) Title: IDENTIFICATION OF OVARIAN CANCER TUMOR MARKERS AND THERAPEUTIC TARGETS

(57) Abstract: The present disclosure provides methods for classifying ovarian tumors into *BRCA1-type*, *BRCA2-type* or non-*BRCA*-type tumor types by measuring expression levels of a plurality of disclosed ovarian tumor markers. The markers disclosed herein are useful in the diagnosis, staging, detection, and/or treatment of ovarian cancer. Also provided are methods of selecting a treatment regimen by selecting the tumor type. Ovarian cancer-linked logarithmic expression ratios and kits for diagnosis, staging, and detection of ovarian cancer using are also provided.

BEST AVAILABLE COPY

**IDENTIFICATION OF OVARIAN CANCER TUMOR MARKERS
AND THERAPEUTIC TARGETS**

PRIORITY CLAIM

5 This application claims the benefit of U.S. Provisional Application No. 60/357,031, filed February 13, 2002, which is incorporated by reference in its entirety herein.

FIELD OF THE DISCLOSURE

10 The present disclosure is related to diagnosing, prognosing, staging, preventing, and treating disease, particularly ovarian cancer.

BACKGROUND

15 Ovarian cancer has one of the highest mortality rates of all cancers, due in part to the difficulty of diagnosis. Currently, epithelial ovarian cancer is the leading cause of death resulting from gynecological cancer (see Welsh *et al.*, *PNAS* 98: 1176-1181, 2001). Studies indicate that the five-year survival rates for ovarian cancer are as follows: Stage I (93%), Stage II (70%), Stage III (37%), and Stage IV (25%) (see Holschneider & Berek, *Semin. Surg. Oncol.* 19: 3-10, 2000). Thus, there is a particular need for improved methods of early diagnosis, prognosis, and monitoring of ovarian cancer.

20 Protein and mRNA levels, and changes in these levels, may be associated with specific types of cancer (and cancer progression). Such association is often specific to the type of cancer, meaning that what is overexpressed in one cancer may be under-expressed (or unchanged) in another. Thus, a collection or set of genes/proteins that are differentially regulated in a specific cancer may be indicative and specifically diagnostic of that type of cancer.

25 Molecular mechanisms involved in the onset and progression of ovarian cancer remain poorly understood. However, some mutations causing ovarian cancer have been identified. Between 5% and 10% of all breast cancers are hereditary. The remaining 90% to 95% are classified as "sporadic," for which no genetic link to development has been identified.

30 Breast cancer susceptibility genes *BRCA1* (GenBank Accession # U14680) and *BRCA2* (GenBank Accession # U43746) are tumor suppressor genes. Germ-line mutations of *BRCA1* and *BRCA2* are responsible for approximately 5-10% of all epithelial ovarian cancers (see Li and Karlan, *Curr. Oncol. Rep.* 3:27-32, 2001). Of inherited breast cancers, it is believed that inherited mutations in *BRCA1* or *BRCA2* are responsible as many as 70% of all cases.

35 Those with inherited mutations in *BRCA1* and *BRCA2* have an approximately 63% lifetime risk of developing breast cancer, whereas the general female population has a 12% lifetime risk. The *BRCA1* and *BRCA2* gene mutations are more often identified in breast cancer patients with poor prognostic factors, which are risk factors that predict for poorer treatment outcomes (e.g., estrogen-receptor-negative tumors, higher growth rates, age less than 35 at onset of disease, breast cancer in both breasts). Development of disease in the opposite breast and ovarian cancer also appear to be

more common in breast cancer patients with *BRCA1* or *BRCA2* mutations. Hence, the presence of *BRCA1* or *BRCA2* mutations may indicate a need for more aggressive therapeutic treatments.

The alleles of *BRCA1* and *BRCA2* must be inactivated before tumor development occurs. *BRCA1* and *BRCA2* are believed to take part in a common pathway involved in maintenance of genomic integrity in cells; however, little is known about the specific molecular mechanisms involved in BRCA mutation associated (BRCA-linked) ovarian carcinogenesis. For example, it is not known whether *BRCA1* and *BRCA2* mutations affect common or unique molecular pathways in ovarian cancer, or if these pathways overlap with those involved in the formation of sporadic tumors. Both BRCA proteins have been implicated in important cellular functions, including embryonic development, DNA damage repair, and transcriptional regulation (see Scully and Livingston, *Nature* 408:429-432, 2000; Zheng *et al.*, *Oncogene* 19:6159-6175, 2000; Welcsh *et al.*, *Trends. Genet.* 16:69-74, 2000; and MacLachlan *et al.*, *J. Biol. Chem.* 275:2777-2785, 2000). *BRCA1* and *BRCA2* have each been implicated in defective homologous recombination DNA repair (see Arvanitis *et al.*, *International Journal of Molecular Medicine* 10:55-63, 2002), and it is believed that each may be a positive regulator of homologous recombination, with *BRCA2* potentially interacting with Rad51, a central homologous recombination effector protein, and *BRCA1* regulating *GADD45*, a DNA damage response gene.

Patients having cervical and endometrial cancer resulting in defects in homologous recombination pathways have been shown to respond favorably to radiotherapy (Arvantis *et al.*). Therefore, patients having ovarian cancer resulting from a defect in *BRCA1* or *BRCA2* may similarly benefit from radiotherapy treatment. Hence, the ability to classify ovarian cancer patients into groups based upon the underlying mutation provides advantages in selecting potential courses of treatment, and in deciding whether to pursue a more aggressive course of treatment.

In sum, there is a need to better understand patterns of gene expression that trigger ovarian cancer; as well as downstream genes that may serve as indicators of ovarian cancer progression or as potential tumor suppressors.

BRIEF SUMMARY OF THE DISCLOSURE

The present disclosure concerns a method of classifying an ovarian tumor as a *BRCA1*-like or *BRCA2*-like or non-BRCA-type tumor, by determining a pattern of expression in the ovarian tumor of a plurality of markers listed in Table 1, wherein the pattern of expression in the ovarian tumor is determined relative to a standard ovarian tissue. The pattern of expression of the markers in the ovarian tumor is then compared to the pattern of expression of the same markers in tissue from a known *BRCA1*-like or *BRCA2*-like or non-BRCA-type tumor. A similarity of the pattern of expression in the ovarian tumor to a pattern of expression of the comparison tissue of the known *BRCA1*-like tumor classifies the ovarian tumor as a *BRCA1*-like tumor; a similarity of the pattern of expression in the ovarian tumor to a pattern of expression of the known *BRCA2*-like tumor classifies the ovarian tumor as a *BRCA2*-like tumor; and a similarity of the pattern of expression in the ovarian

tumor to a pattern of expression of the known sporadic tumor classifies the ovarian tumor as a sporadic tumor.

The patterns of expression are determined, for example, by determining a pattern of over-expression or under-expression of the plurality of markers in the ovarian tumor to over-expression or under-expression of the plurality of markers of the comparison tissue. Alternatively, a pattern of both over-expression and under-expression of the plurality of markers in the ovarian tumor is compared to over-expression and under-expression of the plurality of markers in the comparison tissue.

It has also been discovered that ovarian tumors that do not contain a BRCA1 or BRCA2 mutation may be BRCA-1-like or BRCA2-like in that the pattern of expression of the markers is similar to a tumor having a BRCA-1 or BRCA-2 mutation. Hence tumors that would otherwise be considered "non-BRCA-type" can be classified as BRCA-1-like or BRCA-2-like, which can contribute to decisions about treatment and prognosis even in the absence of the mutation.

Standard ovarian tissue serves as a baseline from which patterns of over expression and under expression can be determined. The "standard" ovarian tissue may be, for example, from an immortalized ovarian cell, ovarian tissue from a subject not having ovarian cancer, a subject not predisposed to developing ovarian cancer, or ovarian tissue from a subject from whom the ovarian tumor was obtained at an earlier point in time. It is also possible for the standard tissue to be tumor tissue taken from a patient at an earlier point in time, for example prior to treatment (for example prior to the administration of chemotherapy). However in most instances the "standard" tissue is "normal" non-tumor ovarian tissue, such as an immortalized ovarian cell line, for example an IOSE cell line.

Many different approaches are described in this disclosure for determining the patterns of expression, and assessing similarities. In specific examples, the patterns of expression are patterns of logarithmic expression ratios, hierarchical clustering patterns, or multidimensional scaling patterns. The patterns may be compared visually or statistically to arrive at conclusions regarding similarity of the patterns. For example, when a multi-dimensional scaling pattern is used to generate a three-dimensional representation of data clusters associated with BRCA1-like, BRCA2-like or non-BRCA-like tumors, the position of a data point obtained from the tumor specimen that is being analyzed can indicate whether the tumor specimen has a pattern of expression associated with one of these groups. If the data point from the tumor specimen is present within or closely associated with one of these clusters, it is assigned a classification the same as the cluster in which it is contained or with which it is associated.

Another approach to comparing patterns of over expression and under expression is to assign different color intensities to standard normal deviation values of the logarithmic expression ratios. Similarities of color patterns can then be used to arrive at a qualitative assignment of a tumor specimen to a classification. In another approach, the logarithmic expression ratios of the plurality markers is compared using compound covariate predictor analysis.

In particular examples discussed herein, a *BRCA1*-like ovarian tumor is differentiated from a non-BRCA-like ovarian tumor by comparing relative logarithmic expression ratios of at least one

marker shown in Table 6. In more particular embodiments, the pattern of expression of all the markers in Table 6 (*CD72*, *SLC25A11*, *LCN2*, *PSTPIP1*, *SIAHBP1*, *UBE1*, *WAS*, *IDH2*, and *PCTK1*) is compared to the pattern of expression of these same markers in the specimen undergoing classification.

5 In another example, a *BRCA2*-like ovarian tumor is distinguished from a non-*BRCA*-like ovarian tumor by comparing relative logarithmic expression ratios of at least one marker shown in Table 7, and in some embodiments both of the markers (*LOC51760* and *LRPAPI*). In yet other examples *BRCA1*- and *BRCA2*-like ovarian tumors are distinguished from non-*BRCA*-like ovarian tumors by comparing relative logarithmic expression ratios of at least one marker shown in Table 8, 10 for example *PSTPIP1*, *IDH2*, and *PCTK1*, or all the markers in Table 8. In other examples, a *BRCA1*-like ovarian tumor is distinguished from a *BRCA2*-like ovarian tumor by comparing relative logarithmic expression ratios of at least one marker shown in Table 10, more than one marker shown in Table 10, or all the markers in Table 10.

15 The disclosed methods also include selecting a treatment strategy based on classifying the ovarian tumor as *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like. For example, the treatment strategy may include selecting a more aggressive treatment regimen for a *BRCA1*-like or *BRCA2*-like tumor (even if the tumor does not contain a *BRCA1* or *BRCA2* mutation). Such treatment regimens can include chemotherapy, radiotherapy, or surgical removal of the tumor and/or surrounding tissue.

20 In yet other disclosed examples, the expression patterns of a tumor specimen and known comparison tissue are compared using a database of patterns (for example a database of logarithmic expression patterns) associated with *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like ovarian tumors. The database can contain, for example, expression ratios of the plurality of markers in standard tissue. The patterns of the expression ratios of the plurality of markers of the tumor specimen can then be compared to the pattern of expression ratios of the same markers in the standard tissue.

25 In some examples, comparisons may be made just of patterns of over expression, for one or more markers that is over expressed as listed in Table 5. Alternatively, comparisons may be made just of patterns of under expression. The patterns of expression may be obtained by using nucleic acid sequences of the markers to perform nucleic acid hybridization of specific oligonucleotide probes to the nucleic acid sequences. The markers may be amplified prior to performing nucleic acid hybridization, and expression quantitated to detect a level of differential expression. The markers are conveniently provided on an array, such as a cDNA microarray. In one example the cDNA microarray contains at least 50, 100, 200, 400 or more of the markers listed in Table 1.

30 The results of these comparisons can be used to diagnose or provide a prognosis of progression of ovarian cancer in a subject. The patterns of expression can also be used to screen for therapeutic agents for the treatment of ovarian cancer, or monitoring response to therapy in a subject, by looking for a return of the patterns of expression of the ovarian tumor toward a non-tumor tissue pattern. Kits are also provided for performing these analyses, and the kit may include arrays with cDNAs of the markers.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the overall expression differences between *BRCA1*-like, *BRCA2*-like, and non-*BRCA*-like ovarian epithelial cancers. **Figure 1A.** Multidimensional scaling model based on the overall gene expression (6,445 filtered spots, Example 1) in *BRCA1*-linked (solid circles), *BRCA2*-linked (open circles), and sporadic tumors (asterisks). **FIG 1B.** The magnitude of differences in gene expression between various tumor groups as revealed by the number of genes differentially expressed among them using the uniform statistical cutoff $P<0.0001$.

Figure 2 illustrates that *BRCA1*- and *BRCA2*-discriminating genes also segregate sporadic ovarian cancers into two groups (*BRCA1*-like and *BRCA2*-like). **Figure 2A.** Hierarchical clustering of 110 non-redundant genes (see Table 9, Addendum) showing significant differential expression between *BRCA1*-linked and (B1) and *BRCA2*-linked (B2) tumors (modified F-test $P<0.0001$). The red and green color intensities represent standard normal deviation (Z-score) values from the mean expression level of each gene (represented as black) across sixty-one tumor samples (Example 1).

Figure 2A' is a duplication of Figure 2A, but is printed in grey tones rather than in color. **Figure 2B.** **Figure 2B.** Hierarchical clustering of sporadic and *BRCA*-linked tumor samples based on the expression pattern of the 110 *BRCA*-discriminating patterns of gene expression. The B-, B2-, and C-labeled samples signify *BRCA1*-linked, *BRCA2*-linked, and sporadic tumors, respectively. **Figure 2C.** Hierarchical clustering of sporadic samples in the absence of *BRCA*-linked tumors reveals two major clusters corresponding to *BRCA1*-type and *BRCA2*-type patterns of gene expression.

Figure 3 shows molecular profiles of sixty-one tumors as defined by the genes whose expression significantly differentiated *BRCA1* and *BRCA2* tumors ($P<0.0001$) (see Example 1, and Table 9). The red and green color intensities represent expression levels shown as standard normal deviation (Z-score) values from the mean expression level of each gene (represented as black) across sixty-one tumor samples. The genes are numbered consecutively 1-61 in Figure 3A, and 62-116 in Figure 3B. **Figure 3A'** and **Figure 3B'** are duplications of Figure 3A and Figure 3B, respectively, but are printed in grey tones rather than in color. **Figure 3C** shows the correlation of the designated rows to genes and SEQ ID NOs for the molecular profile in Figure 3A and **Figure 3D** shows the correlation of the designated rows to genes and SEQ ID NOs for the molecular profile in Figure 3B.

Figure 4 shows gene expression differences between *BRCA*-linked and sporadic tumors. A modified F-test with a statistical significance level of $P<0.0001$ was used to evaluate genes differentially expressed between tumor types. The red and green color intensities represent expression levels shown as standard normal deviation (Z-score) values from the mean expression level of each gene (represented as black) across all sixty-one tumor samples. Each gene name is followed by the corresponding I.M.A.G.E. clone number spotted on the array. **Figure 4A.** Genes differentially expressed between *BRCA1*-linked (B) and sporadic (C) samples. Genes located on Xp11 appear in red. **Figure 4B.** Examples of genes differentially expressed between *BRCA2*-linked (B2) and sporadic (C) samples. **Figure 4C.** Examples of differentially expressed genes between the combined *BRCA1*- and *BRCA2*-linked group (B and B2, respectively) and the sporadic (C) samples. **FIG 4A-C'** is a duplication of Figure 4A-C, but is printed in grey tones rather than in color.

Figure 4D *BRCA1*-linked tumors exhibit significantly higher expression levels ($P<0.001$) of all six genes mapped to Xp11.23 compared to the sporadic cancers. Error bars reflect standard error.

5 **Figure 5** is a bar graph showing an evaluation of gene expression patterns common to *BRCA*-linked and sporadic tumors. **Figure 5A** shows the expression of twenty-five genes that showed two-fold or greater down-regulation as compared to the IOSE reference cell line. **Figure 5B** shows the expression of twenty-five genes that showed two-fold or greater up-regulation as compared to the IOSE reference cell line. Error bars reflect standard error. (*FOS*, *HE4* and *CD24*) have been previously reported to be overexpressed in ovarian cancers. Several of the overexpressed genes that have been demonstrated to be interferon-responsive are presented in italics. The * symbol denotes 10 immediate-early response genes.

15 **Figure 6** is a series of bar graphs illustrating semi-quantitative RT-PCR (sqRT-PCR) analysis of gene expression confirms the cDNA microarray data. Expression patterns of select genes were examined using sqRT-PCR in representative *BRCA1*-linked (bars 1-5), *BRCA2*-linked (bars 6-10), and sporadic (bars 11-15) samples. The expression level of each gene in the tumor samples was compared to those of normal postmenopausal ovary (N) and the reference IOSE cells (R). All data has been normalized to β -actin is presented as fold expression compared to the IOSE reference RNA. 20 **Figure 6A** shows results for genes *HE4*, *RSG1*, and *CD74*. **Figure 6B** shows results for genes *ZFP36*, *TOP2A* and *HLA-DRB1*.

20

BRIEF DESCRIPTION OF THE TABLES

25 **TABLE 1** (see Addendum) lists 822 ovarian cancer-related nucleic acid molecules that show altered expression in ovarian cancer. The nucleic acids are identified by their SEQ ID NO, their gene name (if one has been assigned), the I.M.A.G.E Clone ID number associated with the nucleic acid sequence, the UniGene number (if one has been assigned), and a description of the gene (if known). Because more than one GenBank Accession Number is sometimes provided for a given nucleic acid molecule, the Table groups the SEQ ID NO assigned to each GenBank Accession Number with nucleic acid molecule. For example, the entry for *BCKDHB* in Table 1 provides SEQ ID NOs: 16-17 (represented by GenBank Accession number AA427739 and GenBank Accession number AA434304). Each of the 822 SEQ ID NOs are included in the attached sequence listing.

30

TABLE 2 catalogs the clinicopathologic features of the tumor samples in a study of sixty-one cases of pathologically-confirmed epithelial ovarian adenocarcinoma.

TABLE 3 lists representative gene-specific primer sequences used to amplify RNA for analysis by semi-quantitative PCR.

35

TABLE 4 (see Addendum) lists markers that were under-expressed in ovarian cancer in a comparison of ovarian epithelial cancer cells to normal postmenopausal ovarian tissue.

TABLE 5 (see Addendum) lists markers that were over-expressed in ovarian cancer in a comparison of ovarian epithelial cancer cells to normal postmenopausal ovarian tissue.

TABLE 6 (see Addendum) lists markers that were differentially expressed between *BRCA1*-linked and sporadic tumors in a comparison to reference immortalized ovarian epithelial cells.

TABLE 7 (see Addendum) lists markers that were differentially expressed between *BRCA2*-linked and sporadic tumors in a comparison to reference immortalized ovarian epithelial cells.

5 TABLE 8 (see Addendum) lists markers that were differentially expressed between combined *BRCA1*-linked and *BRCA2*-linked versus sporadic tumors in a comparison to reference immortalized ovarian epithelial cells.

TABLE 9 (see Addendum) lists markers that were differentially expressed between *BRCA1*-linked and *BRCA2*-linked tumors in a comparison to reference immortalized ovarian epithelial cells.

10 TABLE 10 (see Addendum) lists markers that can be used to segregate *BRCA1*-like from *BRCA2*-like tumor types using compound covariate prediction analysis.

10 TABLE 11 (see Addendum) lists the results of compound covariate predictor analysis for the sixty-one tumors disclosed herein, analyzed using the markers in Table 10.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

15 The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and single letter code for amino acids, as defined in 37 C.F.R. § 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:

20 SEQ ID NO: 1 is a 63-nucleotide synthetic primer containing a T7 RNA polymerase binding site.

SEQ ID NOs: 2 and 3 are *ACTB* gene-specific primers used for amplification during semi-quantitative RT-PCR.

25 SEQ ID NOs: 4 and 5 are *HE4* gene-specific primers used for amplification during semi-quantitative RT-PCR.

SEQ ID NOs: 6 and 7 are *ZFP36* gene specific primers used for amplification during semi-quantitative RT-PCR.

SEQ ID NOs: 8 and 9 are *RGS1* gene specific primers used for amplification during semi-quantitative RT-PCR.

30 SEQ ID NOs: 10 and 11 are *CD74* gene specific primers used for amplification during semi-quantitative RT-PCR.

SEQ ID NOs: 12 and 13 are *TOP2A* gene specific primers used for amplification during semi-quantitative RT-PCR.

35 SEQ ID NOs: 14 and 15 are *HLA-DRBI* gene specific primers used for amplification during semi-quantitative RT-PCR.

SEQ ID NOs: 16 through 822 are ovarian cancer-related nucleic acid molecules that show altered expression in ovarian cancer. These nucleic acid molecules are listed in Table 1, and their sequence information is provided in the attached sequence listing.

DETAILED DESCRIPTION

I. Abbreviations

5	cDNA:	complementary DNA
	DNA:	deoxyribonucleic acid
	ELISA:	enzyme-linked immunosorbent assay
	EST:	expressed sequence tag
	I.M.A.G.E.:	Integrated Molecular Analysis of Genomes and their Expression Consortium
10	IOSE:	immortalized ovarian surface epithelial cell lines
	MDS:	multidimensional scaling
	PCR:	polymerase chain reaction
	RIA:	radioimmunoassay
	RNA:	ribonucleic acid
15	RT-PCR:	reverse transcription-polymerase chain reaction
	siRNA:	small inhibitory RNA molecule
	sqRT-PCR:	semi-quantitative reverse transcription-polymerase chain reaction
	STS:	sequence-tagged site

20 II. Terms

Unless otherwise noted, technical terms are used according to conventional usage.

Definitions of common terms in molecular biology may be found in Benjamin Lewin, *Genes V*, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew *et al.* (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

In accordance with the present disclosure, conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art are used. Such techniques are fully explained in the literature (see, *e.g.*, Sambrook *et al.*, 1989. *Molecular cloning, a laboratory manual*. 30 2nd ed. Cold Spring Harbor Laboratory, Cold spring Harbor, New York; Glover, 1985, *DNA Cloning: A practical approach*, volumes I and II oligonucleotide synthesis, MRL Press, LTD., Oxford, U.K.; Hames and Higgins, 1985, *Transcription and translation*; Hames and Higgins, 1984, *Animal Cell Culture*; Freshney, 1986, *Immobilized Cells And Enzymes*, IRL Press; and Perbal, *A Practical Guide to Molecular Cloning*, John Wiley & Sons, New York, 1988).

35 In order to facilitate review of the various embodiments of the invention, the following explanations of specific terms are provided:

Altered expression or differential expression refers to expression of a nucleic acid (*e.g.*, mRNA or protein) in a subject or biological sample from a subject that deviates from that expression in a subject or biological sample from a subject having normal (wild-type) characteristics for the 40 biological condition associated with the nucleic acid. Normal expression can be found in a control, a standard for a population, etc. For instance, where the altered expression manifests as a diseased condition, such as growth of a tumor or neoplasia or onset of a cancer such as ovarian cancer, characteristics of normal expression might include an individual who is not suffering from the condition (*e.g.*, a subject not displaying neoplasia growth or not having ovarian cancer), a population

standard of individuals believed not to be suffering from the disease, etc. For instance, certain altered expression (such as altered expression of a *BRCA* nucleic acid), can be described as being associated with the biological conditions of altered (e.g., over-expressed or under-expressed) nucleic acid expression and a tendency to develop gynecological cancer, such as ovarian cancer. Likewise, 5 altered expression may be associated with a disease. The term "associated with" includes an increased risk of developing the disease.

Controls or standards (e.g., a reference cell line, such as immortalized epithelial ovarian cells) for comparison to a sample (e.g., an ovarian cancer tumor), for the determination of altered expression, include samples believed to be normal for the studied characteristic, as well as laboratory 10 values, even though possibly arbitrarily set, keeping in mind that such values may vary from laboratory to laboratory. Laboratory standards and values may be set based on a known or determined population value and may be supplied in the format of a graph or table that permits easy comparison of measured, experimentally determined values.

When used in reference to a nucleic acid, **amplification** includes techniques that increase 15 the number of copies of a nucleic acid molecule in a sample or specimen. An example of amplification is the polymerase chain reaction, in which a biological sample collected from a subject is contacted with a pair of oligonucleotide primers, under conditions that allow for the hybridization of the primers to nucleic acid template in the sample. The primers are extended under suitable conditions, dissociated from the template, and then re-annealed, extended, and dissociated to amplify 20 the number of copies of the nucleic acid. The product of *in vitro* amplification can be characterized by electrophoresis, restriction endonuclease cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic acid sequencing, using standard techniques. Other examples of *in vitro* amplification techniques include strand displacement amplification (see U.S. Patent No. 5,744,311); transcription-free isothermal amplification (see U.S. Patent No. 6,033,881); repair chain reaction 25 amplification (see WO 90/01069); ligase chain reaction amplification (see EP-A-320 308); gap filling ligase chain reaction amplification (see U.S. Patent No. 5,427,930); coupled ligase detection and PCR (see U.S. Patent No. 6,027,889); and NASBA™ RNA transcription-free amplification (see U.S. Patent No. 6,025,134).

An **array** is an arrangement of molecules, particularly biological macromolecules (such as 30 polypeptides or nucleic acids) or cell or tissue samples, in addressable locations on or in a substrate. The array may be regular (arranged in uniform rows and columns, for instance) or irregular. The number of addressable locations on the array can vary, for example from a few (such as three) to more than 50, 100, 200, 500, 1000, 10,000, or more. A **microarray** is an array that is miniaturized so as to require or be aided by microscopic examination for evaluation or analysis. A **cDNA** 35 **microarray** is an array of multiple cDNA molecules, fixed in addressable locations, to which complementary nucleic acids in applied samples may hybridize (see Hegde *et al.*, *Biotechniques* 29(3): 548-562, 2000). cDNA microarrays of the disclosure provide for qualitative and quantitative analysis of gene expression of the molecules contained in the array.

Within an array, each arrayed sample (feature) is addressable, in that its location can be reliably and consistently determined within the at least two dimensions of the array. Thus, in ordered arrays the location of each sample is assigned to the sample at the time when it is applied to the array, and a key may be provided in order to correlate each location with the appropriate target or feature position. Often, ordered arrays are arranged in a symmetrical grid pattern, but samples could be arranged in other patterns (e.g., in radially distributed lines, spiral lines, or ordered clusters). Addressable arrays usually are computer readable, in that a computer can be programmed to correlate a particular address on the array with information about the sample at that position (e.g., expression data, including for instance signal intensity as well as the identity of the sample). In some examples of computer readable formats, the individual features in the array are arranged regularly, for instance in a Cartesian grid pattern, which can be correlated to address information by a computer.

The sample application location on an array (the "feature") may assume many different shapes. Thus, though the term "spot" may be used herein, it refers generally to a localized placement of molecules or tissue or cells, and is not limited to a round or substantially round region. For instance, substantially square regions of application can be used with arrays encompassed herein, as can be regions that are, for example, substantially rectangular, triangular, oval, irregular, or another shape. Within a single array, feature shapes do not usually vary, though they will in some embodiments.

In certain example arrays, one or more features will occur on the array a plurality of times (e.g., twice) to provide internal controls.

A **biological sample** is any sample in which the presence of a protein and/or ongoing expression of a protein may be detected. Suitable biological samples include samples containing genomic DNA or RNA (including mRNA), obtained from body cells of a subject, such as but not limited to those present in peripheral blood, urine, saliva, cells obtained by pap smear, sera, tissue biopsy, surgical specimen, amniocentesis samples and autopsy material.

A **BRCA1-like tumor** is a tumor in which the gene expression pattern is substantially similar to the gene expression pattern in a tumor from a subject who has a mutation in *BRCA1*. Similarly, a **BRCA2-like tumor** is a tumor in which the gene expression pattern is substantially similar to the gene expression pattern in a tumor from a subject who has a mutation in *BRCA2*. As described herein, sporadic tumors may share gene expression patterns with BRCA-linked and or BRCA2-linked tumors. Hence, sporadic and other tumors (such as tumors for which no BRCA genetic test has been conducted) that have gene expression patterns similar to a BRCA1-linked tumor are "BRCA1-like" tumors.

A **cancer** is a biological condition in which a malignant tumor or other neoplasm has undergone characteristic anaplasia with loss of differentiation, increased rate of growth, invasion of surrounding tissue, and/or which is capable of metastasis.

The term cancer includes ovarian cancer, such as ovarian epithelial cancer, which originates in the ovaries and may manifest as epithelial tumors, germ cell tumors, or stromal tumors. Also included are different stages of a single cancer, for instance both primary and recurrent ovarian

cancer, and cancer at any progressive stage, such as Stages I-IV. Ovarian cancer is considered a gynecological cancer.

5 A subject may be classified into an **ovarian cancer stage** based upon evaluation of a biological sample from the subject for indices known in the art or disclosed herein as being indicative of that stage of ovarian cancer. For example, a subject may be classified as having a cancer state of cancer-free, active ovarian cancer (*i.e.*, stage I, II, III, or IV ovarian cancer), or in remission from previous ovarian cancer.

10 cDNA is a piece of DNA lacking internal, non-coding segments (introns) and regulatory sequences that determine transcription. cDNA is generally synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.

15 **Compound covariate prediction analysis** is a method of predicting into which of two groups a sample will be assinged using a given statistical significance cutoff (*e.g.*, $P<0.0005$). The method creates a multivariate predictor for one of two classes to each sample and includes in the multivariate predictor only those components (*e.g.*, nucleic acids expressing on a cDNA microarray) that meet the statistical significance cutoff. The multivariate predictor is a weighted linear combination of logarithmic ratios for components that are univariately significant. The weight consists of the univariate t-statistics for comparing the classes.

20 DNA is a polymer that comprises the genetic material of most living organisms (some viruses have genomes comprising RNA). The repeating units in most natural DNA polymers are four different nucleotides, each of which comprises one of the four bases, adenine, guanine, cytosine and thymine, bound to a deoxyribose sugar to which a phosphate group is attached. Triplets of nucleotides (referred to as codons) code for each amino acid in a polypeptide, or for a stop signal. The term codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the DNA sequence is transcribed.

25 Unless otherwise specified, any reference to a DNA molecule is intended to include the reverse complement of that DNA molecule. Except where single-strandedness is required by the text herein, DNA molecules, though written to depict only a single strand, encompass both strands of a double-stranded DNA molecule. Thus, a reference to the nucleic acid molecule that encodes a specific protein, or a fragment thereof, encompasses both the sense strand and its reverse complement. Thus, for instance, it is appropriate to generate primers from the reverse complement sequence of the disclosed nucleic acid molecules.

30 An **expressed sequence tag (EST)** is a unique stretch of DNA within a coding region of a gene that is useful for identifying full-length genes and serves as a landmark for gene mapping. An EST is a sequence tagged site (STS) derived from cDNA.

35 **Expression** of a gene is the process by which the coded information of a gene is converted into an operational or non-operational part of a cell, often including the synthesis of a protein. Gene expression can be influenced by external signals. For instance, exposure of a cell to a hormone may stimulate expression of a hormone-induced gene. Different types of cells may respond differently to an identical signal.

5 Expression of a gene also may be regulated in the pathway from DNA to RNA to protein. Ways in which regulation occurs include through controls acting on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation or compartmentalization or degradation of specific protein molecules after they have been made.

Changes in gene expression may be associated with specific types of cancer (and cancer progression). Such association is fairly specific to the type of cancer, and thus what is overexpressed in one cancer may be underexpressed (or unchanged) in another.

10 The expression of several genes may be grouped into an **expression pattern or expression profile**. Such patterns or profiles may be unique to an individual sample depending upon certain factors, for instance biological stimuli introduced into the subject from which the sample was taken (e.g., a hormone) or ongoing disease within the subject (e.g., ovarian cancer). Thus, a collection or set of genes/proteins that are differentially regulated in a specific cancer may be indicative and specifically diagnostic of that type of cancer. In addition, specific expression patterns may indicate 15 particular mutations within the individual that correlate and/or cause the disease, for instance a mutation in *BRCA1* or *BRCA2*, or may indicate a larger class of disease, such as a *BRCA1*-like or *BRCA2*-like cancer. Furthermore, changing the expression patterns of these genes to restore the normal state, or bring the condition closer to the normal state in one or more characteristic, may constitute a treatment for cancer.

20 As disclosed herein, the expression pattern of an unknown tumor may be compared to the expression pattern of known *BRCA1*-linked and *BRCA2*-linked markers to determine if the expression patterns are sufficiently similar to classify the unknown as a *BRCA1*-like or *BRCA2*-like tumor.

25 **Gene amplification or genomic amplification** is an increase in the copy number of a gene or a fragment or region of a gene or associated 5' or 3' region, as compared to the copy number in normal tissue. An example of a genomic amplification is an increase in the copy number of an oncogene. A "gene deletion" is a deletion of one or more nucleic acids normally present in a gene sequence and, in extreme examples, can include deletions of entire genes or even portions of chromosomes.

30 A **gene expression fingerprint (or profile)** is a distinct or identifiable pattern of gene expression, for instance a pattern of high and low expression of a defined set of genes or gene-indicative nucleic acids such as ESTs; in some instances, as few as one or two genes may provide a profile, but often more genes are used in a profile, for instance at least three, at least 5, at least 10, at least 20, at least 25, or at least 50 or more. Gene expression fingerprints (also referred to as profiles) 35 can be linked to a tissue or cell type, to a particular stage of normal tissue growth or disease progression, or to any other distinct or identifiable condition that influences gene expression in a predictable way. Gene expression fingerprints can include relative as well as absolute expression levels of specific genes, and often are best viewed in the context of a test sample compared to a baseline or control sample fingerprint. By way of example, a gene expression profile may be read on

an array (e.g., a polynucleotide or polypeptide array). Arrays are now well known, and for instance gene expression arrays have been previously described in published PCT application number WO9948916 ("Hypoxia-Inducible Human Genes, Proteins, and Uses Thereof"), incorporated herein by reference in its entirety.

5 As disclosed herein, the gene expression profile of an unknown tumor may be compared for similarities and differences to the expression profile of a tumor known to express in a BRCA-like manner (e.g., a BRCA1-like or BRCA2-like tumor).

10 A **genomic target sequence** is a sequence of nucleotides located in a particular region in the human genome that corresponds to one or more specific genetic abnormalities, such as a nucleotide polymorphism, a deletion, or amplification. The target can be for instance a coding sequence; it can 15 also be the non-coding strand that corresponds to a coding sequence.

15 **Gynecological cancers** are cancers of the female reproductive system, and include cancers of the uterus (e.g., endometrial carcinoma), cervix (e.g., cervical carcinoma), ovaries (e.g., ovarian carcinoma, serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid tumors, celioblastoma, clear cell carcinoma, unclassified carcinoma, granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma), embryonal rhabdomyosarcoma, and fallopian tubes (e.g., carcinoma).

20 An **isolated** biological component (such as a nucleic acid, peptide or protein) has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs, *i.e.*, other chromosomal and extrachromosomal DNA and RNA, and proteins. Nucleic acids, peptides and proteins that have been isolated thus include nucleic acids and proteins purified by standard purification methods. The term 25 also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.

30 A **marker** is a diagnostic indicator of disease. A marker may consist of any signal indicating the presence of the disease, *e.g.*, a physiological change in the body of a subject or increased or decreased levels of a substance such as a protein correlated to the disease. Markers are often found in body fluid samples from a subject. By way of example, prostate specific antigen is a tumor marker used to detect progression of prostate cancer. The molecules disclosed herein, for instance in Table 1 are useful as tumor markers for diagnosing, prognosing, staging, preventing, and treating cancerous disease, such as ovarian cancer.

35 A **mutation** includes any change of the DNA sequence within a gene or chromosome. In some instances, a mutation will alter a characteristic or trait (phenotype), but this is not always the case. Types of mutations include base substitution point mutations (*e.g.*, transitions or transversions), deletions, and insertions. Missense mutations are those that introduce a different amino acid into the sequence of the encoded protein; nonsense mutations are those that introduce a new stop codon. In the case of insertions or deletions, mutations can be in-frame (not changing the frame of the overall

sequence) or frame shift mutations, which may result in the misreading of a large number of codons (and often leads to abnormal termination of the encoded product due to the presence of a stop codon in the alternative frame).

5 This term specifically encompasses variations that arise through somatic mutation, for instance those that are found only in disease cells, but not constitutionally, in a given individual. Examples of such somatically-acquired variations include the point mutations that frequently result in altered function of various genes that are involved in development of cancers. This term also encompasses DNA alterations that are present constitutionally, that alter the function of the encoded protein in a readily demonstrable manner, and that can be inherited by the children of an affected 10 individual. In this respect, the term overlaps with "polymorphism," as defined below, but generally refers to the subset of constitutional alterations that have arisen within the past few generations in a kindred and that are not widely disseminated in a population group. In particular embodiments, the term is directed to those constitutional alterations that have major impact on the health of affected individuals, such as those resulting in onset of a disease such as a gynecological cancer.

15 An **oligonucleotide** is a plurality of joined nucleotides joined by native phosphodiester bonds, between about 6 and about 300 nucleotides in length. An oligonucleotide analog refers to moieties that function similarly to oligonucleotides but have non-naturally occurring portions. For example, oligonucleotide analogs can contain non-naturally occurring portions, such as altered sugar moieties or inter-sugar linkages, such as a phosphorothioate oligodeoxynucleotide. Functional analogs of naturally 20 occurring polynucleotides can bind to RNA or DNA, and include peptide nucleic acid (PNA) molecules.

25 Particular oligonucleotides and oligonucleotide analogs can include linear sequences up to about 200 nucleotides in length, for example a sequence (such as DNA or RNA) that is at least 6 bases, for example at least 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or even 200 bases long, or from about 6 to about 50 bases, for example about 10-25 bases, such as 12, 15 or 20 bases.

30 A **neoplasm** is a new and abnormal growth, particularly a new growth of tissue or cells in which the growth is uncontrolled and progressive. A tumor is an example of a neoplasm.

35 A **non-BRCA-type tumor** is a tumor in which the gene expression pattern of the BRCA1-linked and BRCA2-linked markers disclosed in Table 1 is not similar to either a BRCA1-like or BRCA2-like gene expression pattern.

40 A **nucleic acid** is a deoxyribonucleotide or ribonucleotide polymer in either single or double stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides.

45 A **nucleic acid sequence (or polynucleotide)** is a DNA or RNA molecule, and includes polynucleotides encoding full-length proteins and/or fragments of such full length proteins which can function as a therapeutic agent.

50 **Nucleotide** includes, but is not limited to, a monomer that includes a base linked to a sugar, such as a pyrimidine, purine or synthetic analogs thereof, or a base linked to an amino acid, as in a

peptide nucleic acid (PNA). A nucleotide is one monomer in a polynucleotide. A nucleotide sequence refers to the sequence of bases in a polynucleotide.

A first nucleic acid sequence is **operably linked** with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.

5 For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.

An **ovarian cancer-related molecule** includes nucleic acids (such as DNA or RNA or cDNA) and proteins that are altered (for example by mutation or abnormal expression) in ovarian cancer.

10 **Pharmaceutically acceptable carriers** include compositions and formulations suitable for pharmaceutical delivery of the nucleotides and proteins herein disclosed. Martin, *Remington's Pharmaceutical Sciences*, published by Mack Publishing Co., Easton, PA, 19th Edition, 1995, describes conventional pharmaceutically acceptable carriers.

15 In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-20 neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

25 Primers are short nucleic acids, preferably DNA oligonucleotides 10 nucleotides or more in length, which are annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.

30 Primers as used in the present disclosure preferably comprise at least 10 nucleotides of the nucleic acid sequences that are shown to encode specific proteins. In order to enhance specificity, longer primers may also be employed, such as primers that comprise 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 consecutive nucleotides of the disclosed nucleic acid sequences. Methods for preparing and using probes and primers are described in the references, for example Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York; Ausubel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publ. Assoc. & Wiley-Intersciences; Innis *et al.* (1990) *PCR Protocols, A Guide to Methods and Applications*, Innis *et al.* (Eds.), Academic Press, San Diego, CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).

When referring to a primer, the term *specific for (a target sequence)* indicates that the primer hybridizes under stringent conditions substantially only to the target sequence in a given sample comprising the target sequence.

5 A **probe** comprises an isolated nucleic acid attached to a detectable label or other reporter molecule. Typical labels include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, *e.g.*, Sambrook *et al.* (In *Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989) and Ausubel *et al.* (In *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1998).

10 A **protein** is a biological molecule expressed by a gene and comprised of amino acids.

A purified molecule is one that has been purified relative to its original environment. The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified protein preparation is one in which the protein referred to is more pure than the protein in its natural environment within a cell or within a production reaction chamber (as 15 appropriate). Non-limiting examples of purified molecules are those that are 50%, 75%, or 90% pure.

20 A **recombinant nucleic acid** is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, *e.g.*, by genetic engineering techniques such as those described in Sambrook *et al.*, In *Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989. The term recombinant includes nucleic acids that have been altered solely by 25 deletion of a portion of the nucleic acid. For instance, a plasmid is recombinant if some portion of the naturally occurring plasmid has been deleted. Equally, if the sequence of such a plasmid has been altered, for example by a nucleotide substitution (or addition or deletion), that plasmid is said to be recombinant.

30 **Sequence identity** is the similarity between two nucleic acid sequences, or two amino acid sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar are the two sequences. Methods of alignment of sequences for comparison are well-known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, *J. Theor. Biol.* 91(2): 379-380, 1981; Needleman and Wunsch, *J. Mol. Bio.* 48:443-453, 1970; Pearson and Lipman, *Methods in Molec. Biology* 24: 307-331, 1988; Higgins and Sharp, *Gene* 73:237-244, 1988; Higgins and Sharp, *CABIOS* 5:151-153, 1989; Corpet *et al.*, *Nucleic Acids Research* 16:10881-10890, 1988; Huang *et al.*, *Computer Applications in BioSciences* 8:155-165, 1992; and Pearson *et al.*, *Meth. Mol. Bio.* 24: 307-331, 1994. Altschul *et al.*, *Nat. Genet.* 6(2): 119-129, 1994 presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (see Altschul *et al.* *J. Mol. Biol.* 215: 403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. The Search Tool can be accessed at the 5 NCBI website, together with a description of how to determine sequence identity using this program.

Nucleic acid sequences that do not show a high degree of identity can nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid molecules that all encode substantially the same protein.

10 **Serial analysis of gene expression (SAGE)** is the use of short diagnostic sequence tags to allow the quantitative and simultaneous analysis of a large number of transcripts in tissue, as described in Velculescu *et al.*, *Science* 270:484-487, 1995.

15 A **standard** is a reference against which a value (e.g., level of expression of a marker) can be compared. By way of example, a non-cancerous cell line may be used as a standard for comparing the level of expression of tumor markers in an ovarian tumor sample. Non-limiting examples of 20 standards useful with the disclosed methods of analysis of patterns of expression of markers include a non-cancerous sample (e.g., normal ovarian tissue), a sample from a subject prior to development of a cancer or at an earlier stage of the cancer, and a cell line (e.g., immortalized ovarian epithelial cells, such as IOSE cells) considered to display wild-type expression levels of the markers. In some embodiments, a reference RNA is arbitrarily chosen, but used consistently in relation to all tumor samples.

25 **A subject** is a living multi-cellular vertebrate organisms, a category that includes both human and non-human mammals.

30 **A therapeutic agent**, as used in a generic sense, is a composition used for treating a subject, such as a pharmaceutical or prophylactic agent.

35 **A transformed cell** is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

40 **Treating a disease** includes inhibiting or preventing the partial or full development or progression of a disease (e.g., ovarian cancer), for example in a person who is known to have a predisposition to a disease. An example of a person with a known predisposition is someone having a history of breast or ovarian cancer in his or her family, or who has been exposed to factors that 45 predispose the subject to a condition, such as exposure to radiation. Furthermore, treating a disease refers to a therapeutic intervention that ameliorates at least one sign or symptom of a disease or pathological condition, or interferes with a pathophysiological process, after the disease or pathological condition has begun to develop.

In some aspects, a more aggressive treatment may be selected if warranted. By way of example, if a subject is found to have a *BRCA1*-like or *BRCA2*-like gene expression pattern, a more aggressive treatment, such as chemotherapy, radiotherapy, or surgical removal of the affected tissue and/or surrounding area may be selected.

5 A tumor is an abnormal mass of tissue, or neoplasm that may be either malignant or non-malignant. "Tumors of the same tissue type" refers to primary tumors originating in a particular organ (such as breast, ovary, bladder or lung). Tumors of the same tissue type may be divided into tumor of different sub-types, for example ovarian carcinomas can be further classified based on tumor histology as

10 adenocarcinoma, serous, endometrial, clear cell or mixed. Tumors may also be classified according to a genetic abnormality associated with the development of that type of tumor. By way of example, a tumor associated with a defect in tumor suppressor genes *BRCA1* or *BRCA2* is referred to herein as a "*BRCA1*- or *BRCA2*-linked" tumor. As described herein, a **sporadic ovarian tumor** is a tumor arising for a reason other than a mutation in *BRCA1* or *BRCA2*. However, the similarities in the 15 pattern of expression of ovarian cancer markers in sporadic tumors to those in *BRCA1*-linked and *BRCA2*-linked tumors can be used to classify sporadic tumors into "*BRCA1*-like" or "*BRCA2*-like" tumors, using the methods of the disclosure. A "non-*BRCA*-type" tumor is one that has a pattern of expression of ovarian cancer markers unlike a *BRCA1*-like or *BRCA2*-like tumor.

20 A vector is a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication, and may also include one or more therapeutic genes and/or selectable marker genes and other genetic elements known in the art. A vector can transduce, transform, or infect a cell, thereby causing the cell to express nucleic acids and/or proteins other than those native to the cell. A vector optionally includes materials to aid in achieving entry of the nucleic 25 acid into the cell, such as a viral particle, liposome, protein coating or the like.

Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The singular terms "a," "an," and "the" include plurals unless the context clearly indicates otherwise. 30 Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. "Comprises" means "includes." It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable 35 methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

III. Description of Several Specific Embodiments

Provided herein are methods of diagnosing or prognosing development or progression of ovarian cancer in a subject, which methods involve detecting altered expression of at least one marker (e.g., a nucleic acid molecule such as one listed in Table 1 or genes, cDNAs or other polynucleotide molecules comprising one of the listed sequences, or a fragment thereof, or a protein, such as one encoded by such a nucleic acid molecule, or fragment of such protein). In certain embodiments, altered expression is detected in more than one marker, for instance in at least 50, at least 100, at least 200, or at least 400 or more nucleic acid molecules listed in Table 1, or encoded for by a nucleic acid molecule listed in Table 1. In certain specific embodiments, no more than the molecules listed in Table 6, Table 7, Table 8, Table 9, Table 10 or Table 11 are included in such analysis.

Additionally provided herein are methods for the classification of ovarian tumors as *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like tumors based upon expression profiles of selected markers. Using the expression profile data, multiple types of comparisons can be made to provide qualitative and quantitative information about the tumor type. Non-limiting examples of such comparisons include visual examination of color profiles of hierarchically clustered markers on a cDNA microarray, multidimensional scaling to determine relative distance of the analyzed markers, and compound covariate prediction analysis to statistically classify a given tumor into one of two classes based upon the logarithmic expression ratio of the expression of at least one known classifying marker. In a specific non-limiting example, logarithmic expression ratios are generated and used to classify tumor types by comparing to markers known to have a logarithmic expression ratio associated with *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like tumors (see Example 4).

Also encompassed herein are arrays containing two or more disclosed markers. Certain of such arrays are nucleic acid arrays that contain at least one marker, for instance at least one or more, such as 5, 10, 15, 25, 50, 100, 150, 200, 250, 300, 350, 400 or more nucleic acid molecules listed in Table 1 (or genes, cDNAs or other polynucleotide molecules comprising one of the listed sequences, or a fragment thereof), or a fragment of such protein, or an antibody specific to such a protein or protein fragment. Such arrays can also contain any particular subset of the nucleic acids (or corresponding molecules) listed in Tables 1-11 or all of those nucleic acids. Certain arrays (as well as the methods described herein) also may include nucleic acid molecules that are not listed in Table 1.

Certain of the encompassed methods involve measuring an amount of the ovarian cancer-related molecule in a sample (such as a serum or tissue sample) derived or taken from the subject, in which a difference (for instance, an increase or a decrease) in level of the ovarian cancer-related molecule relative to a standard such as a sample derived or taken from the subject at an earlier time, is diagnostic or prognostic for development or progression of ovarian cancer.

In some embodiments, altered expression of ovarian cancer-related nucleic acid molecules is detected using, for instance, *in vitro* nucleic acid amplification and/or nucleic acid hybridization. The

results of such detection methods can be quantified, for instance by determining the amount of hybridization or the amount of amplification of the nucleic acid molecules.

Specific embodiments of methods for detecting altered expression of at least one ovarian cancer-related molecule use the arrays disclosed herein. Such arrays may be nucleotide (e.g., 5 polynucleotide or cDNA) or protein (e.g., peptide, polypeptide, or antibody) arrays. In such methods, an array may be contacted with polynucleotides or polypeptides (respectively) from (or derived from) a sample from a subject. The amount and/or position of expression of the subject's polynucleotides or polypeptides then can be determined, for instance to produce a gene expression profile for that subject. Such gene expression profile can be compared to another gene expression profile, for 10 instance a control gene expression profile from a subject having a known ovarian cancer-related condition. Similarly, protein arrays can give rise to protein expression profiles. Both protein and gene expression profiles can more generally be referred to as expression profiles. Expression profile data can be used to generate logarithmic expression ratios for use in compound covariate prediction analysis.

15 Other embodiments are methods that involve providing nucleic acids from the subject; semi-quantitatively amplifying the nucleic acids to form nucleic acid amplification products using primers; quantifying the amount of the nucleic acid amplification products; and comparing results to expression levels obtained using cDNA microanalysis. The sequence of such primers may be selected to bind specifically to a nucleic acid molecule listed in Table 1, or a nucleic acid molecule 20 represented by those listed in Table 1. In specific examples of such methods, the primers are selected to amplify a nucleic acid product encoding topoisomerase II (*TOP2A*) (SEQ ID NO: 448), regulator of G-protein signaling 1 (*RGS1*) (SEQ ID NO: 398), invariant gamma-chain-associated protein (CD74) (SEQ ID NO: 89-91), epididymis-specific, whey-acidic protein (*HE4*) (SEQ ID NO: 60), major histocompatibility complex, class II, DR beta 1 protein (*HLA-DRB1*) (SEQ ID NO: 87-88), or 25 zinc finger protein (*ZFP36*) (SEQ ID NO: 167-168).

Also encompassed are methods of ovarian cancer therapy, in which classification of a tumor of a patient into a *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like tumor type aids in the selection of a treatment regimen. In some examples, the treatment selected is specific and tailored for the subject, based on the analysis of that subject's profile for one or more ovarian cancer-related molecules.

30 Other embodiments are kits for classifying tumors into a *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like tumor class, which kits may include a binding molecule that selectively binds to the marker that is the target of the kit. In some examples of such kits where the marker is an ovarian cancer-related protein, the binding molecule provided in the kit may be an antibody or antibody fragment that selectively binds to the target ovarian marker protein. In other examples of such kits 35 where the ovarian cancer-related marker level is a nucleic acid, the binding molecule provided in the kit may be an oligonucleotide capable of hybridizing to the nucleic acid marker molecule.

Further embodiments are methods of screening for a compound useful in treating, reducing, or preventing ovarian cancer or development or progression of ovarian cancer. Such methods involve determining if a test compound alters the gene expression profile of a subject (or cells of an *in vitro*

assay) so that the profile more closely resembles a wild-type expression profile than it did prior to such treatment, and selecting a compound that so alters the gene expression profile. In specific examples of such methods, the test compound is applied to a test cell. In some of such methods, the profile is determined or measured in an array format.

5 Also encompassed are compounds selected using the methods described herein, which are useful in treating, reducing, or preventing ovarian cancer or development or progression of ovarian cancer.

10 Also disclosed herein are uses of identified target ovarian cancer-related molecules for the development of antibodies, including therapeutic antibodies that affect an ovarian cancer-related pathway. It is also envisioned that the disclosed ovarian cancer-related molecules can be used as vaccines, for instance as "cancer vaccines" to elicit an immune response from a subject that renders the subject more resistant to developing or progressing through a stage of ovarian cancer.

IV. Gene expression profiling of ovarian cancer tumor tissue using disclosed markers

15 The present disclosure concerns gene expression profiling of ovarian tumor tissue from a subject for use in diagnosing, prognosing, staging, preventing, and treating the disease. Measurement of expression of genes within a tissue sample provides information regarding proteins that may be active during cancer mechanisms. Hence, the gene expression profile of tumor tissue may be compared against the profile for known markers for ovarian cancer, such as those disclosed herein

20 (see Table 1).

Using the gene expression profile, an ovarian tumor from a subject may be classified into a *BRCA1*-like, *BRCA2*-like, or non-*BRCA*-like tumor. Because the prognosis for a patient having a *BRCA1* or *BRCA2* mutation is poorer than for patient having non-*BRCA*-like mutations, classification of tumors into these groups is helpful in selecting treatment strategies and aids a 25 clinician in deciding whether to employ a more aggressive regimen in treating the patient, for instance radiotherapy, chemotherapy, or surgical removal of the affected tissue. In addition, classification of a sporadic tumor into a *BRCA1*-like or *BRCA2*-like classification may provide similar guidance in treating the patient. For example, a subject who has a *BRCA1*-like or *BRCA2*-like sporadic tumor may be treated similarly to a subject who has a *BRCA1*-linked or *BRCA2*-linked 30 tumor. The identification of *BRCA1*- or *BRCA2*-like sporadic tumors also allows tumors (or subjects) to be selected for specific drug regimens that are particularly effective with the associated mutation type.

35 The ovarian cancer-linked markers disclosed herein are believed to be useful as diagnostic or prognostic indicators of *BRCA1*-like, *BRCA2*-like and non-*BRCA*-like ovarian cancer. In addition, the markers are believed to be useful in applications for treating ovarian cancer as the basis of new therapeutic targets, for the development of new anti-cancer therapeutic compounds, and/or to select particularly appropriate existing treatments. For example, the expression levels of these markers can be examined to monitor the effectiveness of anti-cancer treatments where an increase in or decreased level of nucleic acid expression opposite of the ovarian cancer-indicative pattern disclosed herein

indicates an effective anti-cancer treatment. Beyond use in generating an expression profile, certain of the identified genes or EST sequences provided herein are believed to have individual use as cancer markers.

5 A. *Generating gene expression information and logarithmic expression ratios.*

cDNA microanalysis allows for simultaneous analysis of the expression of multiple genes within various tissue samples, and is therefore useful in generating gene expression profiles. To perform cDNA microarray analysis, RNA is isolated from a subject and cDNA is synthesized from the RNA according to standard methods (see Sambrook *et al.*, *Molecular cloning, a laboratory manual*. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Relative over-expression of the mRNA in the cancerous tissues can be measured against non-cancerous reference baselines (e.g., ovarian tissue from a subject not having ovarian cancer or an ovarian cell line, such as an immortalized ovarian cell line), to provide a framework for determining normal expression versus altered expression (genes that are either overexpressed or underexpressed).
10 Nucleic acids that are overexpressed may be used as markers for ovarian cancer, while genes that are underexpressed may be putative tumor suppressors.

CDNA microarrays containing 7,651 sequence-verified features were constructed and applied to analyze the mRNA expression profile of sixty-one subjects with pathologically-confirmed epithelial ovarian adenocarcinoma having matched clinicopathologic features (see Alizadeh *et al.*, *Nature* 403: 503-511, 2000; Perou *et al.*, *Nature* 406: 747-752, 2000; Bubendorf *et al.*, *J Natl. Cancer Inst.*, 91(20): 1758-64, 1999; Welsh *et al.*, *Proc Natl Acad Sci. U S A* 98: 1176-1181, 2001). These included eighteen cases linked to *BRCA1* founder mutations, sixteen cases linked to *BRCA2* founder mutations, and 27 cases negative for any founder mutations (e.g., sporadic ovarian epithelial cancer). These samples were compared to expression levels of these same features in an immortalized normal ovarian surface epithelium cell line (IOSE). Statistical tools, including a modified F-test with P<0.0001 considered significant (e.g., a 99.99% confidence level) were then used to analyze the data (e.g., to differentiate gene expression profiles associated with ovarian cancer), enabling a comprehensive, genomics-based analysis of the mRNA expression profiles of these ovarian cancer subjects.
20 25

30 The logarithmic expression ratios for the spots on each array were normalized by subtracting the median log ratio for the same array. Data were filtered to exclude spots with size less than 25 μ m, intensity less than two times background or less than 300 units in both red and green channels, and any flagged or missing spots. In addition, any features found to be missing or flagged in greater than 10% of the arrays were not included in the analysis. Application of these filters resulted in the inclusion of 6,445 of the total 7,651 features in subsequent analyses. Statistical comparison between tumors groups was performed using the "BRB Array Tools" software (developed by Dr. Richard Simon and Amy Peng, Biometrics Research Branch, Division of Cancer Treatment and Diagnosis, NCI, USA), consisting of a modified F-test with P < 0.0001 (99.99% confidence level) considered significant (see Example 4). This stringent P value is selected in lieu of the Bonferroni correction for
35

multiple comparisons, which was deemed excessively restrictive (see Bland and Altman, *B.M.J.*; 310: 170, 1995). See Example 4 for an example of how an ovarian tumor is analyzed using the disclosed methods.

In addition to statistical analysis, multidimensional scaling (MDS) and hierarchical clustering techniques using a correlation metric and average linkage were used for evaluating overall gene expression. Using these techniques, a large set of genes and other encoding sequences (e.g., expressed sequence tags, ESTs) have been identified (Table 1), the expression of which varies in subjects having ovarian cancer (see Addendum). Other confidence levels could be used to select ovarian cancer-related molecules, such as 98%, 95%, 90%, 85%, and so forth (see Jain *et al.*, *IEEE Transactions on Pattern Analysis and Machine Intelligence* 22(1): 4-37, 2000). Molecules identified as being linked to ovarian cancer (referred to generally herein as ovarian cancer-related molecules) using the methods described herein can be arranged on arrays for use in diagnostic and prognostic methods. Specific arrays are contemplated that are constructed using molecules identified at differing confidence levels. Specific examples of such arrays include arrays that detect altered expression of at least 2, 5, 10, 20, 30, or 50 of these molecules.

B. Comparison of ovarian epithelial adenocarcinoma cells to immortalized ovarian surface epithelium cells.

In a comparison of ovarian epithelial adenocarcinoma cells to immortalized ovarian surface epithelium cells, the largest contrast in gene expression was observed between *BRCA1*- and *BRCA2*-linked tumors, with multiple genes showing significant differences in expression levels. This group of genes was also able to segregate the sporadic tumors into two major "*BRCA1*-like" and "*BRCA2*-like" subgroups, indicating that *BRCA*-related pathways are also involved in sporadic ovarian cancers. In addition, two previously unreported gene expression patterns were noted. First, six of the genes differentially expressed between *BRCA1*-linked and sporadic tumors map to Xp11.23 and all exhibited higher mean expression levels in the *BRCA1*-linked samples [*WAS* (SEQ ID NO: 524-526), *EBP* (SEQ ID NO: 529), *SMCIL1* (SEQ ID NO: 529), *PCTK1* (SEQ ID NO: 527-528), *ARAF1* (SEQ ID NO: 531-532), and *UBE1* (SEQ ID NO: 533), see Figure 3]. Second, compared to immortalized ovarian surface epithelium cells, several interferon-inducible genes were noted to be overexpressed in the majority of all tumor samples [*SIAT1* (SEQ ID NO: 73), *TNFSF10* (SEQ ID NO: 104-106), *ABCB1* (SEQ ID NO: 164-166), *CP* (SEQ ID NO: 83-84), *HLA-DRB5* (SEQ ID NO: 85-86), *HLA-DRB1* (SEQ ID NOS: 87-88, 100, 101-103), *CD74* (SEQ ID NO: 92-93), *HLA-DRA* (SEQ ID NO: 94-96), *HLA-DPA* (SEQ ID NO: 97-99), *IFITM1* (SEQ ID NOS: 50-51, 52-54), *IFITM2* (55-57, 58-59), *A2M* (SEQ ID NO: 193-195), *GIP3* (68-69), *IGKC* (SEQ ID NOS: 112-114, 115-116), *SCYB10* (SEQ ID NO: 120-121), *Col3A1* (SEQ ID NO: 141-143), *HLA-B* (SEQ ID NO: 154-156), and *HLA-C* (SEQ ID NO: 157-159), see Figure 4]. In terms of overall differential gene expression, *BRCA1* and *BRCA2*-linked tumors express genes more different from each other than from sporadic (non-*BRCA*-linked) tumor samples.

The identified ovarian cancer-related genes represent putative mediators of ovarian cancer, and as such are candidate targets for the development of novel therapeutics for the treatment of ovarian cancer using conventional techniques. By way of example, a candidate drug, targeted at restoring expression of a gene of the disclosure, could be examined using cDNA microarray analysis 5 for utility in influencing growth of ovarian cancer cells. Thus, use of cDNA microarray techniques for genomics-based discovery of genes variably expressed during ovarian cancer provides for the identification of novel therapeutic targets for treatment of ovarian cancer.

It is contemplated that certain of the ovarian cancer markers identified herein encode or correspond to soluble proteins, while others encode or correspond to membrane associated or 10 membrane integral proteins, some of which are exposed at least to a certain extent on the exterior of a cell in which they are expressed. In some embodiments, those ovarian cancer-related molecules that are expressed at or on the surface of a cell are selected as therapeutic targets, for instance for targeting with an antibody-based therapy, which is facilitated by the access of the ovarian cancer-related molecule to the extracellular matrix. These ovarian cancer markers may be described as being 15 "drug accessible." In addition, such soluble ovarian cancer markers, if secreted, may be detected in a blood or serum sample from the subject.

C. Comparison of ovarian epithelial cancer cells to normal postmenopausal ovarian samples.

20 cDNA microarrays containing 7,600 sequence-verified features were constructed and applied to analyze the mRNA expression profile of 61 subjects with ovarian epithelial cancer as compared to two normal postmenopausal ovarian samples.

Gene expression in each sample (normal or tumor) was directly compared to a "reference 25 RNA" consisting of a mix of nine different human cell lines (breast adenocarcinoma, hepatoblastoma, cervical adenocarcinoma, testicular embryonal carcinoma, glioblastoma, melanoma, liposarcoma, histiocytic lymphoma, T cell lymphoblastic leukemia, and plasmacytoma/myeloma, Stratagene, La Jolla, CA). The raw gene expression data was used to calculate the logarithmic expression ratio for each gene. The logarithmic expression ratios ("log ratio") obtained from this comparison were then normalized and statistically compared to one another, providing for indirect comparison of gene 30 expression in tumors and normal ovarian samples. This was accomplished by scoring the magnitude of differential expression of each gene (between normal and cancer samples) according to the formula:

$$\frac{(\text{average cancer log ratio} - \text{average normal log ratio})}{(\text{standard deviation cancer} + \text{standard deviation normal})} = \text{magnitude of differential expression}$$

In genes showing a large mean expression difference between normal and cancerous samples, the magnitude of differential expression has a greater value, while the intra-group variability in expression ratios is low.

Genes were then ranked according to the magnitude of differential expression and the highest-ranking genes were considered to be the best candidates for differentiating normal from malignant ovarian samples (see Furey *et al.*, *Bioinformatics* 16(10): 906-14, 2000).

Using these techniques, a large set of genes and other encoding sequences (e.g., ESTs) that are under-expressed in subjects having ovarian cancer have been identified (see Table 4). These under-expressed ovarian cancer markers represent putative tumor suppressors, and as such are candidate targets for the development of novel therapeutics for the treatment of ovarian cancer using conventional techniques. By way of example, induction of expression of one or more of these markers through therapeutic means (e.g., induction by a drug or gene therapy) may inhibit tumor growth and/or increase tumor cell death, for instance through stimulation of apoptotic pathways.

Furthermore, a large set of genes and other encoding sequences (e.g., ESTs) have been identified (see Table 5), the expression of which is overexpressed in subjects having ovarian cancer. These overexpressed ovarian cancer markers represent putative mediators of ovarian cancer, and as such are candidate targets for the development of novel therapeutics for the treatment of ovarian cancer using conventional techniques. Over-expression of one or more such markers can also be detected in the body (for example using a serum test to detect or monitor progression of ovarian cancer).

In addition, six of the markers identified herein (e.g., *WAS* (SEQ ID NO: 524-526), *PCTK1* (SEQ ID NO: 527-528), *UBE1* (SEQ ID NO: 533), *SMCIL1* (SEQ ID NO: 529), *ARAF1* (SEQ ID NO: 531-532), and *EBP* (SEQ ID NO: 529)) have all been mapped to chromosome Xp11 (see Example 1). Hence, this chromosome could contain additional genes and ESTs that may be useful as markers for prognosing, diagnosing and monitoring ovarian cancer. The methods of the disclosure can be used to find additional genes and ESTs in this region for use as ovarian cancer markers.

25 **V. Methods of Classifying Tumors into Subgroups**

Disclosed herein are multiple methods of classifying tumors into subtypes based upon the expression of disclosed ovarian tumor markers (see Table 1).

30 **A. Comparison of raw expression data**

The expression data of one or more ovarian cancer markers can be compared between samples and analyzed to detect differences in expression between the markers. The expression of an individual marker can be stated in ratio or "fold" form relative to the expression of the standard. For instance, in Table 4, the average logarithmic ratio of the gene expression for the standard ("normal") for *ITM2A* (SEQ ID NO: 202) is 1.145, while the average logarithmic ratio of the gene expression in cancer cells was -2.036. These numbers can be compared to derive a value for the difference in expression by calculating the expression ratio of each number, and dividing the expression ratio for the average log cancer value by the expression ratio for the average log normal value. Hence:

Expression ratio of average log normal: $2^{1.145} = 2.211$

Expression ratio of average log cancer $2^{-2.036} = 0.244$

Ratio (cancer to normal) = $(0.244)/(2.211) = 0.110$

5 Thus, *ITM2A* is under-expressed in cancer by a ratio of 0.110 to 1 (i.e., in ovarian cancer tissue, *ITM2A* expresses at approximately 10% of the expression level seen in wild-type cells).

Collections of such data can be assembled to provide a gene expression profile, as discussed above. With such profiles, the standard deviation of the expression ratio of each gene can be
10 measured by obtaining the square root of the variance of the expression data as described by Jaccard and Becker (in *Statistics for the Behavioral Sciences*, 2nd ed., Wadsworth Publishing Co., Belmont, California, 1990) and Myers and Well. (in *Research Design and Statistical Analysis*, University of Massachusetts, Amherst, Massachusetts, 1995).

15 Further analysis can include a Student's t-test, to determine if the mean expression of two groups (e.g., *BRCA1*-like and non-*BRCA*-like, *BRCA2*-like and non-*BRCA*-like, etc.) are statistically different from each other.

20 Due to the range over which genes may express, it may be useful to perform statistical analyses using the logarithmic expression value for each marker (see Example 1). However, calculations using the logarithmic expression values may dilute the ability of certain analyses to determine differences. Hence, it may be useful to employ multiple methods of analysis to ascertain relative values in expression (see Jain *et al.*, *IEEE Transactions on Pattern Analysis and Machine Intelligence* 22(1): 4-37, 2000).

B. Visual analysis of hierarchical clustering

25 Methods disclosed herein include hierarchical clustering analysis of genes with statistically significant differential expression between sets of tumor groups. Hierarchical clustering can be used to cluster objects (e.g., genes, such as the ovarian cancer markers listed in Table 1) to represent relationships among the objects. The relationships are represented, for example by a tree whose branch lengths reflect the degree of similarity between the objects (see e.g., Figure 2B).

30 Optionally, hierarchical clustering can be combined with a graphical representation of the primary data by representing each data point with a color that quantitatively and qualitatively reflects the original experimental observations. The use of color representations, along with statistical organization, provides a graphical display that provides visual information about expression of the genes. Hence, the methods disclosed herein can provide visual information regarding degrees of similarity (e.g., patterns of under-expression or over-expression) between assessed genes in different samples, for instance in samples of *BRCA1*-linked, *BRCA2*-linked and sporadic ovarian tumor samples (see Figure 2B).

At the first iteration, each object is considered to be its own group, and the pair of objects with the smallest distance between them is merged into a new group. Each subsequent iteration

merges two groups to form a new group, until finally all objects end up merged into a single group. The classification tree, or dendrogram, graphically represents the sequence of clusters formed at each iteration of merges, as well as the distance between clusters at each merge (here, Figure 2). This technique is widely employed to represent gene expression information obtained from microarray 5 experiments (see Eisen *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95(25): 14863-8, 1998).

The gene expression data disclosed herein were analyzed by calculating the Pearson correlation coefficient to obtain a gene expression similarity metric. To describe, G_i is (log-transformed) primary gene expression data for gene G in each tumor sample, represented as variable i . For any two genes X and Y observed over a series of N tumor samples, a similarity score can be 10 computed as follows:

$$S(X, Y) = \frac{1}{N} \sum_{i=1,N} \left(\frac{X_i - X_{\text{offset}}}{\Phi_X} \right) \left(\frac{Y_i - Y_{\text{offset}}}{\Phi_Y} \right)$$

where

$$\Phi_G = \sqrt{\sum_{i=1,N} \frac{(G_i - G_{\text{offset}})^2}{N}}.$$

When G_{offset} is set to the mean of the gene expression levels of the tumor samples for gene G , then Φ_G becomes the standard deviation of G , and $S(X, Y)$ is exactly equal to the Pearson correlation 15 coefficient of the gene expression levels for genes X and Y . Values of G_{offset} that are not the average of the gene expression levels for gene G are used when there is an assumed unchanged or reference state (e.g., the gene is not over-expressed or under-expressed) represented by the value of G_{offset} against which changes are to be analyzed; in all of the examples presented here, G_{offset} is set to 0, corresponding to a fluorescence ratio of 1.0.

20 By way of example, Figures 2A and 2A' demonstrate that expression of the disclosed markers can be used to visualize different tumor types. Hierarchical clustering was performed using with a Pearson correlation metric and average linkage were used for evaluating overall gene expression for the sixty-one *BRCA1*-linked, *BRCA2*-linked and sporadic tumors (see Example 1). When applicable, all statistical tests were two-sided.

25 In Figure 2, B2 represents *BRCA2*-linked tumors, and B1 represents *BRCA1*-linked tumors. The red and green intensities represent standard normal deviation (Z score) values from each marker's means expression level (represented as black) across the sixty-one tumors samples. Red represents increased expression and green represents decreased expression. The differences in gene expression can be appreciated by looking at the groupings apparent in Figure 2A. The genes in the 30 left half of the Figure 2A are from *BRCA2*-linked tumors and the genes in the right half are from *BRCA1*-linked tumors. As can be seen with casual observation, gene expression between these two tumor groups differs relative to the control (IOSE cells). Specifically, *BRCA2*-linked tumors contain under-expressing genes that correlate to these genes in the upper left and lower right quadrants of

Figure 2A, which are represented as primarily green in color. Furthermore, the genes in the upper right and lower left quadrant, which are represented as primarily red in color, correlate to genes that are generally over-expressed relative to the control IOSE cells. Hence, hierarchical clustering can be used to qualitatively visualize differences in the expression patterns of samples.

5

C. *Multidimensional Scaling*

Multidimensional scaling is a dimension reduction procedure that can be used for visualization purposes. Each experiment can be represented by its expression profile, which is a K-dimensional vector of log-ratios, where K is the number of clones represented after filtering. The 10 multidimensional scaling procedure reduces each experiment's expression profile from K-dimensional space to 3-dimensional space, by attempting to preserve distances between the N experiment vectors. The distance metric needs to be specified when using the multidimensional scaling tool. First, the $N \times N$ distance matrix is computed, which quantifies the relationships between the N experiments in the series of chips. For each of the N vectors in K-dimensional space, the 15 multidimensional scaling procedure finds a vector in 3-dimensional space, such that the $N \times N$ distance matrix computed in 3-dimensional space approximates the $N \times N$ distance matrix computed in K-dimensional space. The relationships between the N experiments can then be visualized by plotting the N vectors in 3-dimensional space, in which each of the N points represents a single experiment. A rotating 3-dimensional visualization tool can be used for discovery of experiment 20 clusters.

By way of example, the gene expression data of 6445 filtered genetic elements of the sixty-one ovarian tumor samples (see Example 1) was used in multidimensional scaling to generate a 3-D diagram for visualization of the respective differences between the expression patterns of each tumor sample. As seen in Figure 1, the data segregate into different areas of the 3-D space based on 25 similarities in gene expression within the tumor type. In particular, the *BRCA1*-linked tumors (dark circles) segregate higher into the cube than the *BRCA2*-linked tumors (open circles). The sporadic tumor samples (asterisks) also fell into higher and lower areas of the cube, indicating that they segregate into *BRCA1*-type and *BRCA2*-type expression patterns. Thus, multidimensional scaling can be used to make a qualitative distinction regarding the expression patterns of these samples.

30 Multidimensional scaling can be used to qualitatively assess the expression pattern of an unknown tumor type. Expression data for a plurality of *BRCA1*-type and *BRCA2*-type markers is generated using the tumor tissue (for instance, on a cDNA microarray) relative to a standard ovarian tissue (e.g., from a subject not having ovarian cancer, immortalized ovarian epithelial cells, etc.), and logarithmic ratios of the gene expression data are calculated. To compare the pattern of expression of 35 the plurality of the known *BRCA1*-type and *BRCA2*-type markers to the unknown ovarian sample, the K-dimensional vectors of the logarithmic expression ratios for all expression data are calculated as discussed above. Next, the K-dimensional vectors are plotted in a 3-dimensional space and the layout of the data compared. Similar to Figure 1, the unknown sample data should cluster either near the *BRCA1*-like or *BRCA2*-like tumors, or alone (which would indicate that it is a non-BRCA-like

tumor). Hence, multidimensional scaling can be used to make a qualitative distinction regarding the expression patterns of an unknown samples in comparison to known *BRCA1*-type and *BRCA2*-type markers. In addition, more than one unknown sample can be used in this analysis.

5 **D. Compound Covariate Predictor Analysis**

Segregation into tumor types can be performed using compound covariate predictor analysis, which creates a multivariate predictor for one of two classes to each sample (see Example 4). Markers included in the multivariate predictor are those that are univariately significant at the selected significance cutoff (e.g., $P < 0.0005$). The multivariate predictor is a weighted linear 10 combination of log-ratios (or log intensities for single-channel arrays) for genes that are univariately significant. The weight consists of the univariate t-statistics for comparing the classes, and is calculated using the equation:

$$CCP = \Phi_i t_i * (x_i - m_i)$$

15 where t_i = t-value for gene i (see Table 10), x_i = logarithmic ratio of the gene expression (i) in the new sample to be classified, and m_i = midpoint between the two classes for gene i (see Table 10). The index i runs over all the genes that are significant in the original analysis (i.e. all 62 genes in Table 10). If the log ratio x_i is missing for gene i in the new sample to be classified, then it should be 20 assigned as m_i for that gene, to cause the result of the calculation to be zero for that gene. If the compound covariate predictor value is positive, then the tumor classified as one of the first type (e.g., *BRCA1*-like). If the compound covariate predictor value is negative, then the tumor is classified as belonging to the second type (e.g., *BRCA2*-like).

25 A second method of tumor classification using a compound covariate predictor model can be found in Radmacher *et al.*, "A paradigm for class prediction using gene expression profiles," found on the National Cancer Institute Internet website. This publication is expressly incorporated by reference herein.

In order to determine whether a tumor is classified as *BRCA1*-like or *BRCA2*-like using a single markers in Table 10, the following steps are used:

30 1. Gene expression information is obtained, for instance on a cDNA microarray, using the same standard (e.g., IOSE cells) that was used to obtain the marker data.

2. The gene expression data is converted into a logarithmic ratio using log base 10. Hence, a tumor that has a gene expression value for gene *KIAA00008* of 0.45 would have a log base 35 10 ratio of -0.346.

3. The midpoint value of Table 10 is subtracted from the logarithmic ratio, and multiplied by the t-value for *KIAA00008* for the data set. Thus,
[(-0.346) - (-.431)] * (-8.0421) = -0.51.

The values for the average logarithmic ratio for *BRCA1*-linked and *BRCA2*-linked values in the data set are then consulted. The obtained value will fall between the midpoint and one of these values because genes in which larger values of the logarithmic ratio are assigned to one class (e.g., *BRCA1*-linked) will have weights of a value that is more negative with respect to the midpoint value (e.g., -0.56864), whereas genes in which larger values of the logarithmic ratios are assigned to the other class (e.g., *BRCA2*-linked) will have weights of a value that is more positive with respect to the midpoint value (e.g., -0.29414). Hence, the obtained value, 0.1930, would fall on the more negative side of this data, and would therefore be classified as a *BRCA2*-like data set.

If this same analysis is performed using multiple markers, the method remains the same except that the data can be summed prior to performing the analysis. This method is a multivariate approach of the compound covariate analysis, and can be used to determine whether the pattern of expression of an unknown tumor is similar to a *BRCA1*-like or *BRCA2*-like pattern of expression.

Further analysis, such as a "leave-one-out" approach may additionally be employed to test the ability of the Compound Covariate Predictor to classify the tumors into additional subtypes, such as resistance to a therapeutic compound. See Radmacher *et al.*, "A paradigm for class prediction using gene expression profiles," found on the National Cancer Institute Internet website.

E. Comparisons using Databases

Due to the large amount of information associated with the analysis methods disclosed herein, it may be particularly useful to construct and/or consult databases of information for use in the analysis.

By way of example, the information generated by the methods of the disclosure can be stored in databases, such as a database of a plurality of markers known to express differently in *BRCA1*-like and *BRCA2*-like tumors (e.g., Table 9). Such databases may be made publicly available, such as the Stanford Microarray Database (maintained by Stanford University, see Sherlock *et al.*, *Nucleic Acids Res.*, 29(1):152-155, 2001). These databases may be used to store reference data for use with the classification methods of the disclosure. In addition, such databases can be used to provide information regarding markers of potential use in diagnosing, prognosing, or monitoring ovarian cancer, for use by clinicians.

The use of databases to search for stored information is disclosed in U.S. 5,871,697 and 6,519,583 the methods of which are expressly incorporated herein.

VI. Kits for measuring the level or function of ovarian cancer-related molecules.

The nucleic acid sequences and ESTs disclosed herein can be supplied in the form of a kit for use in detection or monitoring ovarian cancer. In such a kit, one or more of the nucleic acid sequences and/or ESTs in Table 1 are provided in one or more containers, or in the form of a microarray. The kit may also contain reagents for use in preparing a biological sample of a subject for screening with the kit. The container(s) in which the reagent(s) and microarray(s) are supplied can be any conventional container that is capable of holding the supplied form, for instance, plastic

boxes, microfuge tubes, ampoules, or bottles. In some applications, negative controls obtained from a subject free from ovarian cancer may be provided in pre-measured (e.g., single use) amounts in individual, typically disposable, tubes or equivalent containers. With such an arrangement, the sample to be tested for the presence of ovarian cancer can be added to the testing container and tested 5 directly.

The amount/number of each testing reagent and container supplied in the kit can be any appropriate amount, depending for instance on the market to which the product is directed. For instance, if the kit is adapted for research or clinical use, the amount of each testing reagent and container provided would likely be an amount sufficient to screen several biological samples. Those 10 of ordinary skill in the art know the amount of testing reagent that is appropriate for use in a single container. General guidelines may for instance be found in Innis *et al.* (*PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc., San Diego, CA, 1990), Sambrook *et al.* (*In Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, 1989), and Ausubel *et al.* (*In Current Protocols in Molecular Biology*, Greene Publ. Assoc. and Wiley-Intersciences, 1992).

15 A kit may include more than two nucleic acid sequences or ESTs, in order to facilitate screening of a larger number of ovarian cancer markers or tumor suppressors. For instance, the sequences set forth in Table 1, or a subset of (e.g., 5, 10, 15, 20, 50, 100, 150, 200, 250, 300, 350, 400 or more) of these sequences, may be provided. By way of example, a provided subset could include the markers set forth in Table 6, Table 7, Table 8, Table 9, or Table 10. These sets of sequences are 20 provided by way of example only, and are not intended to be limiting examples.

25 In some embodiments of the current disclosure, kits may also include the reagents necessary to carry out screening reactions, including, for instance, RNA sample preparation reagents, appropriate buffers (e.g., polymerase buffer), salts (e.g., magnesium chloride), and secondary detection reagents (e.g., cyanine 5-conjugated dUTP).

20 Kits may in addition include either labeled or unlabeled sequences for use in detection of the expression levels.

Embodiments of the disclosure are illustrated by the following non-limiting Examples.

EXAMPLE 1

30 **Identification of Genes with Altered Expression in Ovarian Cancer**

This example describes how a first subset of the disclosed ovarian cancer-related nucleic acid molecules were identified. These ovarian cancer-related molecules show differences in expression in subjects having ovarian cancer compared to normal ovarian surface epithelial cells and 35 are classified according to their *BRCA-1*, *BRCA-2*, and sporadic tumor status. The results of these studies have been published in Jazaeri *et al.*, *J. Natl. Cancer Inst.*, 94(13): 990-1000, 2002, which is incorporated by reference in its entirety herein.

Methods and Material:

Clinicopathologic characteristics of BRCA-linked and sporadic ovarian cancers: Sixty-one cases of pathologically-confirmed epithelial ovarian adenocarcinoma from the Memorial Sloan-Kettering Cancer Center were studied and screened for founder mutations. These included eighteen cases linked to *BRCA1*, sixteen cases linked to *BRCA2*, and twenty-seven sporadic cases. All patients were self-identified as Ashkenazi Jews and after informed consent underwent genotyping for germ-line founder mutations in *BRCA1* (185delAG and 5382insC) and *BRCA2* (6174delT) (see Boyd *et al.*, *JAMA*: 283: 2260-2265, 2000). Those cases with a *BRCA* mutation were categorized as having hereditary ovarian cancer and those without such a mutation as having sporadic ovarian cancer.

10 *Tumor samples:* In order to minimize confounding variables, *BRCA1*-linked, *BRCA2*-linked, and sporadic tumors of similar stage, grade, and histology were selected from the sixty-one individuals studied [18 *BRCA1* (185delAG, 5382insC), 16 *BRCA2* (6174delT), 27 sporadic tumors]. The majority of tumors in all three groups were characterized by advanced stage, moderate to high grade (grade 2 or 3), and a predominance of serous histology. Hence, the clinicopathologic 15 parameters of selected samples were well-matched and in agreement with those reported previously for these tumor types (see Boyd *et al.*, *JAMA*: 283: 2260-2265, 2000; Ramus *et al.*, *Genes Chrom. Cancer*: 25: 91-96, 1999).

20 All tumor samples had been flash frozen, embedded in OCT medium, and stored at -80° C. Isolation of RNA was performed using the RNeasy columns (Qiagen, Valencia, CA) according to the manufacturer's instructions. The integrity of RNA was verified by denaturing gel electrophoresis. Total RNA was linearly amplified using a modification of the Eberwine method (see Van Gelder *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87: 1663-1667, 1990). Table 2 catalogs the clinicopathologic features of the tumor samples studied.

Table 2. Clinicopathologic features of tumor samples			
Variable	BRCA1-linked	BRCA2-linked	Sporadic
Number of samples	18	16	27
Median Age* (SD)	50 (11)	60 (9)	69 (11)
Stage			
I	2 (11.1%)	0	0
II	0	2 (12.5%)	3 (11.1%)
III	11 (61.1%)	12 (75%)	24 (88.9%)
IV	5 (27.8 %)	2 (12.5%)	0
Grade			
1	0	0	0
2	4 (22.2%)	6 (37.5 %)	8 (29.6%)
3	14 (77.8%)	7 (43.8%)	16 (59.3%)
No.	0	3 (18.7%)	3 (11.1%)
Histology**			
Serous	9 (50%)	12 (75%)	16 (59.3%)
Endometrioid	3 (16.7%)	0	2 (7.4%)
Mucinous	0	0	0
Clear Cell	2 (11.1%)	0	0
Adenocarcinoma NOS	3 (16.7%)	3 (18.8%)	9 (33.3%)
other	1 (5.5%)	1 (6.2%)	0

* F test, P = .0002/ Data are the median +/- standard deviation.
 ** Chi test P value for differences in histology among tumor groups= 0.17
 NOS = not otherwise specified

cDNA Microarrays: The cDNA microarrays consisted of 7,651 total features representing different (non-redundant) genes, and were manufactured at the National Cancer Institute microarray facility.

5 Total RNA was reverse-transcribed by using a 63 nucleotide synthetic primer containing the T7 RNA polymerase binding site (5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCCGG(T)₂₄-3' (SEQ ID NO: 1). Second strand cDNA synthesis (producing double-stranded cDNA) was performed with RNase H, *Escherichia coli* DNA polymerase I, and *E. coli* DNA ligase (Invitrogen, Carlsbad, CA). After 10 cDNA was blunt-ended with T4 DNA polymerase (Invitrogen, Carlsbad, CA), it was purified by extraction with a mixture of phenol, chloroform, and isoamyl alcohol and by precipitation in the presence of ammonium acetate and ethanol. The double-stranded cDNA was then transcribed using T7 polymerase (T7 Megascript Kit, Ambion, Austin, TX), yielding amplified antisense RNA that was purified using RNeasy mini-columns (Qiagen, Valencia, CA). Pooled total RNA from two SV40 15 immortalized ovarian surface epithelial cell-lines (IOSE) was amplified and used as reference for cDNA microarray analysis.

Four μ g of amplified RNA was reverse transcribed and directly labeled using cyanine 5-conjugated dUTP (tumor RNA) or cyanine 3-conjugated dUTP (IOSE RNA, provided by Dr. Jeff Boyd, Memorial Sloan-Kettering). Hybridization was performed in a solution of 5X SSC and 25%

formamide for 14-16 hours at 42°C. Slides were washed, dried, and scanned using an Axon 4000a laser scanner (Axon Instruments, Inc., Union City, CA).

5 *Imaging and I.M.A.G.E. Analysis:* Fluorescence intensities at the immobilized targets were measured by using an Axon GenePix Scanner and Genepix Pro 3.0 analysis software (Axon Instruments, Union City, CA). The raw data were then uploaded to a relational database maintained by the Center for Information Technology at the National Institutes of Health. The cDNA clones are identified by their Integrated Molecular Analysis of Genomes and their Expression Consortium (I.M.A.G.E.) clone number.

10 *Amplification of RNA:* The first strand of RNA was synthesized, by adding 1-3 µg of total RNA into a reaction tube (e.g., Eppendorf, or other container of suitable size), adding 1 µl T7-(dT)₂₄ primer (2 µg/µl), and bringing to a volume of 20 µl with nuclease-free water. The reaction was incubated at 70°C for 10 minutes, then spun briefly in a centrifuge and placed on ice. Four µl 5X first strand cDNA buffer was added, then 2 µl 0.1M DTT, 2 µl 10mM dNTP mix (Amersham-Pharmacia, Piscataway, NJ 08855-1327 USA), 1 µl RNasin (Promega, Madison, WI 53711 USA), and 2 µl 15 Superscript II. The reaction was mixed well and incubated at 42°C for 1 hour. The tube was centrifuged briefly, and placed on ice. To synthesize the second strand, 91 µl DEPC-treated water was added, then 30 µl second strand buffer, 3 µl 10 mM dNTP mix, 4 µl DNA Polymerase I (10U/µl), 1 µl DNA Ligase (10U/µl), and 1 µl RNase H (2U/µl). The final reaction volume equaled 150 µl. Next, the tube was gently tapped to mix, then briefly centrifuged. The tube was incubated at 20 16°C for two hours, then 2 µl (10U) T4 DNA Polymerase was added. The tube was cooled for five minutes at 16°C, then the reaction stopped with 10 µl of 0.5 M EDTA. Ten µl of 1M NaOH were added, then the reaction was incubated at 65°C for 10 minutes. The solution was neutralized by addition of 25 µl Tris-HCl (pH=7.5).

25 *Clean Up of Double Stranded cDNA:* The Phase Lock Gel (PLG) was pelleted in a microcentrifuge at maximum speed for 30 seconds. 198 µl (equal volume) of (25:24:1) Phenol : chloroform : isoamyl alcohol (saturated with 10 mM Tris-HCl pH 8.0/1 mM EDTA) was added to the final DNA synthesis preparation (198 µl) to a final volume of 396 µl. The solution was mixed well by pipetting up & down vigorously. The entire cDNA-phenol/chloroform mixture was transferred to the PLG tube, and microcentrifuged at maximum speed for two minutes. The aqueous supernatant was 30 transferred to a new 1.5 ml tube, and 1 µl linear acrylamide was added. 0.5 volumes of 7.5M Ammonium Acetate + 2.5 volumes (include the added Ammonium Acetate) of 95% ethanol stored at -20 to the sample was added and the solution was vortexed, then centrifuged at maximum speed in a microcentrifuge at room temperature for 20 minutes. The supernatant was removed and the pellet was washed with 0.5 ml of 80% ethanol. The solution was centrifuged at maximum speed for 5 35 minutes at room temperature. The 80% ethanol was poured off, and the 80% ethanol wash repeated. The pellet was air dried for approximately 15 minutes, then resuspended in 16 µl of nuclease-free water.

In Vitro Transcription: Using an Ambion T7 Megascript kit (Ambion, Austin, TX 78744-1832, USA), the manufacturer's instructions were followed to create a 40 µl reaction (i.e., the 20 µl

standard reaction was doubled and incubated at 37°C for 4-5 hours). The reaction was assembled at room temperature using 16 µl of template double-stranded DNA, to avoid the precipitation of spermidine, which can occur if done on ice. Four µl of 10x reaction buffer were added, then 4 µl of ATP solution (75mM T7), 4 µl of CTP solution (75mM T7), 4 µl of GTP solution (75mM T7), 4 µl of UTP solution (75mM T7), 4 µl of Enzyme Mix, and the reaction was incubated at 37°C for 5-6 hours. Sixty µl nuclease-free water was added to bring the total volume up to 100 µl. The RNA was "cleaned" using the "RNA clean-up" protocol provided in the Qiagen RNeasy Mini Handbook, May 1999, pp. 48-49, Qiagen, Valencia CA. RNA was eluted with 30 µl of nuclease-free water, and the optical density ratio was measured (the sample should have an optical density of greater than 1.8 when measured at 260/280 nanometers). The expected yield from this preparation was ten times the starting amount of total RNA, and the RNA was then ready for use in generating probe for microarrays using total RNA (see below).

Second Round Amplifications: 0.5-1.0 µg of amplified RNA were resuspended in 11 µl ultrapure water.

15 First Strand Synthesis: One µl Random hexamer (1 mg/ml) was added and the reaction was incubated at 70°C for 10 minutes, then chilled on ice, then allowed to equilibrate at room temperature for 10 minutes. Four µl 5X First strand cDNA buffer, 2 µl 0.1M DTT, 2 µl 10mM dNTP mix, 1µl RNasin were added, and the reaction was mixed incubated at 42°C for 2 minutes. Two µl Superscript II were added, and the reaction was mixed well and incubated at 42°C for 1 hour.

20 One µl RNase H was added, and the reaction was incubated at 37°C for 20 minutes, then heated to 95°C for 2 minutes to quell the reaction, then chilled on ice.

25 Second Strand Synthesis: One µl T7-oligodT primer (0.5 mg/ml) was added, and the reaction was incubated at 70°C for 5 minutes and at 42°C for 10 minutes. Then, 91 µl DEPC treated H₂O were added, then 30 µl Second strand buffer, 3 µl 10 mM dNTP mix, 4 µl DNA Polymerase I (10U/ µl), 1 µl DNA Ligase (10U/µl), and 1 µl RNase H (2U/µl) to a final volume of 150 µl. The tube was tapped gently to mix, then briefly centrifuged. The reaction was incubated at 16°C for two hours, then 2 µl (10U) T4 DNA Polymerase were added, and the reaction was cooled for 5 minutes at 16°C. The reaction was stopped with 10 µl of 0.5 M EDTA, then 10 µl of 1M NaOH were added. The reaction was incubated at 65°C for 10 minutes, then neutralized by addition of a 30 solution with 25 µl Tris-HCl (pH=7.5). The protocol for "Clean Up of Double Stranded cDNA" and "In Vitro Transcription" was followed to generate cDNA for use in preparation of the probe for microarray hybridization.

35 *Preparation of Probe and Microarray Hybridization Using Amplified RNA:* To prepare the probe, reverse transcription labeling reaction mixes were created for each probe containing the component Random Primer (InVitrogen, Carlsbad, California 92008, USA). Three µg/µl in 2µl were added, then 5-6 µg amplified RNA. The reaction was brought to a final volume of 17 µl with water, then incubated at room temp for 10 minutes. To each probe, 5X first strand buffer in 8 µl, 20X lowT-dNTP mix in 2 µl, 0.1 M DTT in 4 µl, RNasin in 1 µl, Cy-3 or Cy-5 dUTP (NEN Life Science, Boston, MA 02118-2512 USA) in 4 µl, and SuperScriptII (GIBCO-BRL, InVitrogen Corporation,

Carlsbad, California 92008 USA) enzyme in 2 μ l was added. The reaction was incubated at 42°C for 60 minutes, then 5 μ l of 500 mM EDTA and 10 μ l of 1M NaOH were added. The reaction was incubated at 65°C for 15 minutes to hydrolyze residual RNA, then cooled to room temperature. Twenty-five 25 μ l of 1 M Tris-HCl (pH7.5) was added to neutralize pH.

5 *Probe Cleanup:* 500 μ l of 1X TE were added to a Microcon-YM30 column and the column was spun at 13,000 rpm for 5-6 minutes to wash the column. Membrane integrity was checked by looking into the top insert, to confirm that a thin film of TE (~50 μ l) covered the membrane. 400 μ l 1X TE was added to each of the sample tubes and all contents were transferred to the washed Microcon-YM30 column (Amicon, Millipore Corp., Bedford, Massachusetts). The column was spun 10 at 13,000 rpm for 5-6 minutes until approximately 50 μ l was left on the membrane. The column was checked for dye crystals along the edge of the column membrane, which indicated that the probe was likely to be good. 450 μ l 1X TE were added to the column and the column was spun down to ~50 μ l as above. The presence of crystals was confirmed. The Cy-3 labeled probe was placed into a clean tube, and the column was spun at 14,000 rpm for 1 minute to elute the probe. The Cy-3 labeled probe 15 was added to the Cy-5 labeled probe in the column, and approximately 450 μ l 1X TE was added to the column. The column was spun at 13,000 rpm until approximately 13-14 μ l of combined probe remained on the membrane, which was checked with a pipette. The combined probe was inverted into a clean tube, and spun at 14,000 for 1 minute to elute. The probe (14 μ l) was transferred into a clean Eppendorf tube and stored at 4 °C until used in the hybridization reaction.

20 *Probe Hybridization:* Twenty μ l of water were added to each humidifying well in the Hybridization Chamber (to maintain humidity). Then, 40 μ l of prehybridization buffer (5X SSC, 0.1% SDS, 1% BSA (Sigma) warmed to 42°C) were placed in the center of the slide and the cover slip was placed on the slide, taking care to prevent bubble accumulation beneath the slip. The margin clamps on the Hybridization Chamber were firmly attached, and the chamber was incubated at 42°C 25 for least 1 hour. The slide was washed in distilled water for 2 minutes, followed by isopropanol for 2 minutes. The slide was dried in a centrifuge (5804R, Eppendorf) at 705 rpm (~70x g) for 4 minutes, then prepared for hybridization as discussed above. The slide was hybridized within 1 hour of the prehybridization step. Two 2 μ l COT1-DNA (Hoffman La Roche, Nutley, New Jersey 07110 USA) (1 μ g/ μ l), 2 μ l polyA (Sigma) (8-10 μ g/ μ l), and 2 μ l yeast tRNA (Sigma, Ronkonkoma, NY 11779 30 USA) (4 μ g/ μ l) were mixed with the probe. Then, the probe was denatured for 1 minute at 100°C, placed briefly on ice to cool the reaction, and spun down in a centrifuge. Twenty μ l of 2X hybridization buffer (50% formamide, 10X SSC, 0.2% SDS, warmed to 42°C) were added to the denatured probe, mixed well (taking care to minimize bubble formation) and kept at 42°C until ready to spot on the slide. The hybridization chamber was prepared as in the prehybridization step with 35 20 μ l of distilled water in each well. The slides were placed face-up in the chambers, and the probe was hybridized with the slide for 14-16 hrs at 42°C.

Slide Washes: The margin clamps on the Hybridization Chamber were carefully removed to prevent water from seeping in and contaminating the array. The slide was removed from the chamber, held with forceps and the cover slip allowed to fall off into the solution containing 2X SSC,

0.1% SDS. The slide was washed for 4 minutes in 1X SSC, 0.1% SDS, for 4 minutes in 0.2X SSC, and for 1 minute in 0.05X SSC. The slide was spun dry in a centrifuge at 705 rpm (approximately 70x g) for 4 minutes. If water droplets were seen on the slide, it was spin again for another 4 minutes. Exposure to light was minimized by placing the dried slides in a slide box until ready for scanning.

5 *Statistical Analysis:* The logarithmic expression ratios for the spots on each array were normalized by subtracting the median logarithmic ratio for the same array. Data were filtered to exclude spots with size less than 25 μ m, intensity less than 2 times background or less than 300 units in both red and green channels, and any poor-quality or missing spots. In addition, any features found to be missing or flagged in greater than 10% of the arrays were not included in the analysis.

10 Application of these filters resulted in the inclusion of 6,445 of the total 7,651 features in subsequent analyses. Statistical comparison between tumors groups was performed using the "BRB Array Tools" software (developed by Dr. Richard Simon and Amy Peng, Biometrics Research Branch, Division of Cancer Treatment and Diagnosis, NCI, USA). A modified F-test is run on each gene's

15 log-ratio values, and the significance of that gene is determined with $P < 0.0001$ considered significant. This stringent P value is selected in lieu of the Bonferroni correction for multiple comparisons, which was deemed excessively restrictive (Figure 1) (see Bland and Altman, *B.M.J.*; 310: 170, 1995).

20 *Semi-quantitative PCR:* Five samples from each tumor group (*BRCA-1*, *BRCA-2*, sporadic) were selected at random. For each sample, 3.5 μ g of total RNA was reverse-transcribed using oligo dT primers and 400 units of Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA) in the presence of all four deoxyribonucleoside 5'-triphosphates (each at 10 mM) (InVitrogen, Carlsbad, CA) and 40 units of RNase inhibitor (Promega, Madison, WI). Reverse transcription was performed in a total reaction volume of 40 μ l, of which 1 μ l was subsequently used for each PCR reaction.

25 Preliminary experiments were performed to identify optimal cycle number for each gene. Thirty cycles was found to be optimal amplification for all amplified RNAs except for *HLA-DRB1* and *CD74*, which were amplified for 26 cycles. Polymerase chain reaction was performed using the GeneAmp PCR kit (PE Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Representative gene specific primer sequences are shown in Table 3:

Table 3. Primer pairs for RNA amplification.

Gene specific primer pair		SEQ ID NO.
<i>ACTB</i>	5'-ATGTGGATCAGCAAGCAGGA-3' 5'-GGTGGCTTTAGGATGGCAA-3'	SEQ ID NO: 2 SEQ ID NO: 3
<i>HE4</i>	5'-TTCGGCTTCACCCTAGTCTCA-3' 5'-AGAGGAATACAGACTCCGAA-3'	SEQ ID NO: 4 SEQ ID NO: 5
<i>ZFP36</i>	5'-ACCCCTGATGAATATGCCAGCA-3' 5'-GCTACTTGTCTTGGAGGGTA-3'	SEQ ID NO: 6 SEQ ID NO: 7
<i>RGS1</i>	5'-GACTCTTATCCCAGGTTCCCTCA-3' 5'-TGACTCCCTGGTTAACAGAGCA-3'	SEQ ID NO: 8 SEQ ID NO: 9
<i>CD74</i>	5'-CCAGTCCCCATGTGAGAGCA-3' 5'-AGCTGATAACAAAGCTTGGCTGA-3'	SEQ ID NO: 10 SEQ ID NO: 11
<i>TOP2A</i>	5'-TGTCCCTCCACGAGAAACAGA-3' 5'-CGTACAGATTTGCCCGAGGA-3'	SEQ ID NO: 12 SEQ ID NO: 13
<i>HLA-DRB1</i>	5'-GCGAGTTGAGCCTAAGGTGA-3' 5'-TTGAAGATGAGGCGCTGTCA-3'	SEQ ID NO: 14 SEQ ID NO: 15

Amplified RT-PCR products were visualized on an agarose gel stained with ethidium bromide. The intensity of each band was an indicator of the quantity of DNA, as previously amplified by PCR. 5 Thus, the intensity served as an indirect measure of the starting amount of the RNA amplified from the respective gene in each sample. Intensity was quantified using an ultraviolet light source and Alpha Imager software (Alpha Innotech Corp, San Leandro, CA). In addition to the above-mentioned tumor samples, sqRT-PCR evaluation of selected genes was also performed on the IOSE RNA for comparison.

10

Results

Global assessment of gene expression differences among tumor groups: Prior to investigating specific inter-group differences, the overall patterns of gene expression in the three tumor types (*BRCA-1*, *BRCA-2*, sporadic) were assessed. Multidimensional scaling (MDS), based on the expression levels of all 6,445 filtered genetic elements in the microarray, revealed that *BRCA1*- and *BRCA2*-linked tumors have distinct molecular profiles. In contrast, the sporadic samples showed a more heterogeneous distribution pattern, with many patterns clustering near the patterns of *BRCA1*-linked or *BRCA2*-linked samples (Figure 1A). The MDS results suggested that the *BRCA1*- and *BRCA2*-associated groups would be the most different and that gene expression patterns for each of the BRCA groups and the sporadic tumors would have fewer differences. In support of this hypothesis, only a few genes showed statistically significant ($P < 0.0001$) differential expression between the sporadic tumors and the *BRCA1*- or *BRCA2*-linked tumors, whereas 110 genes were differentially expressed between *BRCA1*-linked and *BRCA2*-linked tumors (Figure 1B). In addition 34 EST sequences were differentially expressed between *BRCA1*- and *BRCA2*-linked tumors. The group of 144 total markers that were differentially expressed between *BRCA1*- and *BRCA2*-type tumor cells compared to normal ovarian epithelial cells is listed in Table 9 (see Addendum).

Differential gene expression among all three groups was also performed, which identified 60 genes and 3 EST sequences whose expression segregated *BRCA1*-linked, *BRCA2*-linked, and

sporadic tumors (modified F test, wherein $P<0.0001$). Fifty-one of these 63 genes and EST sequences were also among the statistically significant discriminators of *BRCA1* and *BRCA2* tumors, highlighting the distinct gene expression profiles of these two groups. In addition, the expression profile of the combined *BRCA1*- and *BRCA2*-linked group was remarkably similar to that of the 5 sporadic tumors, as demonstrated by only three genes showing differential expression ($P<0.0001$) between these groups [*PSTPIP1* (SEQ ID NO: 538-540), *IDH2* (SEQ ID NO: 541-542), and *PCTK1* (SEQ ID NO: 527-528)]. These observations were in agreement with the multidimensional scaling analysis and demonstrated that, in terms of the overall pattern of gene expression, the *BRCA1*- and *BRCA2*-linked tumors are distinct from one another. Furthermore, the gene expression profiles of the 10 sporadic tumors appear to share features of either *BRCA1*- or *BRCA2*-linked cancers, and these sporadic tumors are referred to herein as *BRCA1*-type or *BRCA2*-type sporadic ovarian tumors.

The group of 144 nucleic acid molecules listed in Table 9 was further investigated using 15 hierarchical clustering (Figure 2A, B). As expected, the *BRCA*-associated tumors showed distinct and contrasting expression profiles (Figure 2A). Strikingly, the sporadic samples also segregated into two groups based on the expression patterns of the same 144 genes, exhibiting sporadic sample had a 20 molecular profile similar to that of either the *BRCA1*- or the *BRCA2*-linked tumors. This observation was illustrated by hierarchical clustering of all samples, revealing distinct "*BRCA1*-type" and "*BRCA2*-type" clusters (Figure 2A). This clustering further demonstrates that sporadic tumors (which do not contain the *BRCA1* or *BRCA2* mutations) can often be classified as *BRCA1*-type or *BRCA2*-type. Classification of sporadic tumors into these subtypes may provide guidance in treating the patient. For example, a subject who has a *BRCA1*-type or *BRCA2*-type sporadic tumor may be treated similarly to a subject who has a *BRCA1*-linked or *BRCA2*-linked tumor. The identification of *BRCA1*- or *BRCA2*-type sporadic tumors also allows tumors (or subjects) to be selected for specific drug regimens that are particularly effective with the associated mutation type.

25 Color-coding is usually used to represent the relative transcript expression ratio, as measured by cDNA microarray analysis. Red customarily indicates the maximum point in gene expression, green the minimum, and levels closer to the mean approach black.

To ensure that the *BRCA*-linked samples were not biasing the observed clustering patterns, the hierarchical architecture of gene expression in sporadic tumors was examined separately. Even in 30 the absence of the *BRCA*-linked samples, two distinct cluster phenotypes were observed, each comprised of those sporadic samples that previously grouped with *BRCA1*- and *BRCA2*-linked tumors (Figure 2B). Tumor histology and patient age were also evaluated for possible confounding effects on the observed *BRCA1*-type and *BRCA2*-type clusters. Neither variable was found to influence clustering patterns (Figure 2A, 2B).

35 Genes differentially expressed between *BRCA1*- and *BRCA2*-linked ovarian carcinomas: The analysis of overall gene expression patterns established that the same genes whose expression differentiated *BRCA1* and *BRCA2*-linked tumors, also identified two major sub-populations of sporadic cancers (Figure 3). As such, these nucleic acids are believed to represent important mediators of common genetic pathways in ovarian cancer and/or carcinogenesis. Many of these

genes are involved in important cellular functions including signal transduction, RNA processing and translation, chemokine signaling and immune modification, and DNA repair. By way of example, the *BRCA1*-associated tumors were characterized by higher *AKT1* (SEQ ID NO: 504-506) and lower *PTEN* (SEQ ID NO: 507-509) relative expression. In addition *UBL1* (SEQ ID NO: 510-512) (also known as *SUMO-1* and sentrin) was more highly expressed in *BRCA1*-associated tumors. This molecule interacts with RAD51 and RAD52 and has been proposed to have a regulatory role in homologous recombination (see Li *et al.*, *Nuc. Ac. Res.* 28: 1145-1153, 2000). The preferential expression of *UBL1* (SEQ ID NO: 510-512) in the *BRCA1*-linked samples may prove to be relevant to possible differences in DNA repair actions of the BRCA tumor suppressor genes.

5 By way of example, the *BRCA2*-linked tumors showed higher relative expression of *WNT2* (SEQ ID NO: 513-514 and *SFRP4* (SEQ ID NO: 515-517), which are members of the wnt- β -catenin-TCF signaling pathway. Another notable observation is that both *BRCA1*- and *BRCA2*-linked tumors showed preferential expression of proto-oncogenes commonly altered in hematologic malignancies. *BRCA1* tumors showed higher expression levels of *RUNX1* (SEQ ID NO: 518-520)/*AML1*, while 10 *BRCA2*-associated samples showed preferential expression of *TAL1* (SEQ ID NO: 521-523)/*SCL*. Both of these oncogenes are transcription factors involved in proliferation, and their preferential expression in *BRCA1*- and *BRCA2*-linked tumors may indicate that the activation of such a 15 "proliferation driver" is a necessary step in ovarian carcinogenesis.

20 *Gene expression differences between BRCA-linked and sporadic tumors:* Nine non-redundant genes showed significant differential expression between *BRCA1*-linked and sporadic tumors [*CD72* (SEQ ID NO: 805), *SLC25A11* (SEQ ID NO: 544), *LCN2* (SEQ ID NO: 545-547), *PSTPIP1* (SEQ ID NO: 538-540), *SIAHBP1* (SEQ ID NO: 543), *UBE1* (SEQ ID NO: 533), *WAS* (SEQ ID NO: 524-526), *IDH2* (SEQ ID NO: 541-542), *PCTK1* (SEQ ID NO: 527-528), P<0.0001, Figure 4A. A noteworthy observation was that three of these genes, *WAS* (SEQ ID NO: 524-526), 25 *PCTK1* (SEQ ID NO: 527-528), and *UBE1* (SEQ ID NO: 533), have all been mapped to the Xp11.23 and all were higher expressed in the *BRCA1*-linked tumors. This observation seemed unlikely to be explained by chance alone as only 35 of the total 6,445 filtered spots (0.5%) on the microarray represent genes mapped to Xp11. To further investigate this pattern, a larger group of 53 genes was 30 considered for differential expression between *BRCA1*-linked and sporadic tumors under the less stringent significance level of P<0.001. Among this group three additional genes, *SMC1L1* (SEQ ID NO: 530), *ARAF1* (SEQ ID NO: 531-532), and *EBP* (SEQ ID NO: 529), were discovered that also mapped to the Xp11.23 locus and also showed higher mean expression in *BRCA1*-associated samples (FIG 4D). Thus, six of fifty-three genes differentially expressed between *BRCA1*-linked and sporadic samples (P<.001) mapped to Xp11.23 and all showed higher mean expression in *BRCA1*-linked 35 tumors. *In silico* analysis of the location of these genes revealed that they are all confined to a 5-Mb region of DNA in Xp11.23 (Ensemble database, Prous Science, Philadelphia, PA 19102, U.S.A.).

The comparison between *BRCA2*-linked and sporadic tumors revealed only two genes with differential expression among these groups at the significance level of P<0.0001 (Figure 3). The gene designated as *LOC51760* (SEQ ID NO: 534-535) is also known as B/K (encoding the

brain/kidney protein) and is moderately homologous to the synaptotagmin family of vesicular transport molecules. The second differentially expressed gene encodes low-density lipoprotein-related protein-associated protein 1 (*LRPAP1*), also known as alpha-2-macroglobulin receptor-associated protein 1.

5 A further comparison consisted of investigating gene expression differences between the combined *BRCA*-linked group and the sporadic group, which revealed only three non-redundant, differentially expressed genes [*PSTPIP1* (SEQ ID NO: 538-540), *IDH2* (SEQ ID NO: 541-542), and *PCTK1* (SEQ ID NO: 527-528), Figure 4C. All three genes were among the group of genes that differentiated *BRCA1*-linked and sporadic samples. This finding is consistent with the observation
10 that the RNA profiles of sporadic ovarian cancers share significant similarities with those of *BRCA1*-linked or *BRCA2*-linked tumors. It is believed that the similarities shown in the RNA profiles is a general characteristic that applies to gene and protein component profiles as well. The small number
15 of differentially expressed genes obtained from the comparison of the combined *BRCA* group to the sporadic tumors is the result of the latter also consisting of *BRCA1*-type and *BRCA2*-type molecular classes.

Gene expression features distinguishing ovarian cancers from ovarian surface epithelial cells: Gene expression patterns common among all tumor types were investigated to identify genes that may be associated with the transformed state, *i.e.*, genes commonly expressed in ovarian tumors irrespective of their hereditary or sporadic nature. Gene expression in all sixty-one primary tumor
20 samples was compared to immortalized ovarian surface epithelial (IOSE) cells used as the common reference. Using the selection criterion of two-fold or greater expression ratio relative to the IOSE reference in at least two-thirds of all tumors, a list of 201 non-redundant genes and ESTs was generated. The top twenty-five overexpressed (*JL8* (SEQ ID NO: 449-451), *GRO1* (SEQ ID NO: 452-453), *ALDHIA3* (SEQ ID NO: 454-456), *MMP1* (SEQ ID NO: 457-459), *OSF-2* (SEQ ID NO: 460-461), *CDC25B* (SEQ ID NO: 462-464), *FLNA* (SEQ ID NO: 465-467), *TFP12* (SEQ ID NO: 468-469), *FGF2* (SEQ ID NO: 470-472), *CD44* (SEQ ID NO: 473-475), *DYT1* (SEQ ID NO: 476-477), *UCHL1* (SEQ ID NO: 478), *FGF2* (SEQ ID NO: 470-472), *PLAU* (SEQ ID NO: 479-480),
25 *LDHA* (SEQ ID NO: 256), *PTGS2* (SEQ ID NO: 481-483), *PRNP* (SEQ ID NO: 484-486), *MTIX* (SEQ ID NO: 487-488), *UGB* (SEQ ID NO: 489-490), *PBEF* (SEQ ID NO: 491-493), *TXNRD1* (SEQ
30 *ID NO: 494-496*), *NT5* (SEQ ID NO: 497-499), *PTGS2* (SEQ ID NO: 481-483), *MT2A* (SEQ ID NO: 500-502), *ZNF220* (SEQ ID NO: 503)) and twenty-five down-regulated (*FLJ22174* (SEQ ID NO: 30-31), *DDRI* (SEQ ID NO: 74-76), *SERPINF2* (SEQ ID NO: 18-19), *HLA-DRB1* (SEQ ID NO: 87-88),
35 *IFITM2* (SEQ ID NOS: 55-57, 58-59), *HGF* (SEQ ID NO: 174-175), *SORLI* (SEQ ID NO: 149-151),
CP (SEQ ID NO: 83-84), *HLA-DRA* (SEQ ID NO: 94-96), *BRF2* (SEQ ID NO: 190-192), *ABCB1*
40 (SEQ ID NO: 164-166), *G1P3* (SEQ ID NO: 68-69), *RGS1* (SEQ ID NO: 122-123), *IFITM1* (SEQ ID
NOS: 50-51, 52-54), *FOS* (SEQ ID NO: 133-135), *PPP1R7* (179-180), *HLA-DPA* (SEQ ID NO: 97-99),
45 *HLA-DRB5* (SEQ ID NO: 85-86), *TLR3* (SEQ ID NO: 199-201), *ZFP36* (SEQ ID NOS: 167-168,
169-171, 172-173), *SGK* (SEQ ID NO: 176-178), *HLA-DRB1* (SEQ ID NO: 87-88), *HE4* (SEQ ID
NO: 60), *CD74* (SEQ ID NO: 89-91), *CD24* (SEQ ID NO: 181-182)) named genes (by order of

magnitude) are presented in Figure 4A and 4B. This analysis revealed two potentially significant functional groups of genes to be overexpressed in ovarian cancers. The first group consisted of several of the genes that have all been previously shown to be interferon-inducible (*HLA-DRB1* (*SEQ ID NO: 87-88*), *HLA-DRB5* (*SEQ ID NO: 85-86*), *HLA-DRA* (*SEQ ID NO: 373-374*), *HLA-DPA* (*SEQ ID NO: 97-99*), *CD74* (*SEQ ID NO: 89-91*), *IFITM1* (*SEQ ID NOS: 50-51, 52-54*), and *IFITM2* (*SEQ ID NOS: 55-57, 58-59*), as indicated by italics in Figure 4A and 4B). The second group consisted of immediate-early response genes (*BRF2*, *ZFP36*, *SGK*, and *FOS*). In addition, several genes previously reported to be overexpressed in ovarian epithelial tumors were present in the list of genes overexpressed in tumors relative to the IOSE cells (Figure 4A and 4B). Elevated levels of *CLU*, *CD24*, and *MUC1* were also observed. These results identify additional potential markers of ovarian cancer. Table 9 lists the 144 nucleic acids that showed significantly elevated expression in ovarian cancer. These genes were selected based on consistency across all the pooled experiments and a significant difference in the average expression in the 40 independent samples, using a criteria of a tumor-to-ovarian surface epithelial cell line ratio of two or greater in at least 66% of all tumors.

15

EXAMPLE 2

Semiquantitative RT-PCR confirms and complements cDNA microarray data

This example describes how the results found in the previous example were confirmed using 20 semiquantitative RT-PCR.

To validate the array data, semiquantitative RT-PCR (sqRT-PCR) analysis of several mRNAs was performed in a representative subset of tumors consisting of five *BRCA1*-linked, five *BRCA2*-linked, and five sporadic RNA samples. The tumor samples were randomly selected. The 25 expression of *TOP2A* (*SEQ ID NO: 448*), *RGS1* (*SEQ ID NO: 398*, *CD74* (*SEQ ID NOS: 89-91, 92-93*), *HE4* (*SEQ ID NO: 60*), *HLA-DRB1* (*SEQ ID NO: 87-88*), and *ZFP36* (*SEQ ID NO: 167-168, 169-171, 172-173*) were evaluated using sqRT-PCR, with β -actin as a normalizing control. Because data obtained from cDNA microarrays is in the form of relative expression ratios between tumors and the reference, RNA from IOSE cells and a histologically normal, postmenopausal ovarian RNA 30 sample in the sqRT-PCR experiments was included for comparison. The results of these sqRT-PCR experiments were consistent with the cDNA microarray relative expression data for all six genes evaluated (Figure 5A and 5B). As anticipated from the microarray results (Figure 4), *HE4* expression was consistently elevated in all fifteen tumor samples compared to IOSE reference cell-line and normal ovary (Figure 5A and 5B). Invariant chain genes, also known as *CD74* and *RGS1*, were 35 overexpressed in the majority of tumors as indicated by microarray analysis (Figure 4). Both were also found to have increased expression in the majority of tumors as evaluated by sqRT-PCR (Figure 5A and 5B). The expression of *TOP2A* was found to be highest in the reference IOSE RNA. Furthermore, compared with the expression level in the normal postmenopausal ovary, twelve of the fifteen tested tumor samples showed elevated and variable *TOP2A* gene expression.

Several members of the immediate-early response cascade showed elevated expression in tumors as compared to IOSE cells in the microarray experiments (as indicated by the notation * in Figure 4A and 4B); however, some of these genes have previously been shown to have lower expression in ovarian cancer compared to normal ovary (see Welsh *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 98: 1176-1181, 2001, and Wang *et al.*, *Gene* 229: 101-108, 1999).
5

This discrepancy suggested that the elevated relative ratio observed in these experiments may be driven by low expression levels of these genes in IOSE cells grown in culture. In order to test this hypothesis, sqRT-PCR was used to compare *ZFP36* (an immediate-early gene also known as *G0S24* and *Tis11*) expression in tumors to that of normal ovary and IOSE cells. As suspected, 10 normal ovary had one of the highest expression levels of *ZFP36*, followed by that of the majority of tumors (Figure 5A), while the lowest expression level was observed in the IOSE cells.

15 In addition to statistical analysis, multidimensional scaling (MDS) and hierarchical clustering techniques using a correlation metric and average linkage were used for evaluating overall gene expression (see Eisen *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95: 14863-14868, 1998).

15

EXAMPLE 3

Identification of Additional Genes with Altered Expression in Ovarian Cancer

20 This example provides a description of how additional disclosed ovarian cancer-related nucleic acid molecules were identified. These ovarian cancer-related molecules show differences in expression in subjects having ovarian cancer compared to expression in normal ovarian surface epithelial cells.

25 Using a different microarrays and methods essentially similar to those described above in Example 1, thirty-one ovarian epithelial cancers were compared to two normal postmenopausal ovarian samples. 141 additional ovarian cancer-related nucleic acid molecules were identified and further characterized (Tables 6 and 7, Addendum).

30 **Methods and Materials:**

Methods and materials were similar to those described in Example 1, except that different microarrays were used. The nucleic acids constituted 7,600 features, and representing different (non-redundant) transcripts including multiple known named genes and ESTs. The cDNA microarrays were constructed by Dr. Eric Chuang (Division of Radiation Oncology) at the Advanced Technology Center (Gaithersburg, MD 20877). The genes represented on these arrays are composed of 7,600 cDNA clones and ESTs and are commercially available (Research Genetics, 2130 Memorial Parkway, Huntsville, AL 35801, U.S.).

The nucleic acid molecule expression patterns of thirty-one ovarian epithelial cancers were compared to two normal postmenopausal ovarian samples. The tissues were analyzed once, as the

correlation coefficient from previously repeated array experiments was shown to be 0.92-0.95. Each tumor and normal sample was directly compared to a "reference RNA" consisting of a mix of nine different human cell lines (Stratagene, La Jolla, CA), allowing for indirect comparison of gene expression in tumors and normal ovarian samples.

5 Hierarchical clustering was performed as described above and as set forth in Eisen *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95: 14863-8, 1998.

Results

Systematically Altered Genes

10 Using these methods, two additional sets of nucleic acid molecules were identified that showed differential expression in subjects having ovarian cancer. Table 4 (see Addendum) provides a list of nucleic acid molecules that were found to be underexpressed in subjects having ovarian cancer, and their average gene log expression ratios. Table 5 (see Addendum) shows nucleic acid molecules that were found to be overexpressed in persons having ovarian cancer, and their average 15 gene log expression ratios.

Genes underexpressed in ovarian tumors (see Table 4) may represent potential tumor suppressors. The induction of the expression of these genes through therapeutic means, for instance by induction through drug or gene therapy, may slow tumor growth and/or increase tumor cell death.

20 Among the 100 underexpressed genes were several oncogenes coding for proteins that are normally associated with the process of malignant transformation, including *JUN* (SEQ ID NO: 137-138), *KIT* (SEQ ID NO: 298-299), and *MAF* (SEQ ID NO: 229-230). The lower expression of these genes in cancers compared to expression in non-cancerous subjects is unexpected and is believed to reflect novel effects unique to ovarian cancer. Additionally, *CDKN1C* (SEQ ID NO: 249), *NBL1* (SEQ ID NO: 273), and *ING1L* (SEQ ID NO: 322) are recognized tumor suppressors, the 25 downregulation of which may be involved in the process of tumor formation and/or progression. *TGF* beta cascade members *TGFBR3* (SEQ ID NO: 216-218) and *EBAF* (SEQ ID NO: 294) (both shown herein to be underexpressed in ovarian cancer) present potential interest in light of the recent implication of the *TGF* beta pathway in normal and oral contraceptive-induced ovarian epithelial cell death and turnover (see Rodriguez *et al.*, *J. Natl. Can. Inst.* 94(1): 50-60, 2002). Thus, 30 downregulation of these nucleic acids may lead to inappropriate growth and possible transformation.

Genes that were overexpressed in ovarian tumors (Table 5) compared to normal tissue are believed to represent suitable targets for therapy and/or diagnosis, prognosis and staging of ovarian cancer. The decrease of the expression of these genes through therapeutic means, for instance by drug or gene therapy, presents a potential method of inhibition of ovarian cancer.

35 Among the fifty-nine overexpressed genes were several genes coding for proteins that are believed to be particularly promising as gene targets, including the following: *SLPI* (Secretory leukocyte protease inhibitor) (SEQ ID NO: 340-341); *SPP1* (Secreted phosphoprotein 1) (SEQ ID NO: 342); *CKS1* (CDC28 protein kinase 1) (SEQ ID NO: 345-347); *ZWINT* (ZW10 interactor) (SEQ ID NO: 354); *BF* (B-factor, properdin) (SEQ ID NO: 343-344); *MMP7* (Matrix metalloproteinase 7)

(SEQ ID NO: 348-349); *FOLR1* (Folate receptor 1) (SEQ ID NO: 364-365); *KLK8* (Kallikrein 8) (SEQ ID NO: 368; *CRIP1* (Cysteine-rich protein 1) (SEQ ID NO: 375; *EYA2* (Eyes absent) (SEQ ID NO: 392-393); and *PAX8* (Paired box gene 8) (SEQ ID NO: 350-351).

SLPI is a particularly promising candidate as a potential ovarian cancer marker or detector.

5 This protein has also been shown to be overexpressed in lung cancer (see Ameshima *et al.*, *Cancer* 89(7): 1448-1456, 2000) and is detectable in the saliva, enabling non-invasive testing (see Shugars *et al.*, *Gerontology*, 47(5): 246-253, 2001). *MMP7* over-expression has been described in primary and metastatic gastric cancers (see Mori *et al.*, *Surgery*, 131(1 Pt 2): S39-S47, 2002) as well as colorectal carcinomas (see Ougolkov *et al.*, *Gastroenterology*, 122(1): 60-71, 2002). *MMP7* appears to be involved in new blood vessel formation, which is a prerequisite for tumor growth (see Nishizuka *et al.*, *Cancer Lett.* 173(2): 175-182, 2001). *SPP1* (otherwise known as osteopondin) has also been associated with a number of malignancies (see Fedarko *et al.*, *Clin. Cancer Res.* 12: 4060-4066, 2001) including a recent report showing higher expression in ovarian cancer (see Mok *et al.*, *J. Natl. Cancer Inst.* 93(19) 1458-64, 2001). *ZWINT* is a newly discovered protein involved in kinetochore binding and centromere function (see Starr *et al.*, *J. Cell Sci.* 113(Pt 11): 1939-1950, 2000).

10 Properdin is involved in immune function and encodes complement factor B, a component of the alternative pathway of complement activation. *CRIP1* is believed to be involved in zinc transport. *Kallikrein 8* (also *TADG14*) is normally expressed in neural tissue, but appears to be altered such that it is highly expressed in ovarian cancers (see Underwood *et al.*, *Cancer Res.* 59(17): 4435-4439, 1999). *EYA2*, named for its involvement in eye development, is an important developmental gene that is potentially important in ovarian cancer. *EYA2* is located on the 20q13 chromosomal locus, which is the most frequently amplified chromosome region in ovarian cancers (see Tanner *et al.*, *Clin. Cancer Res.* 5: 1833-1839, 2000). Other genes localized to the same 20q13 chromosomal region are *BMP7*, which is also involved in development, and *SLPI* (discussed above), as well as *HE4* (identified in Example 1, above), all of which show higher expression in ovarian tumors. Thus, the upregulation of these nucleic acids may in part be due to amplification of 20q13 in the tumors studied.

20

25

PAX8 is involved in thyroid differentiation and normal function (see Pasca *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 97(24): 13144-13149, 2000). Furthermore, the folate receptor has been shown to be overexpressed in ovarian cancer (see Hough *et al.*, *Cancer Res.* 61(10): 3869-3876, 2001 and Bagnoli *et al.*, *Oncogene*, 19(41): 4754-4763, 2000). Finally, the specific pattern of caveolin (*CAVI*) under-expression and Folate receptor (*FOLR1*) over-expression disclosed herein (see Tables 4 & 5, Addendum) is consistent with the reciprocal regulation of the expression of genes in ovarian cancer (see Bagnoli *et al.*, *Oncogene*, 19(41): 4754-4763, 2000).

30

35

For each of the above specifically enumerated genes, a survey of the Serial Analysis of Gene Expression (SAGE) database (available through the UniGene search engine on the National Center for Biotechnology Information website) revealed that the expression of these genes is limited to a relatively small number of tissues, including ovarian cancers and some other tumors, for instance

pancreatic or breast. In addition, SLPI and SPP1 are secreted proteins that may be detectable as a diagnostic marker in the serum of a subject.

EXAMPLE 4**Classification of a Tumor into *BRCA1*-linked or *BRCA2*-linked tumor class.**

This example describes how to classify a tumor into a *BRCA1*-like or *BRCA2*-like tumor type using compound covariate prediction analysis.

Class prediction can be performed using a Compound Covariate Predictor tool, available as part of the BRB Array Tools software provided for download on the National Cancer Institute Internet website. Detailed information about the Compound Covariate Predictor is provided by the 10 Biometric Research Branch, National Cancer Institute and can be found in the following technical reports listed at that site" McShane *et al.*, "Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data" and Radmacher *et al.*, "A paradigm for class prediction using gene expression profiles."

The compound covariate predictor tool creates a multivariate predictor for one of two 15 classes for each sample using markers in the multivariate predictor that are univariately significant at the selected significance cutoff for a given set of data (see discussion above in *Section V. D, "Compound Covariate Predictor Analysis."*). The statistical significance cutoff for a given set of data can be chosen based upon the level of confidence desired.

By way of example, the markers provided in Table 10 satisfy a cutoff of $P<0.0005$, and are 20 therefore suitable for use with compound covariate predictor analysis. The multivariate predictor is a weighted linear combination of log-ratios for genes that are univariately significant. The weight consists of the univariate t-statistics for comparing the classes.

Using the compound covariate predictor and the markers provided in Table 10, a sample of 25 ovarian tissue can be classified into a *BRCA1*-like or *BRCA2*-like tumor. Samples are prepared as described in Example 1, and logarithmic expression ratios obtained for each marker used in the compound covariate predictor analysis.

The markers provided in Table 10 were used to segregate *BRCA1*-linked and *BRCA1*-type 30 sporadic tumor samples from *BRCA2*-linked and *BRCA2*-type sporadic samples, in a multivariate analysis. Based upon the information regarding these classes that was obtained using other approaches (such as hierarchical clustering, see Example 1), compound covariate predictor analysis classified the tumors with 92% accuracy (see Table 11).

Using this method, an unknown tumor can be classified into one of any two groups provided 35 that markers that are univariately significant at the selected significance cutoff for the desired groups are known. In addition, the gene expression data for the markers should be obtained using the same reference standard as the sample tumor.

Further analysis, such as a "leave-one-out" approach may be employed to check the 40 veracity of the compound covariate predictor model. In this approach, each of the tumors is individually segregated, and the analysis completed using that tumor against the remaining samples. In this way, the strength of the data set is measured against each individual sample (tumor),

confirming that the data set is useful, independently of any individual sample. See Radmacher *et al.*, "A paradigm for class prediction using gene expression profiles," available on the Biometric Research Branch, National Cancer Institute Internet site.

5

EXAMPLE 5 Expression of Ovarian Cancer-related Polypeptides

This example describes how to express the ovarian cancer-related proteins disclosed herein using various techniques.

10

The disclosed ovarian cancer-related proteins (and fragments thereof) can be expressed by standard laboratory technique. After expression, the purified ovarian cancer-related protein or polypeptide may be used for instance for functional analyses, antibody production, diagnostics, prognostics, and patient therapy, *e.g.*, for prevention or treatment of ovarian cancer. Furthermore, the 15 DNA sequences encoding the disclosed ovarian cancer-related proteins can be manipulated in studies to understand the expression of these genes and the function of their products. Mutant forms of human ovarian cancer-related proteins (and corresponding encoding sequences) may be isolated based upon information contained herein, and may be studied in order to detect alteration in expression patterns in terms of relative quantities, tissue specificity and functional properties of the 20 encoded mutant ovarian cancer-related protein. Partial or full-length cDNA sequences that encode the subject protein may be ligated into bacterial expression vectors. Methods for expressing large amounts of protein from a cloned gene introduced into *Escherichia coli* (*E. coli*) or other prokaryotes may be utilized for the purification, localization, and functional analysis of proteins. For example, 25 fusion proteins consisting of amino terminal peptides encoded by a portion of the *E. coli lacZ* or *trpE* gene linked to an ovarian cancer-related protein may be used to prepare polyclonal and monoclonal antibodies against these proteins. Thereafter, these antibodies may be used to purify proteins by immunoaffinity chromatography, in diagnostic assays to quantitate the levels of protein and to 30 localize proteins in tissues and individual cells by immunofluorescence.

Intact native protein may also be produced in *E. coli* in large amounts for functional studies. 30 Methods and plasmid vectors for producing fusion proteins and intact native proteins in bacteria are described in Sambrook *et al.* (*In Molecular Cloning: A Laboratory Manual*, Ch. 17, CSHL, New York, 1989). Such fusion proteins may be made in large amounts, are easy to purify, and can be used to elicit antibody response. Native proteins can be produced in bacteria by placing a strong, regulated promoter and an efficient ribosome-binding site upstream of the cloned gene. If low levels of protein 35 are produced, additional steps may be taken to increase protein production; if high levels of protein are produced, purification is relatively easy. Suitable methods are presented in Sambrook *et al.* (*In Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989) and are well known in the art. Often, proteins expressed at high levels are found in insoluble inclusion bodies. Methods for extracting proteins from these aggregates are described by Sambrook *et al.* (*In Molecular Cloning: A*

Laboratory Manual, Ch. 17, CSHL, New York, 1989). Vector systems suitable for the expression of *lacZ* fusion genes include the pUR series of vectors (see Ruther and Muller-Hill, *EMBO J.* 2:1791, 1983), pEX1-3 (see Stanley and Luzio, *EMBO J.* 3:1429, 1984) and pMR100 (see Gray *et al.*, *Proc. Natl. Acad. Sci. USA* 79:6598, 1982). Vectors suitable for the production of intact native proteins include pKC30 (see Shimatake and Rosenberg, *Nature* 292:128, 1981), pKK177-3 (see Amann and Brosius, *Gene* 40:183, 1985) and pET-3 (see Studiar and Moffatt, *J. Mol. Biol.* 189:113, 1986). Fusion proteins, for instance fusions that incorporate a portion of an ovarian cancer-related protein, may be isolated from protein gels, lyophilized, ground into a powder and used as an antigen. The DNA sequence can also be transferred from its existing context to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (see Burke *et al.*, *Science* 236:806-812, 1987). These vectors may then be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria, fungi (see Timberlake and Marshall, *Science* 244:1313-1317, 1989), invertebrates, plants (see Gasser and Fraley, *Science* 244:1293, 1989), and animals (see Pursel *et al.*, *Science* 244:1281-1288, 1989), which cell or organisms are rendered transgenic by the introduction of the heterologous ovarian cancer-related cDNA.

For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV) 40 promoter in the pSV2 vector (see Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981), and introduced into cells, such as monkey COS-1 cells (see Gluzman, *Cell* 23:175-182, 1981), to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, for example with neomycin (see Southern and Berg, *J. Mol. Appl. Genet.* 1: 327-341, 1982) or mycophenolic acid (see Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78: 2072-2076, 1981).

DNA sequences can be manipulated with standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-alteration via single-stranded bacteriophage intermediate or with the use of specific oligonucleotides in combination with PCR.

The cDNA sequence (or portions derived from it) or a mini gene (a cDNA with an intron and its own promoter) may be introduced into eukaryotic expression vectors by conventional techniques. These vectors are designed to permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation. Vectors containing the promoter and enhancer regions of the SV40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV40 are readily available (see Mulligan *et al.*, *Proc. Natl. Acad. Sci. USA* 78:1078-2076, 1981; Gorman *et al.*, *Proc. Natl. Acad. Sci. USA* 78:6777-6781, 1982). The level of expression of the cDNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express cDNAs at high levels in *S. frugiperda* cells (see Summers and Smith, In *Genetically Altered Viruses and the Environment*,

Fields *et al.* (Eds.) 22:319-328, CSHL Press, Cold Spring Harbor, New York, 1985) or by using vectors that contain promoters amenable to modulation, for example, the glucocorticoid-responsive promoter from the mouse mammary tumor virus (see Lee *et al.*, *Nature* 294:228, 1982). The expression of the cDNA can be monitored in the recipient cells 24 to 72 hours after introduction
5 (transient expression).

In addition, some vectors contain selectable markers such as the *gpt* (see Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981) or *neo* (see Southern and Berg, *J. Mol. Appl. Genet.* 1:327-341, 1982) bacterial genes. These selectable markers permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the cDNA). The vectors can be
10 maintained in the cells as episomal, freely replicating entities by using regulatory elements of viruses such as papilloma (see Sarver *et al.*, *Mol. Cell Biol.* 1:486, 1981) or Epstein-Barr (see Sugden *et al.*, *Mol. Cell Biol.* 5:410, 1985). Alternatively, one can also produce cell lines that have integrated the vector into genomic DNA. Both of these types of cell lines produce the gene product on a continuous
15 basis. One can also produce cell lines that have amplified the number of copies of the vector (and therefore of the cDNA as well) to create cell lines that can produce high levels of the gene product (see Alt *et al.*, *J. Biol. Chem.* 253:1357, 1978).

The transfer of DNA into eukaryotic, in particular human or other mammalian cells, is now a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate (see Graham and vander Eb, *Virology* 52:466, 1973) or strontium phosphate (see Brash *et al.*, *Mol. Cell Biol.* 7:2013, 1987), electroporation (see Neumann *et al.*, *EMBO J* 1:841, 1982), lipofection (see Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413, 1987), DEAE dextran (see McCuthan *et al.*, *J. Natl. Cancer Inst.* 41:351, 1968), microinjection (see Mueller *et al.*, *Cell* 15:579, 1978), protoplast fusion (see Schafner, *Proc. Natl. Acad. Sci. USA* 77:2163-2167, 1980), or pellet guns (see Klein *et al.*, *Nature* 327:70, 1987).
20 Alternatively, the cDNA, or fragments thereof, can be introduced by infection with virus vectors. Systems are developed that use, for example, retroviruses (see Bernstein *et al.*, *Gen. Engr'g* 7:235, 1985), adenoviruses (see Ahmad *et al.*, *J. Virol.* 57:267, 1986), or Herpes virus (see Spaete *et al.*, *Cell* 30:295, 1982). MB1 encoding sequences can also be delivered to target cells *in vitro* via non-infectious systems, for instance liposomes.
25

These eukaryotic expression systems can be used for studies of ovarian cancer-related nucleic acids (such as those listed in Table 1) and mutant forms of these molecules, as well as ovarian cancer-related proteins and mutant forms of these protein. Such uses include, for example, the identification of regulatory elements located in the 5' region of ovarian cancer-related genes on genomic clones that can be isolated from human genomic DNA libraries. The eukaryotic expression systems may also be used to study the function of the normal ovarian cancer-related proteins, specific portions of these proteins, or of naturally occurring or artificially produced mutant versions of ovarian cancer-related proteins.
30

Using the above techniques, the expression vectors containing ovarian cancer-related gene sequence or cDNA, or fragments or variants or mutants thereof, can be introduced into human cells,

mammalian cells from other species or non-mammalian cells as desired. The choice of cell is determined by the purpose of the treatment. For example, monkey COS cells (see Gluzman, *Cell* 23:175-182, 1981) that produce high levels of the SV40 T antigen and permit the replication of vectors containing the SV40 origin of replication may be used. Similarly, Chinese hamster ovary

5 (CHO), mouse NIH 3T3 fibroblasts or human fibroblasts or lymphoblasts may be used.

The present disclosure thus encompasses recombinant vectors that comprise all or part of an ovarian cancer-related gene or cDNA sequence (e.g., those listed in Table 1), for expression in a suitable host. In some embodiments, the ovarian cancer-related nucleic acid sequence is operatively linked in the vector to an expression control sequence to form a recombinant DNA molecule, so that 10 the ovarian cancer-related polypeptide can be expressed. The expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses, and combinations thereof. The expression control sequence may be 15 specifically selected from the group consisting of the *lac* system, the *trp* system, the *tac* system, the *trc* system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors, and combinations thereof.

15 The host cell, which may be transfected with the vector of this disclosure, may be selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus subtilis*, *B. stearothermophilus* or other 20 bacilli; other bacteria; yeast; fungi; insect; mouse or other animal; or plant hosts; or human tissue cells.

25 It is appreciated that for mutant or variant ovarian cancer-related DNA sequences, similar systems are employed to express and produce the mutant product. In addition, fragments of an ovarian cancer-related protein can be expressed essentially as detailed above. Such fragments include individual ovarian cancer-related protein domains or sub-domains, as well as shorter fragments such as peptides. Ovarian cancer-related protein fragments (e.g., those having therapeutic properties) may be expressed in this manner also.

EXAMPLE 6

30 Suppression of Ovarian Cancer-related Increased Gene Expression

This example describes how the ovarian cancer-related nucleic acids disclosed herein may be suppressed using various techniques.

35 A reduction of ovarian cancer-related protein expression in a transgenic cell may be obtained by introducing into cells an antisense construct based on an ovarian cancer-related protein encoding sequence, such as a cDNA or gene sequence or flanking regions thereof of any one of the proteins encoded by the nucleic acid molecules listed in Table 1, Table 9 or elsewhere herein. For antisense suppression, a nucleotide sequence encoding an ovarian cancer-related protein that is overexpressed

in ovarian cancer, *e.g.* all or a portion of the small cell lung carcinoma cluster 4 antigen (*CD24*) (SEQ ID NO: 181-182), secretory leukocyte protease inhibitor antileukoproteinase (*SLPI*) (SEQ ID NO: 340-341), secreted phosphoprotein 1 (*SPPI*) (SEQ ID NO: 342), B-factor, properdin (*BF*) (SEQ ID NO: 343-344), "homolog of Cks1=p34Cdc28/Cdc2-associated protein" (*CKS1*) (SEQ ID NO: 345-347), matrix metalloproteinase 7 (*MMP7*) (SEQ ID NO: 348-349), paired box gene 8 (*PAX8*) (SEQ ID NO: 350-351), serine protease inhibitor, Kunitz type, 2 (*SPINT2*) (SEQ ID NO: 352-353), ZW10 interactor (*ZWINT*) (SEQ ID NO: 354), diacylglycerol kinase (*DGKH*) (SEQ ID NO: 355), high-mobility group (nonhistone chromosomal) protein isoforms I and Y (*HMG1Y*) (SEQ ID NO: 356), Syndecan-4 - amphiglycan - ryudocan core protein (*SDC4*) (SEQ ID NO: 357-359), cyclin-dependent kinase inhibitor 2A (*CDKN2A*) (SEQ ID NO: 360), sodium channel, nonvoltage-gated 1 alpha (*SCNN1A*) (SEQ ID NO: 361-362), lactate dehydrogenase A (*LDHA*) (SEQ ID NO: 363), adult folate receptor (*FOLR1*) (SEQ ID NO: 364-365), Triosephosphate isomerase 1 (*TP1I*) (SEQ ID NO: 366-367), kallikrein 8 (neuropsin/ovasin) (*KLK8*) (SEQ ID NO: 368), CXC chemokine receptor 4- fusin-neuropeptide Y receptor-L3 (*CXCR4*) (SEQ ID NO: 200), kinesin-like 1 (*KNSL1*) (SEQ ID NO: 369-370), H2A histone family, member O (*H2AFO*) (SEQ ID NO: 371-372), major histocompatibility complex, class II, DR alpha, HLA-DRA, cysteine-rich protein 1 (intestinal) (*CR1PI*) (SEQ ID NO: 375), pyrophosphatase (inorganic), (*PP*) (SEQ ID NO: 376), EST 666391, glucose transporter (HepG2) (*SLC2A1*) (SEQ ID NO: 379-381), EST 897770, hepatoma-derived growth factor (*HDGF*) (SEQ ID NO: 383-385), argininosuccinate synthetase (*ASS*) (SEQ ID NO: 386), claudin 4 (*CLDN4*) (SEQ ID NO: 387-388), preferentially expressed antigen in melanoma (*PRAME*) (SEQ ID NO: 389), LAR = LCA-homologue (*PTPRF*) (SEQ ID NO: 390-391), eyes absent (*Drosophila*) homolog 2 (*EYA2*) (SEQ ID NO: 392-393), L-myc (*MYCL1*) (SEQ ID NO: 394-396), STAT1=IFN alpha/beta-responsive transcription factor ISGF3 beta subunits (p91/p84) (*STAT1*) (SEQ ID NO: 397-399), mitochondrial carrier homolog 2 (*MTCH2*) (SEQ ID NO: 400-401), 5-hydroxytryptamine (serotonin) receptor 3A (*HTR3A*) (SEQ ID NO: 402), cyclin E1 (*CCNE1*) (SEQ ID NO: 403-404), cadherin 6, type 2, K-cadherin (fetal kidney) (*CDH6*) (SEQ ID NO: 405), 5'-AMP-activated protein kinase - gamma-1 subunit (*PRKAG1*) (SEQ ID NO: 406-408), defensin beta 1 (*DEFB1*) (SEQ ID NO: 409), actin related protein 2/3 complex, subunit 1A (41 kD) (*ARPC1B*) (SEQ ID NO: 410-411), PKC iota=Protein kinase C, iota (*PRKCI*) (SEQ ID NO: 412-414), glyceraldehyde-3-phosphate dehydrogenase (*GAPD*) (SEQ ID NO: 415), complement component 2 (C2) (SEQ ID NO: 416-417), H2A histone family, member Y (*H2AFY*) (SEQ ID NO: 418-419), transmembrane 4 superfamily member 1 (*TM4SF1*) (SEQ ID NO: 420-421), glyceraldehyde-3-phosphate dehydrogenase (*GAPD*) (SEQ ID NO: 422-423), Interferon-inducible protein 1-8U (*IFITM3*) (SEQ ID NO: 424-426), glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P) (*GLDC*) (SEQ ID NO: 427-428), calumenin (*CALU*) (SEQ ID NO: 429-430), hemoglobin alpha 2 (*HBA2*) (SEQ ID NO: 431-432), S100 calcium-binding protein A11 (calgizzarin) (*S100A11*) (SEQ ID NO: 433), Lactate dehydrogenase A (*LDHA*) (SEQ ID NO: 434-436), ubiquitin-conjugating enzyme E2C (*UBE2C*) (SEQ ID NO: 437), E2F-3=pRB-binding transcription factor=KIAA0075 (*E2F3*) (SEQ ID NO: 438-440), E-cadherin (*CDH1*) (SEQ ID NO: 441-442), proteasome (prosome, macropain)

activator subunit 2 (PA28 beta) (*PSME2*) (SEQ ID NO: 443-444), OP-1=osteogenic protein in the TGF-beta family (*BMP7*) (SEQ ID NO: 445-447), and topoisomerase II (*TOP2A*) (SEQ ID NO: 448) cDNA or gene, is arranged in reverse orientation relative to the promoter sequence in the transformation vector. Other aspects of the vector may be chosen as for any other expression vector (see, e.g., Example 4).

5 (see, e.g., Example 4).
1. at least a full length human ovarian cancer-related cDNA or

The introduced sequence need not be a full-length human ovarian cancer-related cDNA or gene, and need not be exactly homologous to the equivalent sequence found in the cell type to be transformed. Generally, however, where the introduced sequence is of shorter length, a higher degree of homology to the ovarian cancer-related sequence likely will be needed for effective antisense suppression. The introduced antisense sequence in the vector may be at least thirty nucleotides in length, and improved antisense suppression will typically be observed as the length of the antisense sequence increases. The length of the antisense sequence in the vector advantageously may be greater than 100 nucleotides.

15 Although the exact mechanism by which antisense RNA molecules interfere with gene expression has not been elucidated, it is believed that antisense RNA molecules bind to the endogenous mRNA molecules and thereby inhibit translation of the endogenous mRNA.

Suppression of endogenous ovarian cancer-related gene expression can also be achieved using ribozymes. Ribozymes are synthetic RNA molecules that possess highly specific endoribonuclease activity. The production and use of ribozymes are disclosed in U.S. Patent No. 4,987,071 to Cech and U.S. Patent No. 5,543,508 to Haselhoff. The inclusion of ribozyme sequences within antisense RNAs may be used to confer RNA cleaving activity on the antisense RNA, such that endogenous mRNA molecules that bind to the antisense RNA are cleaved, which in turn leads to an enhanced antisense inhibition of endogenous gene expression.

25 In addition, dominant negative mutant forms of the disclosed ovarian cancer-related sequences may be used to block endogenous activity of the corresponding gene products.

Suppression can also be achieved using small inhibitory RNA molecules (siRNAs) (see, for instance, Caplen *et al.*, *Proc. Natl. Acad. Sci.* 98(17): 9742-9747, 2001, and Elbashir *et al.*, *Nature* 411: 494-498, 2001). Thus, this disclosure also encompasses siRNAs that correspond to an ovarian cancer-related nucleic acid, which siRNA is capable of suppressing the expression or function of its cognate (target) ovarian cancer-related protein. Also encompassed are methods of suppressing the expression or activity of an ovarian cancer-related molecule using an siRNA.

35 Suppression of expression of an ovarian cancer-related gene can be used, for instance, to treat, reduce, or prevent cell proliferative and other disorders caused by over-expression or unregulated expression of the corresponding ovarian cancer-related gene. In particular, suppression of expression of sequences disclosed herein as being up-regulated in ovarian cancer can be used to treat, reduce, or prevent progression to a later stage of ovarian cancer.

EXAMPLE 7
Nucleic Acid-Based Analysis

This example describes how to use the ovarian cancer-related nucleic acids disclosed herein
5 to detect and analyze neoplasms and mutations in ovarian cancer-related nucleic acids that may result in neoplasms.

The ovarian cancer-related nucleic acid molecules provided herein, and combinations of these molecules, can be used in methods of genetic testing for neoplasms (e.g., ovarian or other
10 cancers) or predisposition to neoplasms owing to altered expression of ovarian cancer-related nucleic acid molecules (e.g., deletion, genomic amplification or mutation, or over- or under-expression in comparison to a control or baseline). For such procedures, a biological sample of the subject, which biological sample contains either DNA or RNA derived from the subject, is assayed for a mutated, amplified or deleted ovarian cancer-related nucleic acid molecule, or for over- or under-expression of
15 an ovarian cancer-related nucleic acid molecule. Suitable biological samples include samples containing genomic DNA or RNA (including mRNA), obtained from body cells of a subject, such as those present in peripheral blood, urine, saliva, tissue biopsy, surgical specimen, amniocentesis samples and autopsy material.

The detection in the biological sample of a mutant ovarian cancer-related nucleic acid
20 molecule, a mutant ovarian cancer-related RNA, an amplified or homozygously or heterozygously deleted ovarian cancer-related nucleic acid molecule, or over- or under-expression of an ovarian cancer-related nucleic acid molecule, may be performed by a number of methodologies, examples of which are provided.

25 **A. Detection of Unknown Mutations:**

Unknown mutations in ovarian cancer-related nucleic acid molecules can be identified through polymerase chain reaction amplification of reverse transcribed RNA (RT-PCR) or DNA isolated from breast or ovary or other tissue, followed by direct DNA sequence determination of the products; single-strand conformational polymorphism analysis (SSCP) (for instance, see Hongyo *et al.*, *Nucleic Acids Res.* 21:3637-3642, 1993); chemical cleavage (including HOT cleavage) (Bateman *et al.*, *Am. J. Med. Genet.* 45:233-240, 1993; reviewed in Ellis *et al.*, *Hum. Mutat.* 11:345-353, 1998); denaturing gradient gel electrophoresis (DGGE); ligation amplification mismatch protection (LAMP); or enzymatic mutation scanning (Taylor and Deeble, *Genet. Anal.* 14:181-186, 1999), followed by direct sequencing of amplicons with putative sequence variations.

35

B. Detection of Known Mutations:

The detection of specific known DNA mutations in ovarian cancer-related nucleic acid molecules may be achieved by methods such as hybridization using allele specific oligonucleotides (ASOs) (see Wallace *et al.*, *CSHL Symp. Quant. Biol.* 51:257-261, 1986), direct DNA sequencing

(see Church and Gilbert, *Proc. Natl. Acad. Sci. USA* 81:1991-1995, 1988), the use of restriction enzymes (see Flavell *et al.*, *Cell* 15:25, 1978; Geever *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 8(8): 5081-5085, 1981), discrimination on the basis of electrophoretic mobility in gels with denaturing reagent (see Myers and Maniatis, *Cold Spring Harbor Symp. Quant. Biol.* 51:275-284, 1986), RNase protection (see Myers *et al.*, *Science* 230:1242, 1985), chemical cleavage (see Cotton *et al.*, *Proc. Natl. Acad. Sci. USA* 85:4397-4401, 1985), and the ligase-mediated detection procedure (see Landegren *et al.*, *Science* 241:1077-1080, 1988). Oligonucleotides specific to normal or mutant MB1 sequences can be chemically synthesized using commercially available machines. These oligonucleotides can then be labeled radioactively with isotopes (such as ^{32}P) or non-radioactively, 5 with tags such as biotin (see Ward and Langer *et al.*, *Proc. Natl. Acad. Sci. USA* 78:6633-6657, 1981), and hybridized to individual DNA samples immobilized on membranes or other solid supports by dot-blot or transfer from gels after electrophoresis. These specific sequences are visualized by methods such as autoradiography or fluorometric (see Landegren *et al.*, *Science* 242:229-237, 1989) 10 or colorimetric reactions (see Gebeyehu *et al.*, *Nucleic Acids Res.* 15:4513-4534, 1987). Using an ASO specific for a normal allele, the absence of hybridization would indicate a mutation in the 15 particular region of the gene, or deleted MB1 gene. In contrast, if an ASO specific for a mutant allele hybridizes to a clinical sample then that would indicate the presence of a mutation in the region defined by the ASO.

20 **C. Detection of Genomic Amplification or Deletion**

Gene dosage (copy number) can be important in neoplasms; it is therefore advantageous to determine the number of copies of ovarian cancer-related nucleic acids in biological samples of a subject, e.g., serum or ovary samples. Probes generated from the disclosed encoding sequence of in 25 ovarian cancer-related nucleic acid molecules can be used to investigate and measure genomic dosage of the corresponding ovarian cancer-related genomic sequence.

Appropriate techniques for measuring gene dosage are known in the art; see for instance, US Patent No. 5,569,753 ("Cancer Detection Probes") and Pinkel *et al.* (*Nat. Genet.* 20:207-211, 1998) ("High Resolution Analysis of DNA Copy Number Variation using Comparative Genomic Hybridization to Microarrays").

30 Determination of gene copy number in cells of a patient-derived sample using other techniques is known in the art. For example, amplification of an ovarian cancer-related nucleic acid sequence in cancer-derived cell lines as well as uncultured ovarian cancer or other cells can be carried out using bicolor FISH analysis. By way of example, interphase FISH analysis of breast cancer cell lines can be carried out as previously described (see Barlund *et al.*, *Genes Chromo. Cancer* 20:372-376, 1997). The hybridizations can be evaluated using a Zeiss fluorescence microscope.

35 For tissue microarrays, the FISH can be performed as described in Kononen *et al.* (*Nat. Med.* 4:844-847, 1998). Briefly, consecutive sections of the array are deparaffinized, dehydrated in ethanol, denatured at 74° C for 5 minutes in 70% formamide/2 x SSC, and hybridized with test and reference probes. The specimens containing tight clusters of signals or >3-fold increase in the

number of test probe as compared to chromosome 17 centromere in at least 10% of the tumor cells may be considered as amplified. Microarrays can be constructed as described in WO 99/44063A2 and WO 99/44062A1.

5 **C. Detection of mRNA Expression Levels**

Altered expression of an ovarian cancer-related molecule also can be detected by measuring the cellular level of ovarian cancer-related nucleic acid molecule-specific mRNA. mRNA can be measured using techniques well known in the art, including for instance Northern analysis, RT-PCR and mRNA *in situ* hybridization. Details of mRNA analysis procedures can be found, for instance, in 10 Example 1, Example 3, and Sambrook *et al.* (ed.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

15 The nucleic acid-based diagnostic methods of this disclosure are predictive of ovarian cancer. Cells of any tumors that demonstrate altered expression levels (e.g., through genomic amplification, deletion, mutation, or other over- or under-expression) of nucleotide sequences that share homology with the ovarian cancer-related nucleic acids disclosed herein are aggressive tumor cells, and result in decreased survival, increased metastasis, increased rates of clinical, and overall worsened prognosis.

EXAMPLE 8

20 **Production of Protein Specific Binding Agents**

This example describes how to use the ovarian cancer-related molecules disclosed herein to produce binding agents useful in preventing ovarian cancer.

25 Monoclonal or polyclonal antibodies may be produced to any of the disclosed ovarian cancer-related proteins, or mutant forms of these proteins. Optimally, antibodies raised against these proteins, or peptides from within such proteins, would specifically detect the protein or peptide with which the antibodies are generated. That is, an antibody generated to the BMP7 protein or another specified protein (see Table 1) or a fragment thereof would recognize and bind that protein and would 30 not substantially recognize or bind to other proteins found in human cells.

35 The determination that an antibody specifically detects a designated protein (e.g., an ovarian cancer-related protein as disclosed herein) can be made by any one of a number of standard immunoassay methods; for instance, the Western blotting technique (see Sambrook *et al.*, In *Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989). To determine that a given antibody preparation (such as one produced in a mouse) specifically detects a designated protein by Western blotting, total cellular proteins are extracted from cells (for example, human ovary) and electrophoresed on a sodium dodecyl sulfate-polyacrylamide gel. The proteins are then transferred to a membrane (for example, nitrocellulose) by Western blotting, and the antibody preparation is incubated with the membrane. After washing the membrane to remove non-specifically bound

antibodies, the presence of specifically bound antibodies is detected by the use of an anti-mouse antibody conjugated to an enzyme such as alkaline phosphatase. Application of an alkaline phosphatase substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a dense blue compound by immunolocalized alkaline phosphatase. Antibodies that 5 specifically detect the designated protein will, by this technique, be shown to bind to the designated protein band (which will be localized at a given position on the gel determined by its molecular weight). Non-specific binding of the antibody to other proteins may occur and may be detectable as a weak signal on the Western blot. The non-specific nature of this binding will be recognized by one skilled in the art by the weak signal obtained on the Western blot relative to the strong primary signal 10 arising from the specific antibody-protein binding.

Substantially pure ovarian cancer-related protein or protein fragment (peptide) suitable for use as an immunogen may be isolated from transfected or transformed cells, as described above. Concentration of protein or peptide in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per milliliter. Monoclonal or polyclonal 15 antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of a designated protein (such as an ovarian cancer-related protein, including one encoded by a nucleic acid listed in Table 1) identified and isolated as described 20 can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (*Nature* 256:495-497, 1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess un-fused cells destroyed by 25 growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall (*Meth. Enzymol.* 70: 419-439, 1980), and derivative methods thereof. Selected positive 30 clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and Lane (*Antibodies, A Laboratory Manual*, CSHL, New York, 1988).

B. Polyclonal Antibody Production by Immunization

35 Polyclonal antiserum containing antibodies to heterogeneous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary

in response to site of inoculations and dose, with either inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appear to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis *et al.* (*J. Clin. Endocrinol. Metab.* 33: 988-991, 1971).

5 Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony *et al.* (*In Handbook of Experimental Immunology*, Wier (ed.) Chapter 19. Blackwell, 1973). Plateau concentration of antibody is usually in the range of about 0.1 to 0.2 mg/ml of serum (about 12 μ M).

10 Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher (*Manual of Clinical Immunology*, Ch. 42, 1980).

C. Antibodies Raised against Synthetic Peptides

15 A third approach to raising antibodies against the subject ovarian cancer-related proteins or peptides is to use one or more synthetic peptides synthesized on a commercially available peptide synthesizer based upon the predicted amino acid sequence of the desired ovarian cancer-related protein or peptide.

D. Antibodies Raised by Injection of Protein Encoding Sequence

20 Antibodies also may be raised against proteins and peptides related to ovarian cancer as described herein by subcutaneous injection of a DNA vector that expresses the desired ovarian cancer-related protein, or a fragment thereof, into laboratory animals, such as mice. Delivery of the recombinant vector into the animals may be achieved using a hand-held form of the Biolistic system (see Sanford *et al.*, *Particulate Sci. Technol.* 5:27-37, 1987) as described by Tang *et al.* (*Nature* 356:152-154, 1992). Expression vectors suitable for this purpose may include those that express the ovarian cancer-related sequence under the transcriptional control of either the human β -actin promoter or the cytomegalovirus (CMV) promoter.

25 Antibody preparations prepared according to these protocols are useful in quantitative immunoassays that determine concentrations of antigen-bearing substances in biological samples; they also can be used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample; or for immunolocalization of the corresponding ovarian cancer-related protein.

30 For administration to human patients, antibodies, e.g., ovarian cancer-related protein specific monoclonal antibodies (such as antibodies to the proteins encoded by the encoding sequences listed to in Table 1), can be humanized by methods known in the art. Antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland, UK; Oxford Molecular, Palo Alto, CA). Alternatively, human antibodies can be produced. Methods for producing human antibodies are known in the art; see, for instance, Canevari *et al.*, *Int. J. Biol. Markers* 8:147-150, 1993 and Green, *J. Immunol. Meth.* 231:11-23, 1999, for instance.

EXAMPLE 9
Protein-Based Analysis

This example describes how to use the ovarian cancer-related molecules disclosed herein to
5 quantitate the level of one or more ovarian cancer-related proteins in a subject.

An alternative method of diagnosing, staging, detecting, or predicting ovarian cancer is to
quantitate the level of one or more ovarian cancer-related proteins in a subject, for instance in the
cells of the subject. This diagnostic tool is useful for detecting reduced or increased levels of ovarian
10 cancer-related proteins. Localization and/or coordinated expression (temporally or spatially) of
ovarian cancer-related proteins can also be examined using well known techniques. The
determination of reduced or increased ovarian cancer-related protein levels, in comparison to such
expression in a normal subject (e.g., a subject not having ovarian cancer or not having a
predisposition developing this condition, disease or disorder, would be an alternative or supplemental
15 approach to the direct determination of ovarian cancer-related nucleic acid levels by the methods
outlined above and equivalents. The availability of antibodies specific to specific ovarian cancer-
related protein(s) will facilitate the detection and quantitation of cellular ovarian cancer-related
protein(s) by one of a number of immunoassay methods which are well known in the art and are
presented in Harlow and Lane (*Antibodies, A Laboratory Manual*, CSHL, New York, 1988).
20 Methods of constructing such antibodies are discussed above, in Example 7.

Any standard immunoassay format (e.g., ELISA, Western blot, or RIA assay) can be used to
measure altered expression of ovarian cancer-related polypeptide or protein levels; comparison is to
wild-type (normal) ovarian cancer-related protein levels, and a difference in ovarian cancer-related
25 polypeptide levels is indicative of a biological condition resulting from altered expression of ovarian
cancer-related polypeptides or proteins, such as neoplasia. Whether the key difference is an increase
or a decrease is dependent on the specific ovarian cancer-related protein under examination, as
discussed herein. Immunohistochemical techniques may also be utilized for ovarian cancer-related
polypeptide or protein detection and quantification. For example, a tissue sample may be obtained
30 from a subject, and a section stained for the presence of an ovarian cancer-related protein using the
appropriate ovarian cancer-related protein specific binding agent and any standard detection system
(e.g., one which includes a secondary antibody conjugated to horseradish peroxidase). General
guidance regarding such techniques can be found in, e.g., Bancroft and Stevens (*Theory and Practice*
of Histological Techniques, Churchill Livingstone, 1982) and Ausubel *et al.* (*Current Protocols in*
Molecular Biology, John Wiley & Sons, New York, 1998).

35 For the purposes of quantitating an ovarian cancer-related protein, a biological sample of the
subject, which sample includes cellular proteins, is required. Such a biological sample may be
obtained from body cells, such as those present in peripheral blood, urine, saliva, tissue biopsy,
amniocentesis samples, surgical specimens and autopsy material, particularly breast cells.
Quantitation of an ovarian cancer-related protein can be achieved by immunoassay and the amount

compared to levels of the protein found in healthy cells. A significant difference (either increase or decrease) in the amount of ovarian cancer-related protein in the cells of a subject compared to the amount of the same ovarian cancer-related protein found in normal human cells is usually about a 10% or greater change, for instance 20%, 30%, 40%, 50% or greater difference. Substantial under-
5 or over-expression of one or more ovarian cancer-related protein(s), may be indicative of neoplasia or a predilection to neoplasia or metastasis, and especially ovarian epithelial cancer.

The protein-based diagnostic methods as described herein are predictive of ovarian cancer. Cells of any tumors that demonstrate altered expression levels (e.g., through genomic amplification, deletion, mutation, or other over- or under-expression) of nucleotide sequences that share homology
10 with the ovarian cancer-related nucleic acids disclosed herein are aggressive tumor cells, and result in decreased survival, increased metastasis, increased rates of clinical recurrence, and overall worsened prognosis.

EXAMPLE 10

15 Gene Therapy

This example describes how to use the ovarian cancer-related molecules and analysis methods disclosed herein to effect gene therapy for the treatment of ovarian cancer.

20 Gene therapy approaches for combating neoplasia (particularly ovarian cancer) in subjects are made possible by the present disclosure.

Retroviruses have been considered a preferred vector for experiments in gene therapy, with a high efficiency of infection and stable integration and expression (see Orkin *et al.*, *Prog. Med. Genet.* 7:130-142, 1988). A full-length ovarian cancer-related gene or cDNA can be cloned into a retroviral
25 vector and driven from either its endogenous promoter or from the retroviral LTR (long terminal repeat). Other viral transfection systems may also be utilized for this type of approach, including adenovirus, adeno-associated virus (AAV) (see McLaughlin *et al.*, *J. Virol.* 62:1963-1973, 1988), *Vaccinia* virus (Moss *et al.*, *Annu. Rev. Immunol.* 5:305-324, 1987), Bovine Papilloma virus (Rasmussen *et al.*, *Methods Enzymol.* 139:642-654, 1987) or members of the herpesvirus group such
30 as Epstein-Barr virus (Margolskee *et al.*, *Mol. Cell. Biol.* 8:2837-2847, 1988).

Developments in gene therapy techniques include the use of RNA-DNA hybrid oligonucleotides, as described by Cole-Strauss *et al.* (*Science* 273:1386-1389, 1996). This technique may allow for site-specific integration of cloned sequences, thereby permitting accurately targeted gene replacement.

35 In addition to delivery of ovarian cancer-related protein encoding sequences to cells using viral vectors, it is possible to use non-infectious methods of delivery. For instance, lipidic and liposome-mediated gene delivery has recently been used successfully for transfection with various genes (for reviews, see Templeton and Lasic, *Mol. Biotechnol.* 11:175-180, 1999; Lee and Huang, *Crit. Rev. Ther. Drug Carrier Syst.* 14:173-206; and Cooper, *Semin. Oncol.* 23:172-187, 1996). For

instance, cationic liposomes have been analyzed for their ability to transfect monocytic leukemia cells, and shown to be a viable alternative to using viral vectors (de Lima *et al.*, *Mol. Membr. Biol.* 16:103-109, 1999). Such cationic liposomes can also be targeted to specific cells through the inclusion of, for instance, monoclonal antibodies or other appropriate targeting ligands (see Kao *et al.*, *Cancer Gene Ther.* 3:250-256, 1996).

5 To reduce the level of ovarian cancer-related gene expression, gene therapy can be carried out using antisense or other suppressive constructs, the construction of which is discussed above (Example 4).

10

EXAMPLE 11

Kits

This example describes various kits for using the ovarian cancer-related molecules and analysis methods disclosed herein.

15

Kits are provided to determine the level (or relative level) of expression of one or more species of ovarian cancer-related nucleic acids (e.g., mRNA) or one or more ovarian cancer-related protein (*i.e.*, kits containing nucleic acid probes or antibodies or other ovarian cancer-related protein specific binding agents). Kits are also provided that contain the necessary reagents for determining 20 gene copy number (genomic amplification or deletion), such as probes or primers specific for an ovarian cancer-related nucleic acid sequence. These kits can each include instructions, for instance instructions that provide calibration curves or charts to compare with the determined (e.g., experimentally measured) values.

25

A. Kits for Detection of Ovarian Cancer-related Genomic Amplification or Deletion

The nucleotide sequence of ovarian cancer-related nucleic acid molecules disclosed herein, and fragments thereof, can be supplied in the form of a kit for use in detection of ovarian cancer-related genomic amplification/deletion and/or diagnosis of progression to or predilection to progress 30 to ovarian epithelial cancer. In such a kit, an appropriate amount of one or more oligonucleotide primer specific for an ovarian cancer-related-sequence is provided in one or more containers. The oligonucleotide primers may be provided suspended in an aqueous solution or as a freeze-dried or lyophilized powder, for instance. The container(s) in which the oligonucleotide(s) are supplied can be any conventional container that is capable of holding the supplied form, for instance, microfuge tubes, ampoules, or bottles. In some applications, pairs of primers may be provided in pre-measured 35 single use amounts in individual, typically disposable, tubes, or equivalent containers. With such an arrangement, the sample to be tested for the presence of ovarian cancer-related genomic amplification/deletion can be added to the individual tubes and *in vitro* amplification carried out directly.

The amount of each oligonucleotide primer supplied in the kit can be any amount, depending for instance on the market to which the product is directed. For instance, if the kit is adapted for research or clinical use, the amount of each oligonucleotide primer provided likely would be an amount sufficient to prime several *in vitro* amplification reactions. Those of ordinary skill in the art know the amount of oligonucleotide primer that is appropriate for use in a single amplification reaction. General guidelines may for instance be found in Innis *et al.* (*PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc., San Diego, CA, 1990), Sambrook *et al.* (*In Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York, 1989), and Ausubel *et al.* (*In Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1998).

A kit may include more than two primers, in order to facilitate the *in vitro* amplification of ovarian cancer-related genomic sequences (or a protein of such a sequence), for instance an ovarian cancer-related nucleic acid listed in Table 1, or the 5' or 3' flanking region thereof.

In some embodiments, kits may also include the reagents necessary to carry out *in vitro* amplification reactions, including, for instance, DNA sample preparation reagents, appropriate buffers (e.g., polymerase buffer), salts (e.g., magnesium chloride), and deoxyribonucleotides (dNTPs). Written instructions may also be included.

Kits may in addition include either labeled or unlabeled oligonucleotide probes for use in detection of the *in vitro* amplified sequences. The appropriate sequences for such a probe will be any sequence that falls between the annealing sites of two provided oligonucleotide primers, such that the sequence the probe is complementary to is amplified during the *in vitro* amplification reaction (if it is present in the sample).

It may also be advantageous to provide in the kit one or more control sequences for use in the *in vitro* amplification reactions. The design of appropriate positive control sequences is well known to one of ordinary skill in the appropriate art.

B. Kits for Detection of mRNA Expression

Kits similar to those disclosed above for the detection of ovarian cancer-related genomic amplification/deletion can be used to detect ovarian cancer-related mRNA expression levels (including over- or under-expression, in comparison to the expression level in a control sample).

Such kits include an appropriate amount of one or more of the oligonucleotide primers for use in, for instance, reverse transcription PCR reactions, similarly to those provided above, with art-obvious modifications for use with RNA.

In some embodiments, kits for detection of ovarian cancer-related mRNA expression may also include reagents necessary to carry out RT-PCR or other *in vitro* amplification reactions, including, for instance, RNA sample preparation reagents (including e.g., an RNase inhibitor), appropriate buffers (e.g., polymerase buffer), salts (e.g., magnesium chloride), and deoxyribonucleotides (dNTPs). Written instructions may also be included.

Kits may in addition include either labeled or unlabeled oligonucleotide probes for use in detection of an *in vitro* amplified target sequence. The appropriate sequences for such a probe will be

any sequence that falls between the annealing sites of the two provided oligonucleotide primers, such that the sequence the probe is complementary to is amplified during the PCR reaction.

It may also be advantageous to provide in the kit one or more control sequences for use in the *in vitro* amplification reactions. The design of appropriate positive control sequences is well known to one of ordinary skill in the appropriate art.

Alternatively, kits may be provided with the necessary reagents to carry out quantitative or semi-quantitative Northern analysis of ovarian cancer-related mRNA. Such kits include, for instance, at least one ovarian cancer-related sequence-specific oligonucleotide for use as a probe. This oligonucleotide may be labeled in any conventional way, including with a selected radioactive isotope, enzyme substrate, co-factor, ligand, chemiluminescent or fluorescent agent, hapten, or enzyme.

C. Kits For Detection of Ovarian Cancer-linked Protein or Peptide Expression

Kits for the detection of ovarian cancer-linked protein expression, for instance altered (over or under) expression of a protein encoded for by a nucleic acid molecule listed in Table 1 or elsewhere, are also encompassed herein. Such kits may include for example at least one target (ovarian cancer-linked) protein (e.g., all or a portion of the small cell lung carcinoma cluster 4 antigen (*CD24*) (SEQ ID NO: 181-182), secretory leukocyte protease inhibitor antileukoproteinase (*SLPI*) (SEQ ID NO: 340-341), secreted phosphoprotein 1 (*SPPI*) (SEQ ID NO: 342), B-factor, properdin (*BF*) (SEQ ID NO: 343-344), "homolog of Cks1=p34Cdc28/Cdc2-associated protein" (*CKS1*) (SEQ ID NO: 345-347), matrix metalloproteinase 7 (*MMP7*) (SEQ ID NO: 348-349), paired box gene 8 (*PAX8*) (SEQ ID NO: 350-351), serine protease inhibitor, Kunitz type, 2 (*SPINT2*) (SEQ ID NO: 352-353), ZW10 interactor (*ZWINT*) (SEQ ID NO: 354), diacylglycerol kinase (*DGKH*) (SEQ ID NO: 355), high-mobility group (nonhistone chromosomal) protein isoforms I and Y (*HMG1Y*) (SEQ ID NO: 356), Syndecan-4 - amphiglycan - ryudocan core protein (*SDC4*) (SEQ ID NO: 357-359), cyclin-dependent kinase inhibitor 2A (*CDKN2A*) (SEQ ID NO: 360), sodium channel, nonvoltage-gated 1 alpha (*SCNN1A*) (SEQ ID NO: 361-362), lactate dehydrogenase A (*LDHA*) (SEQ ID NO: 363), adult folate receptor (*FOLR1*) (SEQ ID NO: 364-365), Triosephosphate isomerase 1 (*TPII*) (SEQ ID NO: 366-367), kallikrein 8 (neuropsin/ovasin) (*KLK8*) (SEQ ID NO: 368), CXC chemokine receptor 4- fusin-neuropeptide Y receptor-L3 (*CXCR4*) (SEQ ID NO: 200), kinesin-like 1 (*KNSL1*) (SEQ ID NO: 369-370), H2A histone family, member O (*H2AFO*) (SEQ ID NO: 371-372), major histocompatibility complex, class II, DR alpha, HLA-DRA, cysteine-rich protein 1 (intestinal) (*CRIP1*) (SEQ ID NO: 375), pyrophosphatase (inorganic), (*PP*) (SEQ ID NO: 376), EST (SEQ ID NO: 377-378) 666391, glucose transporter (HepG2), (*SLC2A1*) (SEQ ID NO: 379-381), EST (SEQ ID NO: 377-378) 897770, hepatoma-derived growth factor (*HDGF*) (SEQ ID NO: 383-385), argininosuccinate synthetase (*ASS*) (SEQ ID NO: 386), claudin 4 (*CLDN4*) (SEQ ID NO: 387-388), preferentially expressed antigen in melanoma (*PRAME*) (SEQ ID NO: 389), LAR = LCA-homologue (*PTPRF*) (SEQ ID NO: 390-391), eyes absent (*Drosophila*) homolog 2 (*EYA2*) (SEQ ID NO: 392-393).

393), L-myc (*MYCL1*) (SEQ ID NO: 394-396), STAT1=IFN alpha/beta-responsive transcription factor ISGF3 beta subunits (p91/p84) (*STAT1*) (SEQ ID NO: 397-399), mitochondrial carrier homolog 2 (*MTCH2*) (SEQ ID NO: 400-401), 5-hydroxytryptamine (serotonin) receptor 3A (*HTR3A*) (SEQ ID NO: 402), cyclin E1 (*CCNE1*) (SEQ ID NO: 403-404), cadherin 6, type 2, K-cadherin (fetal kidney) (*CDH6*) (SEQ ID NO: 405), 5'-AMP-activated protein kinase - gamma-1 subunit (*PRKAG1*) (SEQ ID NO: 406-408), defensin beta 1 (*DEFB1*) (SEQ ID NO: 409), actin related protein 2/3 complex, subunit 1A (41 kD) (*ARPC1B*) (SEQ ID NO: 410-411), PKC iota=Protein kinase C, iota (*PRKCI*) (SEQ ID NO: 412-414), glyceraldehyde-3-phosphate dehydrogenase (*GAPD*) (SEQ ID NO: 415), complement component 2 (*C2*) (SEQ ID NO: 416-417), H2A histone family, member Y (*H2AFY*) (SEQ ID NO: 418-419), transmembrane 4 superfamily member 1 (*TM4SF1*) (SEQ ID NO: 420-421), glyceraldehyde-3-phosphate dehydrogenase (*GAPD*) (SEQ ID NO: 422-423), Interferon-inducible protein 1-8U (*IFITM3*) (SEQ ID NO: 424-426), glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P) (*GLDC*) (SEQ ID NO: 427-428), calumenin (*CALU*) (SEQ ID NO: 429-430), hemoglobin alpha 2 (*HBA2*) (SEQ ID NO: 431-432), 15 S100 calcium-binding protein A11 (calgizzarin) (*S100A11*) (SEQ ID NO: 433), Lactate dehydrogenase A (*LDHA*) (SEQ ID NO: 434-436), ubiquitin-conjugating enzyme E2C (*UBE2C*) (SEQ ID NO: 437), E2F-3=pRB-binding transcription factor=KIAA0075 (*E2F3*) (SEQ ID NO: 438-440), E-cadherin (*CDH1*) (SEQ ID NO: 441-442), proteasome (prosome, macropain) activator subunit 2 (PA28 beta) (*PSME2*) (SEQ ID NO: 443-444), OP-1=osteogenic protein in the TGF-beta 20 family (*BMP7*) (SEQ ID NO: 445-447), or topoisomerase II (*TOP2A*) (SEQ ID NO: 448) specific binding agent (e.g., a polyclonal or monoclonal antibody or antibody fragment), and may include at least one control. The ovarian cancer-linked protein specific binding agent and control may be contained in separate containers. The kits may also include a means for detecting ovarian cancer-related protein:agent complexes, for instance the agent may be detectably labeled. If the detectable 25 agent is not labeled, it may be detected by second antibodies or protein A, for example, either of both of which also may be provided in some kits in one or more separate containers. Such techniques are well known.

Additional components in some kits include instructions for carrying out the assay. Instructions will allow the tester to determine whether ovarian cancer-linked expression levels are 30 elevated or reduced in comparison to a control sample. Reaction vessels and auxiliary reagents such as chromogens, buffers, enzymes, etc. also may be included in the kits.

EXAMPLE 12
Identification of Therapeutic Compounds

This example describes how to use the ovarian cancer-related molecules disclosed herein to
5 identify compounds for potential therapeutic use in treating, reducing, or preventing ovarian cancer or
development or progression of ovarian cancer.

The ovarian cancer-related molecules disclosed herein, and more particularly the linkage of
these molecules to cancer, can be used to identify compounds that are useful in treating, reducing, or
10 preventing ovarian cancer or development or progression of ovarian cancer. These molecules can be
used alone or in combination, for instance in sets of two or more that are linked to cancer or cancer
progression.

By way of example, a test compound is applied to a cell, for instance a test cell, and at least
one ovarian cancer-related molecule level and/or activity in the cell is measured and compared to the
15 equivalent measurement from a test cell (or from the same cell prior to application of the test
compound). If application of the compound alters the level and/or activity of an ovarian cancer-
related molecule (for instance by increasing or decreasing that level), then that compound is selected
as a likely candidate for further characterization. In particular examples, a test agent that opposes or
inhibits an ovarian cancer-related change is selected for further study, for example by exposing the
20 agent to an ovarian epithelial cancer cell *in vitro*, to determine whether *in vitro* growth is inhibited.
Such identified compounds may be useful in treating, reducing, or preventing ovarian cancer or
development or progression of ovarian cancer. In particular embodiments, the compound isolated
will inhibit or inactivate an ovarian cancer-related molecule, for instance those represented by the
nucleic acids listed in Table 1.

25 Methods for identifying such compounds optionally can include the generation of an ovarian
cancer-related gene expression profile, as described herein. Control gene expression profiles useful
for comparison in such methods may be constructed from normal ovarian tissue, including primary
ovarian cancer tissue.

30

EXAMPLE 12
Gene Expression Profiles (Fingerprints)

This example describes how to use the ovarian cancer-related nucleic acids and analysis
methods disclosed herein to generate and use gene expression profiles, or "fingerprints."

35

With the provision herein of methods for determining molecules that are linked to ovarian
cancer, and the provision of a large collection of such ovarian cancer-linked molecules (as
represented for instance by those listed in Table 1), gene expression profiles that provide information
on the ovarian cancer-state of a subject are now enabled.

Ovarian cancer-related expression profiles comprise the distinct and identifiable pattern of expression (or level) of sets of ovarian cancer-related genes, for instance a pattern of high and low expression of a defined set of genes, or molecules that can be correlated to such genes, such as mRNA levels or protein levels or activities. Useful sets of molecules for constructing nucleic acid expression profiles include at least one that is represented by the following genes and ESTs:

5 *BCKDHB* (SEQ ID NO: 16-17), *ZNF33A* (SEQ ID NO: 20-22), EST 192198 (SEQ ID NO: 25), EST 128738 (SEQ ID NO: 26-27), EST 429211 (28-29), *FLJ22174* (SEQ ID NO: 30-31), EST 415562 (SEQ ID NO: 32-33), EST 296488 (SEQ ID NO: 34-35), EST 120124 (SEQ ID NO: 36-37), EST 132142 (SEQ ID NO: 38-39), EST 50635 (SEQ ID NO: 40), *POR* (SEQ ID NO: 41-43), EST 73702 (SEQ ID NO: 46-47), EST 2218314 (SEQ ID NO: 48), EST 2261113 (SEQ ID NO: 49), *IFITM1* (SEQ ID NO: 50-54), *IFITM2* (SEQ ID NO: 55-59), *KIAA0203* (SEQ ID NO: 61-62), *GIP3* (SEQ ID NO: 68-69), *BST2* (SEQ ID NO: 70-72), EST 1384797 (SEQ ID NO: 196), *TLR3* (SEQ ID NO: 199-201), *SPON1* (SEQ ID NO: 160-161), *HSRNASEB* (SEQ ID NO: 162-163), EST 294506 (SEQ ID NO: 146-148), *SORL1* (SEQ ID NO: 149-151), *SIAT1* (SEQ ID NO: 73), *PL1* (SEQ ID NO: 77), EST 108422 (SEQ ID NO: 78-79), *CEBPG* (SEQ ID NO: 80), *HLA-DPA* (SEQ ID NO: 97-99), *H2AFL* (SEQ ID NO: 107-109), *IGKC* (SEQ ID NO: 112-116), *SCYB10* (SEQ ID NO: 120-121), *RGS1* (SEQ ID NO: 122-126), *LSR68* (SEQ ID NO: 168), *SGK* (SEQ ID NO: 176-178), and *ZFP36* (SEQ ID NO: 167-173). These genes and ESTs, which have not previously been correlated with cancer, present potentially useful novel markers for cancer, and in particular, ovarian cancer.

20 A second example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by the SEQ ID NOs in Table 9. These nucleic acids, which are disclosed herein to be differentially expressed in ovarian cancer (see Figure 2), are suitable for markers to diagnose, prognose, and monitor ovarian cancer in a subject. In addition, these genes and ESTs are potentially useful as markers for classifying tumors 25 into types, for instance into *BRCA1*-type or *BRCA2*-type tumors, using the methods disclosed herein.

30 A third example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NOs: 417, 284, 285, 281, 283, 278, 273, 282, 274. These represent markers disclosed herein that were found to be differentially expressed between *BRCA1*-Linked and sporadic tumors in a comparison to reference Immortalized Ovarian Epithelial Cells (IOSE). These markers are useful for classifying tumors into *BRCA1*-linked and sporadic types, and present potential targets for treatment of ovarian cancer.

35 A fourth example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NOs: 279-280, which, as disclosed herein, are markers that were found to be differentially expressed between *BRCA2*-Linked and sporadic tumors in a comparison to reference Immortalized Ovarian Epithelial Cells. These markers are useful for classifying tumors into *BRCA2*-linked and sporadic types, and present potential targets for treatment of ovarian cancer.

A fifth example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NOs: 281, 282

and 274, which, as disclosed herein, are markers that were found to be differentially expressed between combined *BRCA*-Linked and sporadic tumors in a comparison to reference Immortalized Ovarian Epithelial Cells. These markers are useful for classifying tumors into *BRCA*-linked and sporadic types, and present potential targets for treatment of ovarian cancer.

5 A sixth example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by the SEQ ID NOs set forth in Table 10, which, as disclosed herein, are markers that can be used to segregate *BRCA1*-linked from *BRCA2*-linked tumor types using compound covariate prediction analysis. These markers are useful for classifying tumors into one of two types of tumors, which provides information helpful to a
10 clinician in choosing a course of treatment for the patient based on the type of tumor into which the sample is classified.

15 A seventh example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NO: 16-201, 565-567, and 803-804. These genes and ESTs were found, as disclosed herein, to be differentially expressed in a comparison of *BRCA1*-linked and *BRCA2*-linked to sporadic tumors. Hence, these genes and ESTs present potentially useful markers for classifying tumors into types, using the methods disclosed herein. Furthermore, they represent potential targets for pharmaceutical treatment
20 of tumors of each respective tumor type.

25 A eighth example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NOs: 124-126, 319, 429-430, 504-523, 533-535, 544, and 548-799. As disclosed herein, these nucleic acids were found to be overexpressed in a comparison of *BRCA1*-linked, *BRCA2*-linked and sporadic tumor samples. Hence, these genes and ESTs present potentially useful markers for classifying tumors into types, using the methods disclosed herein. Furthermore, they represent potential targets for
25 pharmaceutical treatment of tumors of each respective tumor type.

30 A ninth example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NOs: 202-339. As disclosed herein, these nucleic acids were found to be overexpressed in ovarian cancer in a comparison of ovarian epithelial cancer to normal postmenopausal ovarian tissue. Hence, these genes and ESTs present potentially useful markers diagnosis, prognosis, and monitoring of ovarian cancer. In addition, they represent potential targets for pharmaceutical treatment of ovarian tumors.

35 A tenth example set of molecules that could be used in a profile would include at least one that is represented by (or correlated to) the genes and ESTs represented by SEQ ID NOs: 97 and 340-448. As disclosed herein, these nucleic acids were found to be underexpressed in ovarian cancer in a comparison of ovarian epithelial cancer to normal postmenopausal ovarian tissue. Hence, these genes and ESTs present potentially useful markers diagnosis, prognosis, and monitoring of ovarian cancer. In addition, they represent potential targets for pharmaceutical treatment of ovarian tumors.

In other examples of ovarian cancer-related gene expression profiles, such profiles may be further broken down by the manner of molecules included in the profile. Thus, certain examples of

profiles may include a specific class of ovarian cancer markers, such as those molecules involved in cell cycle control.

Particular profiles may be specific for a particular stage of normal tissue (e.g., ovarian tissue) growth or disease progression (e.g., progression of ovarian cancer). Thus, gene expression profiles can be established for a pre-ovarian cancer tissue (i.e., normal ovarian tissue), and a primary ovarian cancer tissue. Each of these profiles includes information on the expression level of at least one, but usually two or more, genes that are linked to ovarian cancer (e.g., ovarian cancer-related genes). Such information can include relative as well as absolute expression levels of specific genes. Likewise, the value measured may be the relative or absolute level of protein expression, which can be correlated with a "gene expression level." Results from the gene expression profiles of an individual subject are often viewed in the context of a test sample compared to a baseline or control sample fingerprint.

The levels of molecules that make up a gene expression profile can be measured in any of various known ways, which may be specific for the type of molecule being measured. Thus, nucleic acid levels (such as direct gene expression levels, such as the level of mRNA expression) can be measured using specific nucleic acid hybridization reactions. Protein levels may be measured using standard protein assays, using immunologic-based assays (such as ELISAs and related techniques), or using activity assays, for instance. Examples for measuring nucleic acid and protein levels are provided herein; other methods are well known to those of ordinary skill in the art.

Examples of ovarian cancer-related gene expression profiles can be in array format, such as a nucleotide (e.g., polynucleotide) or protein array or microarray. The use of arrays to determine the presence and/or level of a collection of biological macromolecules is now well known (see, for example, methods described in published PCT application number WO9948916, describing hypoxia-related gene expression arrays). In array-based measurement methods, an array may be contacted with polynucleotides (in the case of a nucleic acid-based array) or polypeptides (in the case of a protein-based array) from a sample from a subject. The amount and/or position of binding of the subject's polynucleotides or polypeptides then can be determined, for instance to produce a gene expression profile for that subject. Such gene expression profile can be compared to another gene expression profile, for instance a control gene expression profile from a subject having a known gynecological or ovary-related condition. Optionally, the subject's gene expression profile can be correlated with one or more appropriate treatments, which may be correlated with a control (or set of control) expression profiles for stages of ovarian cancer, for instance.

This disclosure provides the identification of ovarian cancer-related molecules that exhibit alterations in expression during development of ovarian cancer, and expression fingerprints (profiles) specific for ovarian cancers. It further provides methods of using these identified nucleic acid molecules, and proteins encoded thereby, and expression fingerprints or profiles, for instance to predict and/or diagnose ovarian cancer, and to elect treatments for instance based on likely response. These identified ovarian cancer-related molecules also can serve as therapeutic targets, and can be

used in methods for identifying, developing and testing therapeutic compounds. It will be apparent that the precise details of the methods described may be varied or modified without departing from the spirit of the described invention. We claim all such modifications and variations that fall within the scope and spirit of the claims below.

CLAIMS

We claim:

- 5 1. A method of classifying an ovarian tumor as a BRCA-1-like or BRCA-2-like or non-BRCA-like tumor, comprising:
 determining a pattern of expression in the ovarian tumor of a plurality of markers listed in Table 1, wherein the pattern of expression in the ovarian tumor is determined relative to a standard ovarian tissue;
- 10 comparing a similarity of the pattern of expression of the plurality of markers in the ovarian tumor to a pattern of expression of the plurality of markers in a comparison tissue of a known BRCA-1-like or BRCA-2-like or non-BRCA-like tumor, wherein the pattern of expression in the comparison tissue is determined relative to the standard ovarian tissue;
 wherein a similarity of the pattern of expression in the ovarian tumor to a pattern of expression of the comparison tissue of the known BRCA-1-like tumor classifies the ovarian tumor as a BRCA-1-like tumor, a similarity of the pattern of expression in the ovarian tumor to a pattern of expression of the known BRCA-2-like tumor classifies the ovarian tumor as a BRCA-2-like tumor, and a similarity of the pattern of expression in the ovarian tumor to a pattern of expression of the known non-BRCA-like tumor classifies the ovarian tumor as a non-BRCA-like tumor.
- 15 2. The method of claim 1, wherein the method comprises determining a pattern of over-expression or under-expression of the plurality of markers in the ovarian tumor to over-expression or under-expression of the plurality of markers of the comparison tissue.
- 20 3. The method of claim 2, wherein the method comprises determining a pattern of both over-expression and under-expression of the plurality of markers in the ovarian tumor to over-expression or under-expression of the plurality of markers in the comparison tissue.
- 25 4. The method of claim 1 wherein the comparison tissue is from a known BRCA-1-like tumor, and the method comprises determining whether the ovarian tumor is a BRCA-1-like tumor by comparing the pattern of expression in the ovarian tumor to the pattern of expression in the comparison tissue.
- 30 5. The method of claim 1 wherein the comparison tissue is from a subject known to have a mutation in BRCA-1 and the method comprises determining whether the ovarian tumor is a BRCA-1-like tumor by comparing the pattern of expression in the ovarian tumor to the pattern of expression in the comparison tissue.

6. The method of claim 1 wherein the comparison tissue is from a subject known to have a mutation in BRCA-2 and the method comprises determining whether the ovarian tumor is a BRCA-2-like tumor by comparing the pattern of expression in the ovarian tumor to the pattern of expression in the comparison tissue.

5

7. The method of claim 1 wherein the comparison tissue is from a known BRCA-2-like tumor, and the method comprises determining whether the ovarian tumor is BRCA-2-like by comparing the pattern of expression in the ovarian tumor to the pattern of expression in the comparison tissue.

10

8. The method of claim 7, wherein classifying the ovarian tumor comprises determining whether a tumor that does not contain a BRCA-1 or BRCA-2 mutation is BRCA-1-like or BRCA-2-like.

15

9. The method of claim 1 wherein the comparison tissue is from a known non-BRCA-like tumor, and the method comprises determining whether the ovarian tumor is non-BRCA-like by comparing the pattern of expression in the ovarian tumor to the pattern of expression in the comparison tissue.

20

10. The method of claim 1, wherein the standard ovarian tissue is tissue from an immortalized ovarian cell, ovarian tissue from a subject not having ovarian cancer, a subject not predisposed to developing ovarian cancer, or ovarian tissue from a subject from whom the ovarian tumor was obtained at an earlier point in time.

25

11. The method of claim 1, wherein the patterns of expression are patterns of logarithmic expression ratios.

12. The method of claim 1, wherein the patterns of expression are multidimensional scaling patterns.

30

13. The method of claim 12 wherein the multi-dimensional scaling patterns are visually compared to determine similarities.

35

14. The method of claim 1, wherein the patterns of expression are hierarchical clustering patterns.

15. The method of claim 14, wherein standard normal deviation values of the logarithmic expression ratios are assigned relative color intensities that assist in the visual comparison.

16. The method of claim 15, wherein the hierarchical clustering patterns are visually compared to determine similarities.

5 17. The method of claim 11 comprising comparing the logarithmic expression ratios of the plurality markers using compound covariate predictor analysis.

10 18. The method of claim 11, wherein the method comprises differentiating a *BRCA1*-like ovarian tumor from a sporadic ovarian tumor by comparing relative logarithmic expression ratios of at least one marker shown in Table 6.

15 19. The method of claim 18, wherein differentiating a *BRCA1*-linked ovarian tumor from a sporadic ovarian tumor comprises comparing the relative logarithmic expression ratios of *CD72* (SEQ ID NO: 805), *SLC25A11* (SEQ ID NO: 544), *LCN2* (SEQ ID NO: 545-547), *PSTPIP1* (SEQ ID NO: 538-540), *SIAHBP1* (SEQ ID NO: 543), *UBE1* (SEQ ID NO: 533), *WAS* (SEQ ID NO: 524-526), *IDH2* (SEQ ID NO: 541-542), or *PCTK1* (SEQ ID NO: 527-528) in the ovarian tumor and comparison tissue.

20 20. The method of claim 11, wherein the method comprises differentiating a *BRCA2*-like ovarian tumor from a non-*BRCA*-like ovarian tumor by comparing relative logarithmic expression ratios of at least one marker shown in Table 7.

25 21. The method of claim 20, wherein the method comprises comparing the relative logarithmic expression ratios of *LOC51760* (SEQ ID NO: 279) or *LRPAP1* (SEQ ID NO: 280) to differentiate a *BRCA2*-like ovarian tumor from a non-*BRCA* like ovarian tumor

30 22. The method of claim 21, wherein the method comprises differentiating a non-*BRCA*-like tumor from a *BRCA*-1-like or *BRCA*-2-like ovarian tumor by comparing relative logarithmic expression ratios of at least one marker shown in Table 8.

35 23. The method of claim 22, wherein the method comprises comparing relative logarithmic expression ratios of *PSTPIP1* (SEQ ID NO: 281), *IDH2* (SEQ ID NO: 282), or *PCTK1* (SEQ ID NO: 274) to differentiate a combined *BRCA1*- and *BRCA2*-linked ovarian tumor from a sporadic ovarian tumor.

24. The method of claim 11, wherein the method comprises differentiating a *BRCA1*-like ovarian tumor from a *BRCA2*-like ovarian tumor by comparing relative logarithmic expression ratios of at least one marker shown in Table 10.

25. The method of claim 1, wherein the method further comprises selecting a treatment strategy based on classifying the ovarian tumor as *BRCA1*-like, *BRCA2*- like or non-*BRCA*-like.

26. The method of claim 25, wherein the treatment strategy comprises selecting a more aggressive treatment regimen for a *BRCA1*-like or *BRCA2*-like tumor.

5 27. The method of claim 26, wherein the treatment is chemotherapy, radiotherapy, or surgical removal of the affected tissue and/or surrounding area.

10 28. The method of claim 25, further comprising treating the subject with the selected treatment.

15 29. The method of claim 11, wherein comparing the patterns of logarithmic expression ratios comprises comparing the logarithmic expression ratios to patterns of logarithmic expression ratios in a database of patterns associated with *BRCA1*-like, *BRCA2*-like or non-*BRCA*-like ovarian tumors.

20 30. The method of claim 11, wherein comparing patterns of logarithmic expression ratios of the plurality of markers comprises obtaining the pattern of expression of the plurality of markers on an array.

31. The method of claim 1, wherein the pattern of expression of the plurality of markers comprises over-expression of one or more markers compared to the standard.

25 32. The method of claim 29, wherein the one or more markers that is overexpressed is listed in Table 5.

30 33. The method of claim 32, wherein determining the pattern of expression comprises providing nucleic acid sequences of the markers, and performing nucleic acid hybridization of specific oligonucleotide probes to the nucleic acid sequences.

34. The method of claim 33, wherein the sequence of the oligonucleotide probe is selected to bind specifically to a nucleic acid molecule listed in Table 1.

35 35. The method of claim 34, further comprising amplifying the one or more markers prior to performing nucleic acid hybridization.

36. The method of claim 33, further comprising quantitating hybridization to detect a level of differential expression.

37. The method of claim 33, wherein providing sequences of the markers comprises providing the nucleic acid sequences on an array carrying the plurality of markers.

5 38. The method of claim 37, wherein the array is a cDNA microarray.

39. The method of claim 33, wherein providing the nucleic acid sequences of the markers comprises providing at least 50 of the markers listed in Table 1.

10 40. The method of claim 33, wherein providing the nucleic acid sequences of the markers comprises providing at least 100 of the markers listed in Table 1.

15 41. The method of claim 33, wherein providing the nucleic acid sequences of the markers comprises providing at least 200 of the markers listed in Table 1.

15 42. A method of diagnosing or prognosing development or progression of ovarian cancer in a subject comprising detecting under-expression of one or more markers in Table 4 relative to a standard.

20 43. The method of claim 42, wherein the standard is immortalized ovarian epithelial cells, ovarian tissue from a subject not having cancer or a subject not predisposed to developing cancer, or ovarian tissue from the subject at an earlier point in time.

25 44. The method of claim 42 wherein the one or more markers comprise a nucleic acid encoded by SEQ ID NOs: 449-503.

45. A method of diagnosing or prognosing development or progression of ovarian cancer in a subject comprising detecting over-expression of one or more markers in Table 5 relative to a standard.

30 46. The method of claim 45, wherein the standard is immortalized ovarian epithelial cells, ovarian tissue from a subject not having cancer or a subject not predisposed to developing cancer, or ovarian tissue from the subject at an earlier point in time.

35 47. The method of claim 45 wherein the one or more markers comprise a nucleic acid encoded by SEQ ID NOs: 18-19, 30-31, 50-51, 52-54, 55-57, 58-59, 60, 68-69, 74-76, 85-86, 87-88, 89-91, 92-93, 94-95, 97-99, 122-123, 133-135, 149-151, 164-166, 167-168, 169-170, 174-175, 176-178, 179-180, 181-182, 190-192, or 199-201.

48. A method of screening for an agent for treating or inhibiting ovarian cancer in a subject, comprising exposing a tumor cell to a therapeutically effective amount of a pharmaceutical compound that restores wild-type expression of at least one *BRCA1*-like or *BRCA2*-like marker listed in Table 1.

5

49. The method of claim 48 wherein the agent corrects under-expression or over-expression of a marker listed in Table 1.

50. A method of monitoring a response to therapy for an ovarian tumor, comprising monitoring expression of the markers in the subject following administration of the therapy.

51. A method of diagnosing or prognosing development or progression of ovarian cancer in a subject comprising detecting differential expression of a gene that maps to Chromosome Xp11.2.

15

52. A kit for classifying one or more ovarian tumors as sporadic, *BRCA1*-like or *BRCA2*-like tumors, comprising components for measuring expression levels of markers in the one or more ovarian tumor samples and for comparing the expression levels of the markers to the markers in Table 10.

20

53. The kit of claim 52, wherein the expression levels of a plurality of markers from each tumor are measured.

25

54. The kit of claim 52, comprising an array carrying a plurality of markers.

55. The kit of claim 52, comprising a binding molecule that selectively binds to a marker in the one or more tumor samples, and wherein the marker is listed in Table 10.

30

56. The kit of claim 52, wherein the expression levels measured are of a non-BRCA-like, *BRCA1*-like or *BRCA2*-like tumor protein, and the binding molecule is an antibody or antibody fragment that selectively binds the tumor protein.

35

57. The kit of claim 52, wherein the expression levels measured are of a BRCA-like, *BRCA1*-like or *BRCA2*-like nucleic acid marker, and the binding molecule is an oligonucleotide capable of hybridizing to the nucleic acid molecule marker.



Figure 1

Figure 2A

BRCA2 BRCA1



Z -2.5 -1.0 0 1.0 2.5

Figure 2A'

BRCA2 BRCA1



Z -2.5 -1.0 0 1.0 2.5


**Figure 2B**


Figure 2C

Figure 3A




Figure 3A'




Figure 3B




Figure 3B'




Figure 3C

DESIGNATIONS IN FIGURE 3-A

Designation	Across (tumor types)	Down (genes)	SEQ ID NO:
1	B2-1	<i>PAK2</i>	557-558
2	B2-10	<i>NCSTN</i>	678
3	B2-16	<i>HGF</i>	585-586
4	B2-2	<i>BAD</i>	587-588
5	B2-20	<i>F23149</i>	766-767
6	B2-21	<i>DKFZP564C186</i>	763-764
7	B2-22	<i>UBL1</i>	510-512
8	B2-23	<i>GCAT</i>	741-742
9	B2-24	<i>RBBP4</i>	691-692
10	B2-25	<i>CALU</i>	375
11	B2-3	<i>RUNX1</i>	518-520
12	B2-4	<i>PTK2B</i>	624-625
13	B2-6	<i>FDFT1</i>	651-652
14	B2-7	<i>IL18R1</i>	618-620
15	B2-8	<i>P14L</i>	743-744
16	B2-9	<i>RALY</i>	712-713
17	B36	<i>KIAA0218</i>	703-704
18	B39	<i>MPI</i>	666-667
19	B40	<i>IL17R</i>	583-584
20	B41	<i>KIAA0008</i>	745-746
21	B52	<i>IL1B</i>	775-776
22	B54	<i>RAB3A</i>	739-740
23	B55	<i>HARS</i>	662-663
24	B60	<i>TUFM</i>	659
25	B61	<i>PEF</i>	719-720
26	B62	<i>GNB2</i>	674-675
27	B63	<i>SECRET</i>	655-656
28	B64	<i>SLC9A1</i>	657-658
29	B70	<i>NAGA</i>	653-654
30	B74	<i>MNAT1</i>	660-661

Figure 3C, continued

DESIGNATIONS IN FIGURE 3-A

Designation	Across (tumor types)	Down (genes)	SEQ ID NO:
31	B77	<i>EST</i>	672-673
32	B78	<i>COVA1</i>	788-789
33	B79	<i>LOX</i>	747-748
34	B80	<i>MAPRE1</i>	760-761
35	C100	<i>FLJ22059</i>	770-771
36	C102	<i>ILK</i>	609-611
37	C103	<i>PISD</i>	749-750
38	C105	<i>PPIA</i>	375
39	C107	<i>EIF4A1</i>	664-665
40	C110	<i>KIAA0144</i>	705-706
41	C117	<i>TCEB2</i>	548-550
42	C118	<i>GART</i>	600-602
43	C77	<i>TAGLN2</i>	668-669
44	C84	<i>UBE1</i>	533
45	C85	<i>FLJ12442</i>	701-702
46	C99	<i>PPY2</i>	733-734
47	C79	<i>MAP2K3</i>	626-628
48	C123	<i>GTPBP1</i>	697-698
49	C87	<i>NM23-H1</i>	551-553
50	C95	<i>SF3B4</i>	777
51	C111	<i>AKT1</i>	504-506
52	C114	<i>PPP2R5A</i>	621-623
53	C15	<i>APMCF1</i>	731-732
54	C16	<i>ZNF173</i>	589-591
55	C17	<i>GS2NA</i>	699-700
56	C1	<i>AFP</i>	786-787
57	C20	<i>SLC25A11</i>	544
58	C41	<i>PPP1CB</i>	597-599
59	C42	<i>RBBP2</i>	792-793
60	C45	<i>SCYB5</i>	554-556
61	C49	<i>SI00A4</i>	559-561

Figure 3D

DESIGNATIONS IN FIGURE 3-B

Designation	Across (tumor type)	Down (gene)	SEQ ID NO:
62	B2-20	<i>KIAA0365</i>	676-677
63	B2-21	<i>SFRS11</i>	682
64	B2-22	<i>KDR</i>	615-617
65	B2-23	<i>SCYA4</i>	612-614
66	B2-24	<i>SCYA4</i>	612-614
67	B2-25	<i>RGS1</i>	398
68	B2-4	<i>RGS1</i>	398
69	B2-6	<i>RGS16</i>	594-596
70	B2-7	<i>RGS16</i>	594-596
71	B2-8	<i>SFRP4</i>	515-517
72	B2-9	<i>ENPP1</i>	603-605
73	B36	<i>PDGFRB</i>	580-582
74	B39	<i>BMP6</i>	687-688
75	B40	<i>MMP13</i>	606-608
76	B41	<i>CSRP2</i>	709
77	B52	<i>WNT2</i>	797-799
78	B54	<i>WNT2</i>	797-799
79	B55	<i>APEX</i>	790-791
80	B60	<i>POLR2A</i>	693-694
81	B61	<i>GOLGA1</i>	782-783
82	B62	<i>CSNK1E</i>	785
83	B63	<i>LOC51605</i>	759
84	B64	<i>ZNF211</i>	757-758
85	B70	<i>FOXO1A</i>	707-708
86	B74	<i>ZFP161</i>	592-593
87	B77	<i>ATP7A</i>	689-690
88	B78	<i>FLJ21940</i>	768-769
89	B79	<i>TNRC12</i>	784


Figure 3D, continued

DESIGNATIONS IN FIGURE 3-B

Designation	Across (tumor type)	Down (gene)	SEQ ID NO:
90	B80	<i>TAL1</i>	521-523
91	C100	<i>NCOA1</i>	565-567
92	C102	<i>BRE</i>	710-711
93	C103	<i>RAB2L</i>	780-781
94	C105	<i>SAST</i>	723-724
95	C107	<i>ITGAE</i>	571-573
96	C110	<i>ARHGEF6</i>	679-681
97	C117	<i>TCF4</i>	779
98	C118	<i>TMEPAI</i>	755-756
99	C77	<i>CD36</i>	577-579
100	C85	<i>PTEN</i>	507-509
101	C99	<i>PDE6A</i>	774
102	C79	<i>CD83</i>	562-564
103	C123	<i>FLJ10701</i>	762
104	C87	<i>LOC51760</i>	534-535
105	C95	<i>SMG1</i>	695-696
106	C111	<i>WNT2</i>	797-799
107	C114	<i>IL7</i>	574-576
108	C15	<i>CRB1</i>	735-736
109	C16	<i>GABRP</i>	685-686
110	C17	<i>PLXNA2</i>	727-728
111	C1	<i>RNAC</i>	319
112	C20	<i>CUGBP1</i>	683-684
113	C41	<i>PON1</i>	670-671
114	C42	<i>RYBP</i>	568-570
115	C45	<i>CD36</i>	577-579
116	C49	<i>FLJ21661</i>	737-738

Figure 4A-C

A



CD72
SLC24A11
LCN2
PSPIP1
SIAHBP1
UBE1
WAS
IDH2
PCTK1

B



LOC51760
LRPAP1

C




PSTPIP1
PSTPIP1
IDH2
PCTK1

Z -2.5 -1.5 -0.5 0 0.5 1.5 2.5

Figure 4A-C'

A



B



C





Figure 4D


Figure 5A


Figure 5B

Figure 6A







Figure 6B



ADDENDUM

Table 1. Markers that were Differentially Expressed in a cDNA Microarray Expression Profile of Sixty-One Ovarian Cancer Tumors

SEQ ID NO.	Gene	IMAGE ID No.	UniGene No.	GenBank Accession No.	Gene Description
16-17	BCKDHB	770835		AA427739; AA434304	Branched chain keto acid dehydrogenase E1, beta polypeptide (maple syrup urine disease)
18-19	SERPINF 2	82195		T68859; T68934	serine (or cysteine) proteinase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), mem
20-22	ZNF33A	346902		D31763; W78164; W79207	KIAA0065
23-24	ZNF33A	246543		N57658; N77515	Zinc finger protein 33a (KOX 31)
25	EST	192198		H41144	Unknown
26-27	EST	128738		R16726; R09980	Homo sapiens cDNA:FLJ23371 fis, clone HEP16068, highly similar to HSTFIISH Homo sapiens mRNA for trar
28-29	EST	429211		AA007283; AA007282	ESTs
30-31	FLJ22174	295939		N67034; W04283	hypothetical protein FLJ22174
32-33	EST	415562		W80701; W78802	Unknown
34-35	EST	296488		N70208; W01059	Unknown
36-37	EST	120124		T95064; T95160	ESTs
38-39	EST	132142		R26164; R23610	Homo sapiens cDNA:FLJ21587 fis, clone COL06946
40	EST	50635		H17921	ESTs
41-43	POR	234180		S90469; H70626; H66247	Cytochrome P450 reductase
44-45	CLU	725877		AA292226; AA292410	Clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate messenger
46-47	EST	73702		T54544; T54585	Unknown
48	EST	2218314		AI744768	Unknown
49	EST	2261113		AI609063	EST

50-51	IFITM1	755599		AA419251; AA419286	Interferon induced transmembrane protein 1 (9-27)
52-54	IFITM1	509641		J04164; AA058323; AA058453	Interferon-inducible protein 9-27=interferon-induced 17kDa membrane protein
55-57	IFITM2	624655		X57351; AA187365; AA187099	Interferon-induced protein 1-8D
58-59	IFITM2	376520		AA041402; AA041501	Interferon-induced protein 1-8D
60	HE4	786675		AA451904	Epididymis-specific, whey-acidic protein type, four-disulfide core; putative ovarian carcinoma marker
61-62	KIAA0203	61008		T40715; T39659	KIAA0203 gene product
63-64	IL8RB	882183		M73969; AA480683	CXCR2=IL-8 Receptor beta
65-67	VDUP1	297954		S73591; N68956; W00656	Brain-expressed HHCNA78 homolog=Induced in HL60 cells treated with vitamin D or cycloheximide
68-69	G1P3	782513		AA448478; AA432030	Interferon, alpha-inducible protein (clone IFI-6-16)
70-72	BST2	811024		D28137; AA485371; AA485528	Bone marrow stromal cell antigen 2
73	SIAT1	897906		AA598652	Sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase)
74-76	DDR1	182288		U48705; H41900; H41939	Receptor protein-tyrosine kinase EDDR1
77	PL1	433573		AA701655	Human endogenous retrovirus envelope region mRNA (PL1)
78-79	EST	108422		T77847; T77926	Homo sapiens, clone MGC:12275, mRNA, complete cds
80	CEBPG	455121		AA676804	CCAAT/enhancer binding protein (C/EBP), gamma
81-82	MUC1	840687		AA488073; AA486365	Mucin 1, transmembrane
83-84	CP	223350		H86554; H86642	ceruloplasmin (ferroxidase)
85-86	HLA-DRB5	811139		AA485739; AA486460	Major histocompatibility complex, class II, DR beta 5
87-	HLA-	417711		W88967;	Major

88	DRB1			W88546	histocompatibility complex, class II, DR beta 1
89-91	CD74	725751		X00497; AA399225; AA292218	Invariant chain=la- associated invariant gamma-chain
92-93	CD74	840681		AA488071; AA486363	Invariant chain=la- associated invariant gamma-chain
94-96	HLA-DRA	117411		K01171; T89719; T89816	MHC Class II=DR alpha
97-99	HLA-DPA	207715		X00457; H62294; H62293	MHC Class II=DP alpha
100	HLA-DRB1	855547		AA664195	Major histocompatibility complex, class II, DR beta 1
101-103	HLA-DRB1	470953		M20430; AA032179; AA033653	MHC Class II=DR beta
104-106	TNFSF10	203132		U57059; H54629; H54628	TRAIL=Apo-2 ligand
107-109	H2AFL	429091		U90551; AA007585; AA007574	Histone-2A-like protein (H2A/I)
110-111	IG lambda	66560		T67053; T67054	Immunoglobulin lambda locus
112-114	IGKC	159142		M63438; R76324; R76323	Immunoglobulin kappa light chain
115-116	IGKC	840451		AA485725; AA485862	Immunoglobulin kappa light chain
117-119	RAD23A	293925		AF004230; N63943; N98412	MIR-7=monocyte/macrophage Ig-related receptor AND RAD23=UV excision repair protein (Double hit)
120-121	SCYB10	967284		X02530; AA527139	IP-10
122-123	RGS1	361323		AA017544; AA017417	regulator of G-protein signaling 1
124-126	RGS1	686248		S59049; AA262268; AA262879	BL34=RGS1=regulator of G-protein signaling which inhibits SDF-1 directed B cell migration
127-129	GAS1	365826		L13698; AA025819; AA025884	Growth arrest-specific 1
130-132	BTG2	358214		U72649; W95415; W95512	BTG2=p53 dependent inducible anti-proliferative gene homologous to P _c 3/Tis21 immediate

					early genes
133-135	FOS	755279		V01512; AA496353; AA496403	c-fos
136	LSR68	1862044		AI053597	Lipopolysaccharide specific response-68 protein
137-138	JUNB	309864		N94468; W23847	Jun B proto-oncogene
139-140	JUNB	122428		T99236; T99280	Jun B proto-oncogene
141-143	COL3A1	122159		X14420; T98612; T98611	Collagen Type III Alpha 1
144-145	LUM	813823		AA447781; AA453712	lumican
146-148	EST	294506		U90916; N71007; W01902	clone 23815 mRNA
149-151	SORL1	279388		Y08110; N48698; N45548	Mosaic protein LR11=hybrid receptor gp250 precursor
152-153	RNASE6 PL	712341		AA405000; AA281840	Ribonuclease 6 precursor
154-156	HLA-B	769753		M28205; AA429012; AA429162	Human Leukocyte Antigen B
157-159	HLA-C	810142		M11886; AA464246; AA464354	Human Leukocyte Antigen C
160-161	SPON1	46173		H09099; H09449	Spondin 1, (f-spondin) extracellular matrix protein
162-163	HSRNAs EB	814526		AA459363; AA459588	RNA-binding region (RNP1, RRM) containing 1
164-166	ABCB1	813256		M14758; AA455911; AA456377	MDR1=Multidrug resistance protein 1=P-glycoprotein
167-168	ZFP36	23804		R38383; T77499	Zinc finger protein homologous to Zfp-36 in mouse
169-171	ZFP36	135880		M63625; R33813; R33812	TTP=tristetraproline=GOS24=zinc finger transcriptional regulator
172-173	ZFP36	727266		AA411987; AA402178	TTP=tristetraproline=GOS24=zinc finger transcriptional regulator
174-175	HGF	41650		R52798; R52797	hepatocyte growth factor (hepatopoietin A; scatter factor)
176-178	SGK	840776		AJ000512; AA486082; AA486140	sgk=putative serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic

					alteration
179-180	PPP1R7	814508		AA459351; AA459572	Protein phosphatase 1, regulatory subunit 7
181-182	CD24	204335		H59916; H59915	CD24 antigen (small cell lung carcinoma cluster 4 antigen)
183-184	TPD52	814306		AA459100; AA459318	Tumor protein D52
185-187	CXCR4	79679		X71635; T62636; T62491	CXC chemokine receptor 4=fusin=neuropeptide Y receptor=L3
188-189	JUND	767784		AA418670; AA418676	Jun D proto-oncogene
190-192	BRF2	485770		U07802; AA039882; AA039967	Tis 11d=ERF- 2=growth factor early response gene
193-195	A2M	377647		M11313; AA055995; AA055907	Alpha-2- macroglobulin
196	EST	1384797		AA856938	Homo sapiens mRNA; cDNA DKFZp434O0227 (from clone DKFZp434O0227)
197-198	CD24	196519		S75311; R91610	CD24
199-201	TLR3	144675		U88879; R76099; R76150	TLR3= Toll-like receptor 3
202	ITM2A	878596	Hs.17109	AA775257	integral membrane protein 2A
203-204	GATM	42558	Hs.75335	R61229; R61228	glycine amidinotransferase (L- arginine:glycine amidinotransferase)
205-207	RNASE4	81417	Hs.283749	D37931; T60163; T60223	ribonuclease L (2',5'- oligoisoadenylate synthetase-dependent)
208-210	LAMA2	471642	Hs.75279	Z26653; AA034939; AA034938	laminin alpha 2 (merosin, congenital muscular dystrophy)
211	PBX3	448386	Hs.294101	AA778198	pre-B-cell leukemia transcription factor 3
212	PLA2G6	1472538	Hs.120360	AA872271	phospholipase A2, group VI (cytosolic, calcium-independent)
213	SMARC A2	814636	Hs.198296	AA481026	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
214-215	CUGBP2	488956	Hs.211610	AA047257; AA057142	CUG triplet repeat, RNA-binding protein 2
216-218	TGFBR3	209655	Hs.79059	L07594; H62473; H61499	TGF beta receptor type III
219	STAR	859858	Hs.3132	AA679454	steroidogenic acute

220	GNG11	1636447	Hs.83381	AA999901	regulatory protein guanine nucleotide binding protein 11
221	CITED2	491565	Hs.82071	AA115076	Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy- terminal domain, 2
222	CTNNAL 1	744647	Hs.58488	AA621315	catenin (cadherin- associated protein), alpha-like 1
223	ABCA8	743773	Hs.38095	AA634308	ATP-binding cassette, sub-family A (ABC1), member 8
224- 226	KLF4	188232	Hs.7934	AF105036; H45668; H45711	GKLF=EZF=KLF4=g ut-enriched Kruppel- like zinc finger protein=expressed in vascular endothelial cells
227- 228	ITPR1	471725	Hs.198443	AA035450; AA035477	inositol 1,4,5- triphosphate receptor, type 1
229- 230	MAF	487793	Hs.30250	AA043501; AA044658	v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog
231- 232	FOXC1	768370	Hs.284186	AA495790; AA495846	forkhead box C1
233	TCF21	461351	Hs.78061	AA699782	transcription factor 21
234- 236	CCNI	248295	Hs.79933	D50310; N58511; N78101	Cyclin I
237- 238	DCN	209367	Hs.76152	H64138; H64086	decorin
239- 240	CBF2	789049	Hs.184760	AA452909; AA453077	CCAAT-box-binding transcription factor
241- 242	EST	68049	Hs.180324	T52830; T52829	Homo sapiens, clone IMAGE:4183312, mRNA, partial cds
122	RNASE4	81417	Hs.283749		ribonuclease L (2',5'- oligoisoadenylate synthetase-dependent)
243	SLC4A1 AP	2094012	Hs.306000	AI424433	solute carrier family 4 (anion exchanger), member 1, adapter protein
244- 245	GSTM5	377731	Hs.75652	AA056232; AA056231	glutathione S- transferase M5
246	C4BPB	460470	Hs.99886	AA677687	complement component 4-binding protein, beta
247- 248	HS3ST1	73609	Hs.40968	T55714; T55756	heparan sulfate (glucosamine) 3-O- sulfotransferase 1
249	CDKN1C	2413955	Hs.106070	AI828088	cyclin-dependent kinase inhibitor 1C (p57, Kip2)
250	HNRPDL	897823	Hs.170311	AA598578	heterogeneous nuclear ribonucleoprotein D-

					like
251	CIRBP	1558799	Hs.119475	AA977242	cold inducible RNA-binding protein
252	RGS2	2321596	Hs.78944	AI675670	regulator of G-protein signalling 2, 24kD
253-254	TCEAL1	786607	Hs.95243	AA478480; AA451969	transcription elongation factor A (SII)-like 1
255-256	CAV1	377461	Hs.323469	AA055835; AA055368	caveolin 1, caveolae protein, 22kD
257	ALDH1A1	855624	Hs.76392	AA664101	aldehyde dehydrogenase 1 family, member A1
258-259	RBPMS	343443	Hs.80248	W67200; W67323	RNA-binding protein gene with multiple splicing
260-261	ADAMTS1	62263	Hs.8230	T41173; T40309	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1
262-263	DSCR1L1	51408	Hs.156007	H19440; H19439	Down syndrome critical region gene 1-like 1
264	DLK1	436121	Hs.169228	AA701996	delta-like homolog (Drosophila)
265-266	CDH11	491113	Hs.75929	AA136983; AA137109	cadherin 11, type 2, OB-cadherin (osteoblast)
138	SGK	840776	Hs.296323		sgk=putative serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume
267	HFL1	450060	Hs.278568	AA703392	H factor (complement)-like 1
268-269	FOG2	38347	Hs.106309	R49439; R35921	Friend of GATA2
270	C7	898122	Hs.78065	AA598478	complement component 7
271-272	SGCE	784109	Hs.110708	AA432066; AA446750	sarcoglycan, epsilon
273	NBL1	898305	Hs.76307	AA598830	neuroblastoma, suppression of tumorigenicity 1
274-275	HBB	173385	Hs.155376	H20968; H21011	hemoglobin, beta
276-278	CARP	840683	Hs.31432	X83703; AA488072; AA486364	Cytokine inducible nuclear protein
279-280	MITF	278570	Hs.166017	N66177; N99168	microphthalmia-associated transcription factor
281-282	CDC20	898062	Hs.82906	U05340; AA598776	p55CDC
283-	EPS8	148028	Hs.2132	U12535;	epidermal growth

285				H13623; H13622	factor receptor kinase substrate (Eps8)
286-287	ARHI	345680	Hs.194695	W72033; W76278	ras homolog gene family, member I
288	B4-2	857002	Hs.75969	AA669637	proline-rich protein with nuclear targeting signal
289-291	SELE	186132	Hs.89546	M30640; H39991; H39560	ELAM1=endothelial leukocyte adhesion molecule I
292-293	PMP22	133273	Hs.103724	R26732; R26960	peripheral myelin protein 22
294	EBAF	340657	Hs.25195	W56771	endometrial bleeding associated factor (left-right determination, factor A; transforming growth factor beta superfamily)
295-296	PRKAR2B	609663	Hs.77439	AA180007; AA181500	protein kinase, cAMP-dependent, regulatory, type II, beta
297	NFKBIE	1573311	Hs.91640	AA953975	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon
298-299	KIT	269806	Hs.81665	N24824; N36279	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
158	JUNB	309864	Hs.198951		jun B proto-oncogene
300	BCKDK	1573108	Hs.20644	AA970731	branched chain alpha-ketoacid dehydrogenase kinase
301-303	BTG1	298268	Hs.77054	X61123; N70463; W03824	BTG1=B-cell translocation gene 1=anti-proliferative
304-305	AKAP12	784772	Hs.788	AA478543; AA478542	A kinase (PRKA) anchor protein (gravin) 12
306-307	NR4A2	898221	Hs.82120	S77154; AA598611	NOT=Immediate early response protein=Nurr1 homologue=Nurr77 orphan steroid receptor family member
308-309	HBB	126531	Hs.155376	R06757; R06806	hemoglobin, beta
310-311	ARHGAP6	768489	Hs.250830	AA495981; AA425035	Rho GTPase activating protein 6
312	PLS3	1568391	Hs.4114	AA953747	plastin 3 (T isoform)
313-314	FNTA	300015	Hs.138381	N78902; W06970	farnesyltransferase, CAAAX box, alpha
315-316	TNFAIP3	770670	Hs.211600	AA476272; AA433807	tumor necrosis factor, alpha-induced protein 3
317-318	EGR1	840944	Hs.326035	AA486533; AA486628	early growth response 1
319	RNAC	795213	Hs.113052	AA453591	RNA cyclase homolog

320	PA26	813584	Hs.14125	AA447661	p53 regulated PA26 nuclear protein
321	C11orf13	1573778	Hs.72925	AA970526	chromosome 11 open reading frame 13
322	ING1L	2169465	Hs.107153	AI564029	inhibitor of growth family, member 1-like
323	RPL9	2577249	Hs.157850	AW075605	ribosomal protein L9
324-325	ADH5	813711	Hs.78989	AA453776; AA453859	alcohol dehydrogenase 5 (class III), chi polypeptide
326-327	FZD7	298122	Hs.173859	N69049; W00697	frizzled (Drosophila) homolog 7
328-329	MATN2	366100	Hs.19368	AA071473; AA082338	matrilin 2
330-331	SLC11A3	71863	Hs.5944	T52564; T57235	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 3
332-333	EST	767641	Hs.122460	AA418293; AA418356	ESTs
334-335	ERCC5	292463	Hs.48576	N62586; N80359	excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))
336-337	MGC2479	43771	Hs.79625	H05655; H05654	hypothetical protein MGC2479
338-339	RPL21	810617	Hs.184108	AA464743; AA464034	ribosomal protein L21
182	CD24	204335	Hs.286124		CD24
340-341	SLPI	378813	Hs.251754	X04470; AA683520	Secretory leukocyte protease inhibitor
342	SPP1	378461	Hs.313	AA775616	Secreted phosphoprotein 1 (osteopontin, bone-sialoprotein I, early T-lymphocyte activation 1)
343-344	BF	741977	Hs.69771	L15702; AA401441	B-factor, properdin
345-347	CKS1	810899	Hs.334883	X54941; AA459292; AA459522	CDC28 protein kinase 1
348-349	MMP7	470393	Hs.2256	AA031514; AA031513	Matrix metalloproteinase 7 (matrilysin)
350-351	PAX8	742101	Hs.73149	AA405767; AA405891	Paired box gene 8
352-353	SPINT2	814378	Hs.31439	AA458849; AA459039	Serine protease inhibitor, Kunitz type, 2
354	ZWINT	451907	Hs.42650	AA706968	ZW10 interactor
355	DGKH	2544675	Hs.159073	AW052032	Diacylglycerol kinase, eta

356	HMGIY	782811	Hs.139800	AA448261	HMGIY High-mobility group (nonhistone chromosomal) protein isoforms I and Y
357-359	SDC4	504763	Hs.252189	X67016; AA148737; AA148736	Syndecan 4 (amphiglycan, ryudocan)
360	CDKN2A	1161155	Hs.1174	AA877595	Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
361-362	SCNN1A	810873	Hs.2794	AA458982; AA459197	Sodium channel, nonvoltage-gated 1 alpha
363	LDHA	43550	Hs.2795	H05914	Lactate dehydrogenase A
364-365	FOLR1	131839	Hs.73769	R24530; R24635	Folate receptor 1
366-367	TPI1	855749	Hs.83848	M10036; AA663983	Triosephosphate isomerase 1
368	KLK8	2514426	Hs.104570	AI963941	Kallikrein 8 (neuropsin/ovasin)
200	CXCR4	79629	Hs.89414		Chemokine (C-X-C motif), receptor 4 (fusin)
369-370	KNSL1	825606	Hs.8878	AA504625; AA504719	Kinesin-like 1
371-372	H2AFO	488964	Hs.795	AA047260; AA057146	H2A histone family, member O
373-374	HLA-DRA	153411	Hs.76807	R47979; R48091	Major histocompatibility complex, class II, DR alpha
375	CRIP1	1323448	Hs.17409	AA873604	Cysteine-rich protein 1
376	PP	950700	Hs.184011	AA608572	Pyrophosphatase (inorganic)
377-378	EST	666391		AA232895; AA232894	
379-381	SLC2A1	207358	Hs.169902	-K03195; H58873; H58872	Solute carrier family 2 (facilitated glucose transporter), member 1
382	EST	897770		AA598508	
383-385	HDGF	813673	Hs.89525	D16431; AA453749; AA453831	Hepatoma-derived growth factor (high-mobility group protein 1-like)
386	ASS	882522	Hs.160786	AA676466	Argininosuccinate synthetase
387-388	CLDN4	770388	Hs.5372	AA430665; AA427468	Claudin 4
389	PRAME	897956	Hs.30743	AA598817	preferentially expressed antigen in melanoma
390-391	PTPRF	897788	Hs.75216	Y00815; AA598513	Protein tyrosine phosphatase, receptor type, F
392-393	EYA2	741139	Hs.29279	AA402754; AA402207	Eyes absent (Drosophila) homolog

					2
394-396	MYCL1	138917	Hs.92137	M19720; R62813; R62862	v-myc myelocytomatosis viral oncogene homolog 1
397-399	STAT1	840691	Hs.21486	M97935; AA488075; AA486367	Signal transducer and activator of transcription 1
400-401	M1CH2	564492	Hs.279609	AA121668; AA121740	microtubular protein homolog 2
402	HTR3A	435597	Hs.2142	AA703169	5-hydroxytryptamine (serotonin) receptor 3A
403-404	CCNE1	68950	Hs.9700	T54121; T54213	Cyclin E1
405	CDH6	739155	Hs.32963	AA421819	Cadherin 6, type 2, K- cadherin
406-408	PRKAG1	531028	Hs.3136	U42412; AA070495; AA070381	Protein kinase, AMP- activated, gamma 1 non-catalytic subunit
409	DEFB1	2403485	Hs.32949	AI769855	Defensin, beta 1
410-411	ARPC1B	626502	Hs.11538	AA188179; AA188155	Actin related protein 2/3 complex, subunit 1B (41 kD)
412-414	PRKCI	71622	Hs.1904	L33881; T57875; T57957	Protein kinase C, iota
415	GAPD	1610448	Hs.169476	AA991856	glyceraldehyde-3- phosphate dehydrogenase
416-417	C2	85497	Hs.2253	T71879; T71878	Complement Component C2
418-419	H2AFY	843075	Hs.75258	AA488627; AA486003	H2A histone family, member Y
420-421	TM4SF1	840567	Hs.3337	AA487893; AA488005	Transmembrane 4 superfamily member 1
422-423	GAPD	50117	Hs.169476	H16958; H16957	glyceraldehyde-3- phosphate dehydrogenase
424-426	IFITM3	809910	Hs.182241	X57352; AA464417; AA464416	interferon induced transmembrane protein 3 (1-8U)
427-428	GLDC	248261	Hs.27	N58494; N78083	Glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)
429-430	CALU	144881	Hs.7753	R78586; R78585	Calumenin
431-432	HBA2	208764	Hs.272572	H63096; H63182	Hemoglobin, alpha 2
433	S100A11	810612	Hs.256290	AA464731	S100 calcium-binding protein A11 (calgizzarin)
434-436	LDHA	897567	Hs.2795	X02152; AA497029; AA489611	Lactate dehydrogenase A
437	UBE2C	769921	Hs.93002	AA430504	Ubiquitin-conjugating

					enzyme E2C
438-440	E2F3	304908	Hs.1189	D38550; N92519; W38841	E2F transcription factor 3
441-442	CDH1	251019	Hs.194657	Z13009; H97778	Cadherin 1, type 1, E-cadherin (epithelial)
443-444	PSME2	210405	Hs.179774	H65395; H65394	Proteasome (prosome, macropain) activator subunit 2 (PA28 beta)
445-447	BMP7	344430	Hs.170195	X51801; W73473; W73527	bone morphogenetic protein 7 (osteogenic protein 1)
448	TOP2A	825470		AA504348	topoisomerase (DNA) II alpha (170kD)
449-451	IL8	328692	Hs.624	M17017; W45324; W40283	interleukin 8
452-453	GRO1	324437	Hs.789	X54489; W46900	GRO1 oncogene (melanoma growth stimulating activity, alpha)
454-456	ALDH1A3	272686	Hs.75746	U07919; N32289; N44575	aldehyde dehydrogenase 1 family, member A3; Aldehyde dehydrogenase 6
457-459	MMP1	624924	Hs.83169	X54925; AA181875; AA186634	matrix metalloproteinase 1 (interstitial collagenase)
460-461	OSF-2	897910	Hs.136348	D13666; AA598653	osteoblast specific factor 2 (fasciclin I-like)
462-464	CDC25B	48398	Hs.153752	S78187; H14343; H14392	cell division cycle 25B; M-phase inducer phosphatase 2
465-467	FLNA	487418	Hs.195464	X53416; AA046721; AA046606	filamin A, alpha (actin-binding protein-280)
468-469	TFP12	726086	Hs.295944	AA399473; AA293402	tissue factor pathway inhibitor 2
470-472	FGF2	23073	Hs.284244	M27968; R38539; T75110	fibroblast growth factor 2 (basic)
473-475	CD44	713145	Hs.169610	X56794; AA283090; AA282906	CD44 antigen; extracellular matrix receptor-III=Hyaluronate receptor
476-477	DYT1	69046	Hs.19261	T54320; T53726	dystonia 1, torsion (autosomal dominant; torsin A)
478	UCHL1	878833	Hs.76118	AA670438	ubiquitin carboxyl-terminal esterase L1 (ubiquitin thioesterase)
479-480	PLAU	1696513	Hs.77274	D00244; AI088434	plasminogen activator, urokinase
256	LDHA	43550	Hs.2795		lactate dehydrogenase

					A
481-483	PTGS2	147050	Hs.196384	U04636; R80217; R80322	cyclooxygenase-2; prostaglandin endoperoxide synthase-2
484-486	PRNP	682013	Hs.74621	M13899; AA256322; AA256449	prion protein
487-488	MT1X	207392	Hs.278462	N80129; W03653	metallothionein 1L, metallothionein 1X
489-490	UGB	81336	Hs.2240	T63761; T63800	uteroglobin
491-493	PBEF	594539	Hs.239138	U02020; AA169813; AA171651	pre-B-cell colony- enhancing factor
494-496	TXNRD1	789376	Hs.13046	X91247; AA464849; AA453335	thioredoxin reductase 1; GRIM-12
497-499	NT5	21655	Hs.153952	X55740; T65120; T65189	5' nucleotidase (CD73)
500-502	MT2A	590150	Hs.118786	J00271; AA156031; AA156201	metallothionein 2A
503	ZNF220	949928	Hs.82210	AA599173	zinc finger protein 220
504-506	AKT1	810331	Hs.71816	U97276; AA464152; AA464217	BPGF-1=bone-derived growth factor; v-akt murine thymoma viral oncogene homolog 1
507-509	PTEN	322160	Hs.10712	U92436; W37864; W37855	MMAC1=PTEN=Tum or suppressor gene at 10q23.3 that is Mutated in Multiple Advanced Cancers=Phosphatase and tensin homolog
510-512	UBL1	758495	Hs.81424	U83117; AA401634; AA401864	ubiquitin-homology domain protein PIC1
513-514	WNT2	302286	Hs.89791	N78828; W17194	wingless-type MMTV integration site family member 2
515-517	SFRP4	841282	Hs.105700	AF026692; AA487193; AA486838	frizzled related protein frpHE
518-520	RUNX1	263251	Hs.129914	D43968; H99599; H99598	AML1 Proto- oncogene
521-523	TAL1	71727	Hs.73828	X51990; T51236; T51350	T-cell acute lymphocytic leukemia 1
524-526	WAS	236282	Hs.2157	U12707; H61193; H62098	Wiskott-Aldrich syndrome protein
527-528	PCTK1	713382	Hs.171834	X66363; AA283125	PCTAIRE 1 serine/threonine protein kinase
529	EBP	295986	Hs.75105	N67038	emopamil-binding protein (sterol

530	SMC1L1	897997	Hs.211602	AA598887	isomerase) SMC1 (structural maintenance of chromosomes 1, yeast)-like 1
531-532	ARAF1	207618	Hs.77183	H59758; H59757	v-raf murine sarcoma 3611 viral oncogene homolog 1
533	UBE1	898262	Hs.2055	AA598670	ubiquitin-activating enzyme E1
534-535	LOC51760	52226	Hs.26971	H23265; H23376	B/K protein
536-537	LRPAP1	842785	Hs.75140	AA486209; AA486313	low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1)
538-540	PSTPIP1	71434	Hs.129758	L07633; T47815; T47814	interferon-gamma IEF SSP 5111; Interferon gamma upregulated protein
541-542	IDH2	869375	Hs.5337	X69433; AA679907	isocitrate dehydrogenase 2 (NADP+), mitochondrial
543	SIAHBP1	854696	Hs.74562	AA630094	fuse-binding protein-interacting repressor
544	SLC25A11	878413	Hs.184877	AA670357	solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11
545-547	LCN2	302127	Hs.204238	X99133; N79823; W38398	lipocalin 2 (oncogene 24p3)
548-550	TCEB2	52162	Hs.172772	L42856; H22966; H24146	Elongin B=RNA polymerase II transcription factor SIII p18 subunit
551-553	NM23H1	176482		X17620; H42520; H43520	nm23-H1=NDP kinase A=Nucleoside diphosphate kinase A
554-556	SCYB5	198699	Hs.89714	X78686; R95077; R95145	ENA78=chemokine
557-558	PAK2	231951	Hs.284275	U25975; H92785	hPAK65=SER/THR-protein kinase PAK-gamma =P21-activated kinase 3
559-561	S100A4	472180	Hs.81256	M80563; AA057375; AA036758	S100 calcium binding protein A4=Placental calcium binding protein=Calvasculin=mts1 PROTEIN=CAPL
562-564	CD83	564503	Hs.79197	Z11697; AA101749; AA101748	CD83=B-G antigen IgV domain homolog=B-cell

					activation protein=HB15
565- 567	NCOA1	609445	Hs.74002	U59302; AA180462; AA179970	SRC-1=steroid receptor coactivator
568- 570	RYBP	649654	Hs.7910	AF179286; AA216739; AA216519	Death effector domain-associated factor=Binds to Caspase 10 DED domain=Homolog of mouse RYBP repressor protein that interacts with Polycomb complex and YY1=YAF2 homolog=DEDAF=Y AF2 homolog=MLNewGen e3
571- 573	ITGAE	665279	Hs.851	L25851; AA195282; AA195146	CD103 alpha=Integrin alpha-E
574- 576	IL7	701422	Hs.72927	J04156; AA287945; AA288010	IL-7
577- 579	CD36	243816	Hs.75613	M98399; N39161; N45238	CD36
580- 582	PDGFRB	773439	Hs.76144	J03278; AA426020; AA428115	Platelet-derived growth factor receptor, beta polypeptide=fused to TEL in t(5;12)(q33;p13) chronic myelomonocytic leukemia
583- 584	IL17R	842122	Hs.129751	U58917; AA634809	IL-17 receptor
585- 586	HGF	1219612	Hs.809	X16323; AA687773	Hepatocyte growth factor (hepatopoietin A; scatter factor)
587- 588	BAD	1286754	Hs.76366	U66879; AA740876	BAD=bbc6=proapopto tic Bcl-2 homolog
589- 591	ZNF173	755176	Hs.1287	U09825; AA421953; AA421952	acid finger protein
592- 593	ZFP161	285742	Hs.156000	D89859; N64141	ZF5=POZ domain zinc finger protein
594- 596	RGS16	470132	Hs.183601	U70426; AA029960; AA029959	A28-RGS14p=G protein signaling regulator
597- 599	PPP1CB	485729	Hs.21537	X80910; AA040285; AA040284	PPP1CB=Protein phosphatase 1, catalytic subunit, beta isoform
600- 602	GART	502761	Hs.82285	X54199; AA126256; AA126360	Phosphoribosylglycina mide formyltransferase,

					phospho-ribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
603-605	ENPP1	786041	Hs.11951	D12485; AA448639; AA448731	PC-1 = alkaline nucleotide pyrophosphatase
606-608	MMP13	786029	Hs.2936	X75308; AA448634; AA448726	MMP-13=Matrix metalloproteinase 13=CL-3=Collagenase 3
609-611	ILK	292313	Hs.6196	U40282; N62542; N79210	ILK=integrin-linked kinase
612-614	SCYA4	205633	Hs.75703	J04130; H62864; H62985	MIP-1 beta=SCAY2=G-26=HC21=pAT 744=LAG-1=Act-2=H400=SIS-gamma=chemokine
615-617	KDR	469345	Hs.12337	AF035121; AA027012; AA026831	Kinase insert domain receptor (a type III receptor tyrosine kinase)
618-620	IL18R1	755054	Hs.159301	U43672; AI821652; AI734039	IL-18 receptor 1=IL-1Rrp
621-623	PPP2R5A	41356	Hs.155079	L42373; R59165; R59164	phosphatase 2A B56-alpha (PP2A)
624-625	PTK2B	180298	Hs.20313	U43522; R85257	protein tyrosine kinase PYK2
626-628	MAP2K3	45641	Hs.180533	D87116; H08749; H08467	Dual specificity mitogen-activated protein kinase kinase 3
629-631	TNFR2R P	124034	Hs.117847	L04270; R02558; R02676	Lymphotoxin-Beta receptor precursor = Tumor necrosis factor receptor 2 related protein = Tumor necrosis factor C receptor
632-633	EST	739852	Hs.328687	AI821550; AA477842	ESTs, Moderately similar to ALU4_HUMAN ALU subfamily SB2 sequence contamination warning entry [H.sapiens]
634-635	EST	1862171	Hs.310541	AI053777; AI792563	ESTs
636	EST	1985026		AI251605	Unknown
637	EST	2002071	Hs.203960	AI249848	ESTs
638	EST	2047317		AI311297	Unknown
639	EST	2215752		AI567814	Unknown
640	EST	2217459		AI744181	Unknown
641	EST	2217834	Hs.328451	AI744330	EST, Weakly similar to PRPP_HUMAN

					salivary proline-rich protein II-1 [H.sapiens]
642	EST	2219300		AI745684	Unknown
643	EST	2220085	Hs.337231	AI798317	EST
644	EST	2220214		AI798385	Unknown
645	EST	2261174	Hs.185554	AI609326	EST
646	EST	2261169		AI609331	Unknown
647	EST	2292810	Hs.224732	AI871559	EST
648	EST	2292831	Hs.337311	AI871678	EST
649	EST	2549950		AI954130	Unknown
650	EST	2550130		AI953438	Unknown
651-652	FDFT1	25725	Hs.48876	R36960; R11842	farnesyl-diphosphate farnesyltransferase 1
653-654	NAGA	28985	Hs.75372	R40255; R14305	N-acetylgalactosaminidase, alpha-
655-656	SECRET	29054	Hs.116428	R40850; R14422	secretagogin
657-658	SLC9A1	30272	Hs.170222	R42414; R14692	solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na+/H+, amiloride sensitive)
659	TUFM	34945	Hs.12084	R45183	Tu translation elongation factor, mitochondrial
660-661	MNAT1	38471	Hs.82380	R49475; R35961	menage a trois 1 (CAK assembly factor)
662-663	HARS	43021	Hs.77798	R60150; R60149	histidyl-tRNA synthetase
664-665	EIF4A1	46171	Hs.129673	H09590; H09589	eukaryotic translation initiation factor 4A, isoform 1
666-667	MPI	50359	Hs.75694	H17096; H17714	mannose phosphate isomerase
668-669	TAGLN2	45544	Hs.75725	H08564; H08563	transgelin 2
670-671	PON1	128143	Hs.1898	R12373; R09781	paraoxonase 1
672-673	EST	813444	Hs.178379	AA455945; AA455554	ESTs
674-675	GNB2	292213	Hs.91299	N68166; N80625	guanine nucleotide binding protein (G protein), beta polypeptide 2
676-677	KIAA0365	811029	Hs.190452	AA485383; AA485539	KIAA0365 gene product
678	NCSTN	199645	Hs.4788	R96527	nicastrin
679-681	ARHGEF6	687990	Hs.79307	D25304; AA236957; AA236617	KIAA0006
682	SFRS11	204755	Hs.11482	H56944	splicing factor, arginine/serine-rich 11
683-684	CUGBP1	25588	Hs.81248	R15111; R12181	CUG triplet repeat, RNA-binding protein 1
685-	GABRP	563598	Hs.70725	AA101225;	gamma-aminobutyric

686				AA102670	acid (GABA) A receptor, pi`
687-688	BMP6	768168	Hs.285671	AA424833; AA426586	bone morphogenetic protein 6
689-690	ATP7A	687820	Hs.606	AA236141; AA236635	ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome)
691-692	RBBP4	773599	Hs.16003	AA428365; AA429422	retinoblastoma-binding protein 4
693-694	POLR2A	740130	Hs.171880	AA479052; AA477535	polymerase (RNA) II (DNA directed) polypeptide A (220kD)
695-696	SMG1	785605	Hs.110613	AA449463; AA448998	PI-3-kinase-related kinase SMG-1
697-698	GTPBP1	826217	Hs.283677	U87964; AA521469	GP-1=putative G-protein
699-700	GS2NA	767994	Hs.183105	AA418821; AA418918	nuclear autoantigen
701-702	FLJ12442	32231	Hs.84753	R42815; R17469	hypothetical protein FLJ12442
703-704	KIAA0218	49404	Hs.75863	H15567; H15627	KIAA0218 gene product
705-706	KIAA0144	245015	Hs.8127	N52646; N72374	KIAA0144 gene product
707-708	FOXO1A	628955	Hs.170133	AA194765; AA194764	forkhead box O1A (rhabdomyosarcoma)
709	CSRP2	75254	Hs.10526	T59334	cysteine and glycine-rich protein 2
710-711	BRE	739993	Hs.80426	AA479741; AA477082	brain and reproductive organ-expressed (TNFRSF1A modulator)
712-713	RALY	825583	Hs.74111	AA504617; AA504712	RNA-binding protein (autoantigenic)
714-716	FGFR2	809464	Hs.282823	M87771; AA443093; AA456160	FGFR2=Fibroblast growth factor receptor 2
717-718	EST	242820	Hs.290870	H94050; H94131	ESTs, Weakly similar to I38588 reverse transcriptase homolog [H.sapiens]
719-720	PEF	137353	Hs.241531	R38031; R38117	PEF protein with a long N-terminal hydrophobic domain (peflin)
721-722	EST	265494	Hs.153445	N21309; N31244	Human mRNA for unknown product, partial cds
723-724	SAST	739625	Hs.227489	AA479623; AA477008	syntrophin associated serine/threonine kinase
725-726	EST	142499		R70037; R70084	Unknown
727-728	PLXNA2	303035	Hs.300622	N91580; W19130	plexin A2
729-730	EST	240694	Hs.167787	H78135; H78134	ESTs

731-732	APMCF1	198904	Hs.12152	R95693; R95692	APMCF1 protein
375	CALU	144881	Hs.7753		calumenin
733-734	PPY2	210873	Hs.20588	H67736; H66312	pancreatic polypeptide 2
735-736	CRB1	248485	Hs.169745	N59646; N78199	crumbs (Drosophila) homolog 1
737-738	FLJ21661	80095	Hs.334718	T63321; T63940	hypothetical protein FLJ21661
739-740	RAB3A	163579	Hs.27744	H14231; H14230	RAB3A, member RAS oncogene family
741-742	GCAT	307094	Hs.54609	N93695; W21033	glycine C-acetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase)
743-744	P14L	809437	Hs.178576	AA458464; AA442976	similar to Bos taurus P14 protein
745-746	KIAA0008	357373	Hs.77695	W93717; W93568	KIAA0008 gene product
747-748	LOX	341680	Hs.102267	W60414; W60413	lysyl oxidase
749-750	PISD	343609	Hs.8128	W69460; W69544	phosphatidylserine decarboxylase
751-752	EST	341834	Hs.27278	W60647; W60905	ESTs, Weakly similar to A Chain A, Cyclophilin A [H.sapiens]
753-754	EST	809490	Hs.3737	AA443117; AA456181	ESTs
755-756	TMEPAI	809824	Hs.83883	AA455519; AA464401	transmembrane, prostate androgen induced RNA
757-758	ZNF211	346947	Hs.15110	W79396; W79316	zinc finger protein 211
759	LOC51605	810343	Hs.128791	AA464166	CGI-09 protein
760-761	MAPRE1	428223	Hs.234279	AA001749; AA001819	microtubule-associated protein, RP/EB family, member 1
762	FLJ10701	430068	Hs.146589	AA009830	hypothetical protein FLJ10701
763-764	DKFZP564C186	366353	Hs.134200	AA026278; AA026277	DKFZP564C186 protein
765	EST	810205	Hs.264606	AA464518	ESTs
766-767	F23149_1	428507	Hs.152894	AA004525; AA004607	hypothetical protein F23149_1
768-769	FLJ21940	810795	Hs.104916	AA458876; AA459066	hypothetical protein FLJ21940
770-771	FLJ22059	292223	Hs.13323	N62464; N79183	hypothetical protein FLJ22059
772-773	EST	241861	Hs.269020	H93115; H93243	ESTs
398	RGS1	361323	Hs.75256		regulator of G-protein signalling 1
774	PDE6A	361840	Hs.182240	W92514	phosphodiesterase 6A, cGMP-specific, rod, alpha
775-	IL1B	491763	Hs.126256	AA150507;	interleukin 1, beta

776				AA156711	
777	SF3B4	432564	Hs.25797	AA699361	splicing factor 3b, subunit 4, 49kD
778	EST	277627	Hs.348427	N45979	Human SH3 domain-containing protein SH3P18 mRNA, complete cds
779	TCF4	854581	Hs.326198	AA669136	transcription factor 4
780-781	RAB2L	741891	Hs.170160	AA401972; AA402117	RAB2, member RAS oncogene family-like
782-783	GOLGA1	34102	Hs.172647	R44140; R23687	golgi autoantigen, golgin subfamily a, 1
784	TNRC12	770000	Hs.306094	AA427519	trinucleotide repeat containing 12
785	CSNK1E	854138	Hs.79658	AA669272	casein kinase 1, epsilon
786-787	AFP	74537	Hs.155421	T59043; T59118	alpha-fetoprotein
788-789	COVA1	588822	Hs.155185	AA156560; AA157732	cytosolic ovarian carcinoma antigen 1
790-791	APEX	740907	Hs.73722	AA478273; AA478331	APEX nuclease (multifunctional DNA repair enzyme)
792-793	RBBP2	841655	Hs.76272	AA487492; AA487706	retinoblastoma-binding protein 2
794-796	GRO1	323238		M36820; W42723; W42812	Human cytokine (GRO-beta) mRNA; GRO2=GRO beta = MIP2 alpha = macrophage inflammatory protein-2 alpha = chemokine
797-799	WNT2	149373		X07876; H04382; H04408	wingless-type MMTV integration site family member 2
800	PTGS2	845477	Hs.196384	AA644211	cyclooxygenase-2; prostaglandin endoperoxide synthase-2
801-802	PRNP	470074	Hs.74621	AA029059; AA029163	prion protein
803-804	WNT5B	323636	Hs.306051	W44518; W44517	Homo sapiens mRNA for WNT5B, complete cds
805	CD72	1241854		AA714696	
806		897774		AA598510	adenine phosphoribosyltransferase
807-808		795893		AA460168 AA460768	protein phosphatase 1, regulatory (inhibitor) subunit 15A
809-810		825214		AA504113 AA504371	M-phase phosphoprotein 10
811-812		154720		R55220 R55219	ARD1 homolog, N-acetyltransferase (S. cerevisiae)
813-814		204214		H59204 H59203	CDC6 cell division cycle 6 homolog (S. cerevisiae)

815-816		815294		AA481547 AA481613	protein tyrosine phosphatase, receptor type, C-associated protein
817		825265		AA504204	polymerase (DNA directed), delta 3
818		2549467		AI952542	unknown EST
819		1056107		AA628360	putative cyclin G1 interacting protein
820-821		809515		AA454565 AA456458	pLK=homologue of Drosophila polo serine/threonine kinase
822	CMKBR6			U45984	CCR6=STRL22=chemokine receptor for MIP-3 alpha/LARC/Exodus on activated B cells

Table 4. Markers that were Under-expressed in Ovarian Cancer in a Comparison of Ovarian Epithelial Cancer to Normal Postmenopausal Ovarian Tissue

SEQ. ID. NO.	IMAGE ID	Nucleic Acid	Description	Average log normal	Average log cancer	Cancer to normal
202	878596	ITM2A	integral membrane protein 2A	1.145	-2.036	0.110
203-204	42558	GATM	glycine amidinotransferase (L-arginine:glycine amidinotransferase)	4.137	0.945	0.109
205-207	81417	RNASE4	ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent)	2.057	-0.744	0.144
208-210	471642	LAMA2	laminin alpha 2 (merosin, congenital muscular dystrophy)	2.806	0.361	0.184
211	448386	PBX3	pre-B-cell leukemia transcription factor 3	2.354	-0.243	0.165
212	1472538	PLA2G6	phospholipase A2, group VI (cytosolic, calcium-independent)	2.604	0.099	0.176
213	814636	SMARCA2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2	3.055	0.231	0.141
214-215	488956	CUGBP2	CUG triplet repeat, RNA-binding protein 2	2.960	-0.043	0.125
216-218	209655	TGFBR3	TGF beta receptor type III	1.956	0.057	0.268
219	859858	STAR	steroidogenic acute regulatory protein	1.685	0.026	0.317
220	1636447	GNG11	guanine nucleotide binding protein 11	1.683	-0.953	0.161
221	491565	CITED2	Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2	1.576	-0.497	0.238
222	744647	CTNNAL1	catenin (cadherin-associated protein), alpha-like 1	1.498	-0.761	0.209
223	743773	ABCA8	ATP-binding cassette, sub-family A (ABC1), member 8	2.317	0.060	0.209
224-226	188232	KLF4	GKLF=EZF=KLF4=gut-enriched Kruppel-like zinc finger protein=expressed in vascular endothelial cells	1.644	-0.741	0.191
227-228	471725	ITPR1	inositol 1,4,5-triphosphate receptor, type 1	1.600	-0.616	0.215
229-230	487793	MAF	v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog	0.765	-2.032	0.144
231-232	768370	FOXC1	forkhead box C1	2.270	-0.021	0.204
233	461351	TCF21	transcription factor 21	1.733	0.193	0.344
234-236	248295	CCNI	Cyclin I	2.460	-0.030	0.178
237-238	209367	DCN	decorin	3.762	0.582	0.110
239-240	789049	CBF2	CCAAT-box-binding transcription factor	2.140	0.019	0.230

241-242	68049		Homo sapiens, clone IMAGE:4183312, mRNA, partial cds	2.074	0.243	0.281
122	81417	RNASE4	ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent)	1.696	-0.117	0.285
243	2094012	SLC4A1AP	solute carrier family 4 (anion exchanger), member 1, adapter protein	1.869	0.195	0.313
244-245	377731	GSTM5	glutathione S-transferase M5	1.558	0.242	0.402
246	460470	C4BPB	complement component 4-binding protein, beta	0.750	-0.851	0.330
247-248	73609	HS3ST1	heparan sulfate (glucosamine) 3-O-sulfotransferase 1	2.017	0.328	0.310
249	2413955	CDKN1C	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	2.739	0.465	0.207
250	897823	HNRPDL	heterogeneous nuclear ribonucleoprotein D-like	1.703	-0.229	0.262
251	1558799	CIRBP	cold inducible RNA-binding protein	1.817	-0.183	0.250
252	2321596	RGS2	regulator of G-protein signalling 2, 24kD	1.607	-0.290	0.269
253-254	786607	TCEAL1	transcription elongation factor A (SII)-like 1	1.737	0.083	0.318
255-256	377461	CAV1	caveolin 1, caveolae protein, 22kD	0.146	-2.506	0.159
257	855624	ALDH1A1	aldehyde dehydrogenase 1 family, member A1	2.030	-0.068	0.233
258-259	343443	RBPMS	RNA-binding protein gene with multiple splicing	1.727	-0.240	0.256
260-261	62263	ADAMTS1	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1	1.589	0.029	0.339
262-263	51408	DSCR1L1	Down syndrome critical region gene 1-like 1	2.054	0.260	0.288
264	436121	DLK1	delta-like homolog (Drosophila)	0.307	-1.944	0.210
265-266	491113	CDH11	cadherin 11, type 2, OB-cadherin (osteoblast)	2.308	0.502	0.286
139	840776	SGK	sgk-putative serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume	1.444	-0.201	0.320
267	450060	HFL1	H factor (complement)-like 1	2.490	0.664	0.282
268-269	38347	FOG2	Friend of GATA2	1.905	0.463	0.368
270	898122	C7	complement component 7	2.643	0.660	0.253
271-272	784109	SGCE	sarcoglycan, epsilon	1.573	-0.213	0.290
273	898305	NBL1	neuroblastoma, suppression of tumorigenicity 1	1.910	0.153	0.296
274-275	173385	HBB	hemoglobin, beta	0.165	-2.317	0.179
276-278	840683	CARP	Cytokine inducible nuclear protein	1.728	0.018	0.306
279-280	278570	MITF	microphthalmia-associated transcription factor	0.242	-1.580	0.283
281-282	898062	CDC20	p55CDC	1.679	-0.043	0.303
283-285	148028	EPS8	epidermal growth factor receptor kinase substrate (Eps8)	1.595	-0.344	0.261

286-287	345680	ARHI	ras homolog gene family, member I	1.595	0.212	0.383
288	857002	B4-2	proline-rich protein with nuclear targeting signal	1.523	0.285	0.424
289-291	186132	SELE	ELAM1=endothelial leukocyte adhesion molecule I	1.480	-0.393	0.273
292-293	133273	PMP22	peripheral myelin protein 22	1.767	0.017	0.297
294	340657	EBAF	endometrial bleeding associated factor (left-right determination, factor A; transforming growth factor beta superfamily)	1.422	-0.076	0.354
295-296	609663	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta	1.357	-0.461	0.284
297	1573311	NFKBIE	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon	1.242	-1.102	0.197
298-299	269806	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	2.324	0.315	0.248
158	309864	JUNB	jun B proto-oncogene	3.465	1.117	0.196
300	1573108	BCKDK	branched chain alpha-ketoacid dehydrogenase kinase	1.306	-1.057	0.194
301-303	298268	BTG1	BTG1=B-cell translocation gene 1=anti-proliferative	1.409	-0.239	0.319
304-305	784772	AKAP12	A kinase (PRKA) anchor protein (gravin) 12	1.568	-0.413	0.253
306-307	898221	NR4A2	NOT=Immediate early response protein=Nurr1 homologue=Nurr77 orphan steroid receptor family member	2.092	0.341	0.297
308-309	126531	HBB	hemoglobin, beta	0.190	-2.034	0.214
310-311	768489	ARHGAP6	Rho GTPase activating protein 6	1.263	-0.109	0.386
312	1568391	PLS3	plastin 3 (T isoform)	1.241	-1.045	0.205
313-314	300015	FNTA	farnesyltransferase, CAAX box, alpha	1.354	0.091	0.417
315-316	770670	TNFAIP3	tumor necrosis factor, alpha-induced protein 3	2.088	0.445	0.320
317-318	840944	EGR1	early growth response 1	3.245	0.765	0.179
319	795213	RNAC	RNA cyclase homolog	1.812	0.043	0.293
320	813584	PA26	p53 regulated PA26 nuclear protein	1.329	0.084	0.422
321	1573778	C11orf13	chromosome 11 open reading frame 13	1.241	-1.048	0.205
322	2169465	ING1L	inhibitor of growth family, member 1-like	1.267	0.031	0.425
323	2577249	RPL9	ribosomal protein L9	1.756	-0.313	0.238
324-325	813711	ADH5	alcohol dehydrogenase 5 (class III), chi polypeptide	1.211	-0.616	0.282
326-327	298122	FZD7	frizzled (Drosophila) homolog 7	2.554	0.747	0.286
328-329	366100	MATN2	matrilin 2	2.205	0.536	0.315
330-331	71863	SLC11A3	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 3	2.466	0.808	0.317
332-333	767641		ESTs	0.965	-0.153	0.461
334-335	292463	ERCC5	excision repair cross-complementing rodent repair deficiency, complementation	1.695	-0.098	0.289

Table 5. Markers that were Over-expressed in Ovarian Cancer in a Comparison of Ovarian Epithelial Cancer to Normal Postmenopausal Ovarian Tissue

SEQ. ID. NO.	IMAGE ID	Nucleic Acid	Description	Average log normal	Average log cancer	Cancer to normal
18-19	82195	SERPINF2	Branched chain keto acid dehydrogenase E1, beta polypeptide (maple syrup urine disease)		1.45	
30-31	295939	FLJ22174	hypothetical protein FLJ22174		1.38	
50-51	755599	IFITM1	Interferon induced transmembrane protein 1 (9-27)		1.74	
55-57	624655	IFITM2	Interferon-induced protein 1-8D		1.53	
60	786675	HE4	Epididymis-specific, whey-acidic protein type, four-disulfide core; putative ovarian carcinoma marker		2.41	
68-69	782513	G1P3	Interferon, alpha-inducible protein (clone IFI-6-16)		1.64	
74-76	182288	DDR1	Receptor protein-tyrosine kinase EDDR1		1.43	
85-86	811139	HLA-DRB5	Major histocompatibility complex, class II, DR beta 5		1.91	
101-103	417711	HLA-DRB1	Major histocompatibility complex, class II, DR beta 1		1.94	
89-91	725751	CD74	Invariant chain=la-associated invariant gamma-chain		2.69	
92-93	840681	CD74	Invariant chain=la-associated invariant gamma-chain		2.58	
94-96	117411	HLA-DRA	MHC Class II=DR alpha		1.62	
97-99	207715	HLA-DPA	MHC Class II=DP alpha		1.85	
122-123	361323	RGS1	regulator of G-protein signaling 1		1.73	
133-135	755279	FOS	c-fos		1.76	
149-151	279388	SORL1	Mosaic protein LR11=hybrid receptor gp250 precursor		1.56	
164-166	813256	ABCB1	MDR1=Multidrug resistance protein 1=P-glycoprotein		1.64	
167-168	23804	ZFP36	Zinc finger protein homologous to Zfp-36 in mouse		1.74	
169-171	135880	ZFP36	TTP=tristetraproline=GOS24=zinc finger transcriptional regulator		2.00	
174-175	41650	HGF	hepatocyte growth factor (hepatopoietin A; scatter factor)		1.54	
176-178	840776	SGK	sgk=putative serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alteration		2.02	
179-180	814508	PPP1R7	Protein phosphatase 1, regulatory subunit 7		1.78	
181-182	204335	CD24	CD24 antigen (small cell lung carcinoma cluster 4 antigen)		2.75	

190-192	485770	BRF2	Tis 11d=ERF-2=growth factor early response gene		1.62	
199-201	144675	TLR3	TLR3= Toll-like receptor 3		1.98	
340-341	378813	SLPI	secretory leukocyte protease inhibitor (antileukoproteinase)	-0.379	2.294	6.377
342	378461	SPP1	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)	-2.657	-0.088	5.938
343-344	741977	BF	B-factor, properdin	-0.362	1.953	4.974
345-347	810899	CKS1	ckshs1=homolog of Cks1=p34Cdc28/Cdc2-associated protein	-1.484	0.637	4.351
348-349	470393	MMP7	matrix metalloproteinase 7 (matrilysin, uterine)	0.673	2.535	3.635
350-351	742101	PAX8	paired box gene 8	-0.566	1.196	3.391
352-353	814378	SPINT2	serine protease inhibitor, Kunitz type, 2	-0.306	1.432	3.336
354	451907	ZWINT	ZW10 interactor	-2.461	-0.856	3.043
355	2544675	DGKH	diacylglycerol kinase, eta	-0.036	1.498	2.896
356	782811	HMG1Y	high-mobility group (nonhistone chromosomal) protein isoforms I and Y	-2.272	-0.760	2.851
357-359	504763	SDC4	Syndecan-4 = amphiglycan = ryudocan core protein	-0.871	0.575	2.725
360	1161155	CDKN2A	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	-0.839	0.593	2.699
361-362	810873	SCNN1A	sodium channel, nonvoltage-gated 1 alpha	0.127	1.534	2.652
363	43550	LDHA	lactate dehydrogenase A	-3.496	-2.152	2.538
364-365	131839	FOLR1	folate receptor 1 (adult)	-0.867	0.467	2.522
366-367	855749	TPI1	Triosephosphate isomerase 1	-2.272	-1.008	2.400
368	2514426	KLK8	kallikrein 8 (neuropsin/ovasin)	-0.491	0.742	2.352
200	79629	CXCR4	CXC chemokine receptor 4=fusin=neuropeptide Y receptor=L3	-0.588	0.618	2.307
369-370	825606	KNSL1	kinesin-like 1	-1.797	-0.602	2.290
371-372	488964	H2AFO	H2A histone family, member O	-1.329	-0.144	2.274
373-374	153411	HLA-DRA	major histocompatibility complex, class II, DR alpha	1.967	3.150	2.270
375	1323448	CRIP1	cysteine-rich protein 1 (intestinal)	0.086	1.246	2.234
376	950700	PP	pyrophosphatase (inorganic)	-1.029	0.118	2.214
377-378	666391	ESTs	Unknown	0.214	1.360	2.212
379-381	207358	SLC2A1	glucose transporter (HepG2)	-1.190	-0.050	2.204
382	897770	ESTs	Unknown	-0.173	0.943	2.167
383-385	813673	HDGF	hepatoma-derived growth factor	-0.786	0.329	2.166
386	882522	ASS	argininosuccinate synthetase	-0.424	0.676	2.143
387-388	770388	CLDN4	claudin 4	0.065	1.159	2.135
389	897956	PRAME	preferentially expressed antigen in melanoma	-2.071	-0.977	2.134
390-391	897788	PTPRF	LAR = LCA-homologue	-0.175	0.900	2.108
392-393	741139	EYA2	eyes absent (Drosophila) homolog 2	-0.133	0.939	2.102
394-396	138917	MYCL1	L-myc	-0.042	1.026	2.096
397-399	840691	STAT1	STAT1=IFN alpha/beta-responsive transcription factor	-0.023	1.044	2.095

			ISGF3 beta subunits (p91/p84)			
400-401	564492	MTCH2	mitochondrial carrier homolog 2	-1.566	-0.512	2.076
402	435597	HTR3A	5-hydroxytryptamine (serotonin) receptor 3A	-0.392	0.656	2.067
403-404	68950	CCNE1	cyclin E1	-0.470	0.577	2.066
405	739155	CDH6	cadherin 6, type 2, K-cadherin (fetal kidney)	-0.286	0.748	2.048
406-408	531028	PRKAG1	5'-AMP-activated protein kinase, gamma-1 subunit	0.148	1.181	2.046
409	2403485	DEFB1	defensin, beta 1	0.335	1.357	2.031
410-411	626502	ARPC1B	actin related protein 2/3 complex, subunit 1A (41 kD)	-0.808	0.213	2.030
412-414	71622	PRKCI	PKC iota=Protein kinase C, iota	-0.202	0.802	2.006
415	1610448	GAPD	glyceraldehyde-3-phosphate dehydrogenase	-1.484	-0.480	2.005
416-417	85497	C2	complement component 2	-0.413	0.589	2.002
418-419	843075	H2AFY	H2A histone family, member Y	-0.829	0.164	1.990
420-421	840567	TM4SF1	transmembrane 4 superfamily member 1	-1.261	-0.270	1.987
422-423	50117	GAPD	glyceraldehyde-3-phosphate dehydrogenase	-2.692	-1.706	1.981
424-426	809910	IFITM3	Interferon-inducible protein 1-8U	-0.099	0.887	1.981
427-428	248261	GLDC	glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	-0.757	0.221	1.970
429-430	144881	CALU	calumenin	-1.579	-0.620	1.943
431-432	208764	HBA2	hemoglobin, alpha 2	-0.114	0.837	1.934
433	810612	S100A11	S100 calcium-binding protein A11 (calgizzarin)	-0.670	0.279	1.931
434-436	897567	LDHA	Lactate dehydrogenase A	-2.982	-2.038	1.925
437	769921	UBE2C	ubiquitin-conjugating enzyme E2C'	-1.429	-0.487	1.922
438-440	304908	E2F3	E2F-3=pRB-binding transcription factor=KIAA0075	-0.526	0.416	1.921
441-442	251019	CDH1	E-cadherin	-0.248	0.682	1.905
443-444	210405	PSME2	proteasome (prosome, macropain) activator subunit 2 (PA28 beta)	-0.715	0.213	1.902
445-447	344430	BMP7	OP-1=osteogenic protein in the TGF-beta family	-0.075	0.852	1.901
448	825470	TOP2A	TOP2A			2

Table 6. Markers that were Differentially Expressed Between *BRCA1*-Linked and Sporadic Tumors in a Comparison to reference Immortalized Ovarian Epithelial Cells.

SEQ ID NO.	Nucleic Acid	Description	Geometric mean of ratios in <i>BRCA1</i>	Geometric mean of ratios in sporadic	Fold difference in geometric means
805	CD72	B-cell differentiation antigen CD72 (human);	1.49	1.17	0.79
544	SLC25A11	solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11	1.27	1.08	0.84
545-547	LCN2	lipocalin 2 (oncogene 24p3)	1.29	0.98	0.76
538-540	PSTPIP1	interferon-gamma IEF SSP 5111; Interferon gamma upregulated protein	1.95; 1.6	1.31; 1.04	0.67; 0.65
543	SIAHBP1	fuse-binding protein-interacting repressor	1.86	1.21	0.65
533	UBE1	ubiquitin-activating enzyme E1	1.54	0.94	0.61
524-526	WAS	Wiskott-Aldrich syndrome protein	1.13	0.79	0.7
541-542	IDH2	isocitrate dehydrogenase 2 (NADP+), mitochondrial	1.69	1.02	0.6
527-528	PCTK1	PCTAIRE 1 serine/threonine protein kinase	1.33	1.12	0.84

Table 7. Markers that were Differentially Expressed Between *BRCA2*-Linked and Sporadic Tumors in a Comparison to reference Immortalized Ovarian Epithelial Cells.

SEQ ID NO.	Nucleic Acid	Description	Geometric mean of ratios in <i>BRCA1</i> -linked tumors	Geometric mean of ratios in sporadic tumors	Fold difference in geometric means
279	LOC51760	B/K protein	1.32	1.1	0.83
280	LRPAP1	low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1)	1.45	1.13	0.78

Table 8. Markers that were Differentially Expressed Between Combined *BRCA*-Linked Group and Sporadic Tumors in a Comparison to reference Immortalized Ovarian Epithelial Cells.

SEQ ID NO.	Nucleic Acid	Description	Geometric mean of ratios in <i>BRCA1</i> -linked tumors	Geometric mean of ratios in sporadic tumors	Fold difference in geometric means
281	PSTPIP1	interferon-gamma IEF SSP 5111=Interferon gamma upregulated protein	1.73; 1.41	1.31; 1.04	0.76; 0.74
282	IDH2	Isocitrate dehydrogenase 2 (NADP+), mitochondrial	1.66	1.02	0.61
274	PCTK1	PCTAIRE 1 serine/threonine protein kinase	1.29	1.12	0.86

Table 9. Markers that were Differentially Expressed between *BRCA1*-like and *BRCA2*-like tumors in a Comparison to reference Immortalized Ovarian Epithelial Cells.

SEQ ID NO:	Gene	Description	Geometric mean of ratios in <i>BRCA1</i>	Geometric mean of ratios in <i>BRCA2</i>	Fold Difference in Geometric Means
122-123	RGS1	regulator of G-protein signalling 1	1.79	4.75	2.65
122-123	RGS1	BL34=RGS1=regulator of G-protein signaling which inhibits SDF-1 directed B cell migration	2.09	5.05	2.41
594-596	RGS16	A28-RGS14p=G protein signaling regulator	1.22	2.32	1.9
612-614	SCYA4	MIP-1 beta=SCAY2=G-26=HC21=pAT 744=LAG-1=Act-2=H400=SIS-gamma=chemokine	1.29	2.23	1.73
612-614	SCYA4	MIP-1 beta=SCAY2=G-26=HC21=pAT 744=LAG-1=Act-2=H400=SIS-gamma=chemokine	1.09	1.79	1.64
515-517	SFRP4	frizzled related protein frpHE	1.13	1.85	1.63
594-596	RGS16	A28-RGS14p=G protein signaling regulator	1.33	2.11	1.58
790-791	APEX	APEX nuclease (multifunctional DNA repair enzyme)	0.66	1.04	1.58
682	SFRS11	splicing factor, arginine/serine-rich 11	0.69	1.09	1.57
507-509	PTEN	MMAC1=PTEN=Tumor suppressor gene at 10q23.3 that is Mutated in Multiple Advanced Cancers=Phosphatase and	1.03	1.56	1.51

		tensin homolog			
774	PDE6A	phosphodiesterase 6A, cGMP-specific, rod, alpha	1.23	1.85	1.51
562-564	CD83	CD83=B-G antigen IgV domain homolog=B-cell activation protein=HB15	1.46	2.19	1.5
592-593	ZFP161	ZF5=POZ domain zinc finger protein	1.03	1.49	1.45
		ESTs	1.17	1.69	1.44
707-708	FOXO1A	forkhead box O1A (rhabdomyosarcoma)	1.38	1.93	1.4
762	FLJ10701	hypothetical protein FLJ10701	1	1.4	1.39
577-579	CD36	CD36	1.32	1.82	1.38
797-799	WNT2	Wnt-2	0.81	1.12	1.38
		Unknown	0.82	1.13	1.38
779	TCF4	transcription factor 4	1.19	1.62	1.36
615-617	KDR	Kinase insert domain receptor (a type III receptor tyrosine kinase)	0.8	1.08	1.35
		ESTs	0.81	1.09	1.35
534-535	LOC51760	B/K protein	0.98	1.32	1.35
797-799	WNT2	Wnt-2	0.99	1.33	1.34
683-684	CUGBP1	CUG triplet repeat, RNA-binding protein 1	0.73	0.98	1.33
709	CSRP2	cysteine and glycine-rich protein 2	0.98	1.31	1.33
		ESTs, Moderately similar to ALU4_HUMAN ALU SUBFAMILY SB2 SEQUENCE CONTAMINATION WARNING ENTRY [H.sapiens]	0.81	1.06	1.32
606-608	MMP13	MMP-13=Matrix metalloproteinase 13=CL-3=Collagenase 3	0.99	1.3	1.32
580-582	PDGFRB	Platelet-derived growth factor receptor, beta polypeptide=fused to TEL in t(5;12)(q33;p13) chronic myelomonocytic leukemia	1.41	1.85	1.31
603-605	ENPP1	PC-1 = alkaline nucleotide pyrophosphatase	1.01	1.32	1.31
		FGFR2=Fibroblast growth factor receptor 2	0.8	1.05	1.31
695-696	SMG1	PI-3-kinase-related kinase SMG-1	1.07	1.4	1.31
521-523	TAL1	scl=tal-1=T-cell acute lymphocytic leukemia 1	1.14	1.49	1.31
727-728	PLXNA2	plexin A2	1.32	1.71	1.3
759	LOC51605	CGI-09 protein	0.8	1.04	1.3
784	TNRC12	trinucleotide repeat containing 12	1.02	1.33	1.3

		EST	0.86	1.12	1.3
797-799	WNT2	wingless-type MMTV integration site family member 2	0.98	1.27	1.29
693-694	POLR2A	polymerase (RNA) II (DNA directed) polypeptide A (220kD)	0.79	1.01	1.29
737-739	FLJ21661	hypothetical protein FLJ21661	0.61	0.79	1.28
780-781	RAB2L	RAB2, member RAS oncogene family-like	1.05	1.35	1.28
577-579	CD36	CD36	1.26	1.61	1.28
568-570	RYBP	Death effector domain-associated factor=Binds to Caspase 10 DED domain=Homolog of mouse RYBP repressor protein that interacts with Polycomb complex and YY1=YAF2 homolog=DEDAF=YAF2 homolog=MLNewGene3	0.89	1.14	1.28
571-573	ITGAE	CD103 alpha=Integrin alpha-E	1.09	1.38	1.27
		Human SH3 domain-containing protein SH3P18 mRNA, complete cds	1.23	1.56	1.27
755-756	TMEPAI	transmembrane, prostate androgen induced RNA	0.99	1.25	1.26
565-567	NCOA1	SRC-1=steroid receptor coactivator	1.04	1.3	1.25
785	CSNK1E	casein kinase 1, epsilon	0.74	0.92	1.25
768-769	FLJ21940	hypothetical protein FLJ21940	0.91	1.14	1.25
723-724	SAST	syntrophin associated serine/threonine kinase	1.05	1.32	1.25
		ESTs	0.89	1.11	1.25
782-783	GOLGA1	golgi autoantigen, golgin subfamily a, 1	0.76	0.95	1.24
574-576	IL7	IL-7	0.99	1.23	1.24
319	RNAC	RNA cyclase homolog	0.92	1.13	1.24
676-677	KIAA0365	KIAA0365 gene product	0.97	1.2	1.23
679-681	ARHGEF6	KIAA0006	1.04	1.28	1.23
710-711	BRE	brain and reproductive organ-expressed (TNFRSF1A modulator)	1.11	1.35	1.22
		Unknown	0.9	1.11	1.22
670-671	PON1	paraoxonase 1	0.93	1.14	1.22
		ESTs, Weakly similar to I38588 reverse transcriptase homolog [H.sapiens]	1.11	1.36	1.22
		ESTs	0.72	0.87	1.21
	ATP7A	ATPase, Cu++ transporting, alpha polypeptide (Menkes	0.99	1.2	1.21

		syndrome)			
		Unknown	1.2	1.45	1.21
735- 736	CRB1	crumbs (Drosophila) homolog 1	0.88	1.06	1.21
757- 758	ZNF211	zinc finger protein 211	0.82	0.99	1.21
		ESTs	0.99	1.16	1.18
685- 686	GABRP	gamma-aminobutyric acid (GABA) A receptor, pi	0.91	1.07	1.17
687- 688	BMP6	bone morphogenetic protein 6	0.95	1.1	1.16
587- 588	BAD	BAD=bbc6=proapoptotic Bcl-2 homolog	1.11	0.94	0.85
678	NCSTN	nicastrin	1.13	0.94	0.83
766- 767	F23149_1	hypothetical protein F23149_1	1.11	0.91	0.82
701- 702	FLJ12442	hypothetical protein FLJ12442	1.04	0.85	0.82
589- 591	ZNF173	acid finger protein	1.16	0.95	0.81
741- 742	GCAT	glycine C-acetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase)	1.12	0.91	0.81
786- 787	AFP	alpha-fetoprotein	1.2	0.96	0.8
		hPAK65=SER/THR-protein kinase PAK-gamma =P21-activated kinase 3	1.05	0.84	0.8
747- 748	LOX	lysyl oxidase	0.93	0.75	0.8
662- 663	HARS	histidyl-tRNA synthetase	0.73	0.57	0.79
544	SLC25A11	solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11	1.27	1	0.78
697- 698	GTPBP1	GP-1=putative G-protein	0.97	0.76	0.78
699- 700	GS2NA	nuclear autoantigen	0.96	0.75	0.78
705- 706	KIAA0144	KIAA0144 gene product	0.87	0.68	0.78
		Unknown	1.02	0.79	0.78
733- 734	PPY2	pancreatic polypeptide 2	1.49	1.16	0.78
653- 654	NAGA	N-acetylgalactosaminidase, alpha-	1.06	0.82	0.78
583- 584	IL17R	IL-17 receptor	1.05	0.82	0.78
657- 658	SLC9A1	solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na+/H+, amiloride sensitive)	0.97	0.75	0.77
691- 692	RBBP4	retinoblastoma-binding protein 4	0.87	0.67	0.76
609- 611	ILK	ILK=integrin-linked kinase	0.88	0.67	0.76
624-	PTK2B	protein tyrosine kinase PYK2	1.07	0.81	0.76

625					
504-506		BPGF-1=bone-derived growth factor=Q6=quiescin=expression is induced by reversible growth arrest, trypsinization and serum starvation and is blocked by SV40 transformation	0.75	0.56	0.75
AKT1					
763-764	DKE7P564C186	DKE7P564C186 protein	0.97	0.73	0.75
554-556	SCYB5	ENA78=chemokine	0.34	0.25	0.75
660-661	MNAT1	menage a trois 1 (CAK assembly factor)	1.24	0.93	0.75
548-550	TCEB2	Elongin B=RNA polymerase II transcription factor SIII p18 subunit	0.98	0.73	0.74
792-793	RBBP2	retinoblastoma-binding protein 2	1.47	1.08	0.74
626-628	MAP2K3	Dual specificity mitogen-activated protein kinase kinase 3	1.06	0.78	0.74
712-713	RALY	RNA-binding protein (autoantigenic)	0.85	0.62	0.74
743-744	P14L	similar to Bos taurus P14 protein	0.87	0.64	0.73
731-732	APMCF1	APMCF1 protein	0.95	0.7	0.73
674-675	GNB2	guanine nucleotide binding protein (G protein), beta polypeptide 2	0.99	0.73	0.73
		Lymphotoxin-Beta receptor precursor=Tumor necrosis factor receptor 2 related protein=Tumor necrosis factor C receptor	1.28	0.93	0.73
		ESTs	1.02	0.73	0.72
666-667	MPI	mannose phosphate isomerase	1.22	0.87	0.71
719-720	PEF	PEF protein with a long N-terminal hydrophobic domain (peflin)	1	0.71	0.71
651-652	FDFT1	farnesyl-diphosphate farnesyltransferase 1	1.09	0.77	0.71
739-740	RAB3A	RAB3A, member RAS oncogene family	0.8	0.57	0.71
		EST	1.49	1.05	0.71
621-623	PPP2R5A	phosphatase 2A B56-alpha (PP2A)	0.89	0.63	0.71
600-602	GART	Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	0.82	0.58	0.7
551-553	NM23H1	nm23-H1=NDP kinase A=Nucleoside diphosphate kinase A	0.71	0.49	0.7
655-656	SECRET	secretagogin	0.84	0.58	0.69

		Unknown	0.8	0.55	0.69
		EST	1.19	0.82	0.69
770-771	FLJ22059	hypothetical protein FLJ22059	0.7	0.49	0.69
659	TUFM	Tu translation elongation factor, mitochondrial	1.16	0.8	0.69
518-520	RUNX1	core binding factor alpha1b subunit=CBF alpha1=PEBP2aA1 transcription factor =AML1 Proto-oncogene=translocated in acute myeloid leukemia	0.69	0.47	0.69
585-586	HGF	Hepatocyte growth factor (hepapoietin A; scatter factor)	0.88	0.6	0.68
		EST, Weakly similar to PRPP_HUMAN SALIVARY PROLINE-RICH PROTEIN II-1 [H.sapiens]	0.98	0.67	0.68
		Unknown	1.02	0.7	0.68
		Human mRNA for unknown product, partial cds	0.57	0.39	0.68
618-620	IL18R1	IL-18 receptor 1=IL-1Rrp	0.88	0.6	0.68
510-512	UBL1	ubiquitin-homology domain protein PIC1	1.49	1.01	0.68
703-704	KIAA0218	KIAA0218 gene product	1.2	0.81	0.68
760-761	MAPRE1	microtubule-associated protein, RP/EB family, member 1	0.6	0.4	0.67
777	SF3B4	splicing factor 3b, subunit 4, 49kD	1.17	0.78	0.67
		Unknown	1.04	0.7	0.67
		ESTs	0.42	0.28	0.66
533	UBE1	ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	1.54	1.01	0.66
		Unknown	1.23	0.81	0.66
788-789	COVA1	cytosolic ovarian carcinoma antigen 1	0.57	0.37	0.64
		Unknown	0.82	0.53	0.64
668-669	TAGLN2	transgelin 2	0.7	0.44	0.64
749-750	PISD	phosphatidylserine decarboxylase	0.8	0.5	0.62
775-776	IL1B	interleukin 1, beta	0.3	0.17	0.58
429-430	CALU	calumenin	0.7	0.39	0.56
597-599	PPP1CB	PPP1CB=Protein phosphatase 1, catalytic subunit, beta isoform	0.78	0.44	0.56
751-752		ESTs, Weakly similar to A Chain A, Cyclophilin A [H.sapiens]	0.78	0.43	0.55
745-746	KIAA0008	KIAA0008 gene product	0.49	0.27	0.55
		Unknown	2	1.09	0.54
664-	EIF4A1	eukaryotic translation initiation	0.7	0.37	0.53

665		factor 4A, isoform 1			
559-561	S100A4	S100 calcium binding protein A4=Placental calcium binding protein=Calvasculin=mts1 PROTEIN=CAPL	2.28	1.21	0.53
375	PPIA	peptidylprolyl isomerase A (cyclophilin A)	0.76	0.39	0.52
		EST	2.56	1.26	0.49

Table 10. Markers that can be used to Classify *BRCA1*-like from *BRCA2*-like Tumor Types using Compound Covariate Prediction Analysis.

SEQ ID NO:	Gene	Description	t-value	Average Log ratios in BRCA2 & BRCA2-like sporadics*	Midpoint of average log-ratios in each class	Average log ratios in BRCA1&BRCA1-like sporadic
659	TUFM	Tu translation elongation factor, mitochondrial	-10	-0.09854	-0.016	0.067443
749-750	PISD	phosphatidylserine decarboxylase	8.2305	-0.28567	-0.187	-0.08778
745-746	KIAA0008	KIAA0008 gene product	8.0421	-0.56864	-0.431	-0.29414
703-704	KIAA0218	KIAA0218 gene product	7.9288	-0.08197	-0.005	0.071882
751-752	EST	ESTs, Weakly similar to A Chain A, Cyclophilin A [H.sapiens]	7.6225	-0.34775	-0.225	-0.10292
621-623	PPP2R5A	phosphatase 2A B56-alpha (PP2A)	-7.469	-0.20343	-0.121	-0.03763
733-734	PPY2	pancreatic polypeptide 2	7.3866	0.06558	0.113	0.160168
649	EST	Unknown	-7.384	-0.27327	-0.183	-0.09313
641	EST	EST, Weakly similar to PRPP_HUMAN SALIVARY PROLINE-RICH PROTEIN II-1 [H.sapiens]	7.3561	-0.17457	-0.095	-0.01592
375	PPIA	peptidylprolyl isomerase A (cyclophilin A)	6.9946	-0.38934	-0.258	-0.12668
770-771	FLJ22059	hypothetical protein FLJ22059	6.9726	-0.31605	-0.228	-0.14026
739	RAB3A	RAB3A, member RAS oncogene family	6.9458	-0.23582	-0.167	-0.098
655-656	SECRET	secretagogin	6.9307	-0.23657	-0.147	-0.0575
629-631	TNFR2RP	Lymphotoxin-Beta receptor precursor=Tumor necrosis factor receptor 2 related protein=Tumor necrosis factor C receptor	6.9268	-0.02733	0.038	0.103462
551-553	NM23H1	nm23-H1=NDP kinase A=Nucleoside diphosphate kinase A	6.8307	-0.32239	-0.242	-0.16241
557-558	PAK2	hPAK65=SER/THR-protein kinase PAK-gamma =P21-activated kinase 3	6.7214	-0.1152	-0.05	0.01536
806	APRT	adenine phosphoribosyltransferase	6.6725	0.044932	0.085	0.125156
807-808	PPP1R15A	protein phosphatase 1, regulatory (inhibitor) subunit 15A	-6.648	-0.21681	-0.144	-0.0716
544	SLC25A11	solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11	6.6083	0.003461	0.047	0.089905

719-720	PEF	PEF protein with a long N-terminal hydrophobic domain (peflin)	6.6034	-0.16368	-0.088	-0.01144
747-748	LOX	lysyl oxidase	6.4441	-0.12784	-0.077	-0.02641
775-776	IL1B	interleukin 1, beta	6.4272	-0.75203	-0.637	-0.52288
809-810	MPHOSPH10	M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein)	-6.425	-0.10347	-0.048	0.007748
653-654	NAGA	N-acetylgalactosaminidase, alpha-	-6.42	-0.09205	-0.034	0.024896
760-761	MAPRE1	microtubule-associated protein, RP/EB family, member 1	-6.39	-0.39254	-0.296	-0.19928
811-812	ARD1	N-acetyltransferase, homolog of <i>S. cerevisiae</i> ARD1	6.3833	-0.1707	-0.11	-0.04915
813-814	CDC6	CDC6 (cell division cycle 6, <i>S. cerevisiae</i>) homolog	-6.371	-0.25964	-0.201	-0.14327
643	EST	EST	6.3541	0.133858	0.253	0.371068
583-584	IL17R	IL-17 receptor	6.3499	-0.08991	-0.035	0.019532
803	WNT5B	wingless-type MMTV integration site family, member 5B	6.3391	-0.06803	-0.017	0.035029
651-652	FDFT1	farnesyl-diphosphate farnesyltransferase 1	6.3387	-0.1152	-0.038	0.039414
664-665	EIF4A1	eukaryotic translation initiation factor 4A, isoform 1	6.2705	-0.39362	-0.263	-0.13253
650	EST	Unknown	6.2573	-0.08355	-0.002	0.079181
657-658	SLC9A1	solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na ⁺ /H ⁺ , amiloride sensitive)	6.2571	-0.13608	-0.077	-0.01682
731-732	APMCF1	APMCF1 protein	6.2387	-0.15677	-0.083	-0.00922
503	ZNF220	zinc finger protein 220	6.2316	-0.13549	-0.072	-0.00922
815-816	PTPRCAP	LPAP=lymphoid-restricted phosphoprotein=CD45 phosphatase binding protein and putative substrate	-6.229	-0.10182	-0.059	-0.01592
817	POLD3	polymerase (DNA directed), delta 3	-6.223	-0.29843	-0.221	-0.14327
788-789	COVA1	cytosolic ovarian carcinoma antigen 1	6.1802	-0.42946	-0.321	-0.21325
701-702	FLJ12442	hypothetical protein FLJ12442	6.1607	-0.07676	-0.027	0.023252
818	EST	Unknown	6.1033	-0.12494	-0.057	0.011993
721-722	EST	Human mRNA for unknown product, partial cds	6.1032	-0.40671	-0.328	-0.24949
662	HARS	histidyl-tRNA synthetase	-	-0.24642	-0.186	-0.12552

663			6.0889			
819	FLJ20746	putative cyclin G1 interacting protein	6.0827	-0.04144	0.017	0.074451
820-821	PLK	pPLK=homologue of Drosophila polo serine/threonine kinase	6.0725	-0.32422	-0.253	-0.18177
784	TNRC12	trinucleotide repeat containing 12	6.0744	0.110253	0.062	0.01368
723-724	SAST	syntrophin associated serine/threonine kinase	6.0991	0.107549	0.065	0.022016
634-635	EST	ESTs	6.1178	0.048053	-0.002	-0.05306
695-696	SMG1	PI-3-kinase-related kinase SMG-1	6.1219	0.146438	0.087	0.028571
534-535	LOC51760	B/K protein	6.1306	0.09691	0.048	-0.00174
574-576	IL7	IL-7	6.1558	0.088845	0.043	-0.00305
670-671	PON1	paraoxonase 1	6.3314	0.058046	0.014	-0.03105
592-593	ZFP161	ZF5=POZ domain zinc finger protein	6.3356	0.196176	0.101	0.006466
632-633	EST	ESTs, Moderately similar to ALU4_HUMAN ALU SUBFAMILY SB2 SEQUENCE CONTAMINATION WARNING ENTRY [H.sapiens]	6.3426	0.028978	-0.029	-0.08725
765		ESTs	6.4363	0.026533	-0.03	-0.08619
822	CCR6	CCR6=STRL22=chemokine receptor for MIP-3 alpha/LARC/Exodus on activated B cells	6.4897	0.116276	0.069	0.022016
679-681	ARHGEF6	KIAA0006	6.5098	0.105169	0.065	0.024075
759	LOC51605	CGI-09 protein	6.662	0.0086	-0.042	-0.09205
762	FLJ10701	hypothetical protein FLJ10701	6.925	0.135133	0.075	0.0141
636	EST	Unknown	7.3197	0.050766	0.005	-0.04144
647	EST	EST	7.5484	0.045714	-0.012	-0.07007
725-726	EST	Unknown	8.058	0.068557	-0.006	-0.07988

Table 11. Results of Compound Covariate Predictor Analysis.

Expld	Pre-specified class label	Correctly classified
B2-1 vs OSE 21083	1	YES
B2-10 vs OSE 21085	1	YES
B2-16 vs OSE 21180	1	YES
B2-2 vs OSE 21090	1	YES
B2-20 vs OSE	1	YES

21181		
B2-21 vs OSE	21182	1
B2-21 vs OSE		YES
B2-22 vs OSE	21183	1
B2-22 vs OSE		YES
B2-23 vs OSE	21091	1
B2-23 vs OSE		YES
B2-24 vs OSE	21092	1
B2-24 vs OSE		NO
B2-25 vs OSE	22038	1
B2-25 vs OSE		YES
B2-3 vs OSE	21093	1
B2-3 vs OSE		YES
B2-4 vs OSE	21094	1
B2-4 vs OSE		YES
B2-5 vs OSE	21095	1
B2-5 vs OSE		NO
B2-7 vs OSE	21096	1
B2-7 vs OSE		YES
B2-8 vs OSE	21097	1
B2-8 vs OSE		YES
B2-9 vs OSE	21098	1
B2-9 vs OSE		YES
C100 vs OSE	21167	1
C100 vs OSE		YES
C102 vs OSE	21168	1
C102 vs OSE		YES
C103 vs OSE	21169	1
C103 vs OSE		YES
C105 vs OSE	21178	1
C105 vs OSE		YES
C107 vs OSE	21099	1
C107 vs OSE		YES
C110 vs OSE	21101	1
C110 vs OSE		YES
C111 vs OSE	21102	1
C111 vs OSE		NO
C117 vs OSE	21105	1
C117 vs OSE		YES
C118 vs OSE	21106	1
C118 vs OSE		YES
C123 vs OSE	21107	1
C123 vs OSE		YES
C46 vs OSE	19741	1
C46 vs OSE		NO
C77 vs OSE	21108	1
C77 vs OSE		YES
C84 vs OSE	21368	1
C84 vs OSE		YES
C85 vs OSE	21179	1
C85 vs OSE		YES
C99 vs OSE	21370	1
C99 vs OSE		YES
B36 vs OSE	19680	2
B36 vs OSE		YES
B39 vs OSE	19682	2
B39 vs OSE		YES
B40 vs OSE	19683	2
B40 vs OSE		YES
B41 vs OSE	19684	2
B41 vs OSE		YES
B52-2 vs OSE	19771	2
B52-2 vs OSE		NO
B54 vs OSE	19687	2
B54 vs OSE		YES
B55 vs OSE	19688	2
B55 vs OSE		YES
B60 vs OSE	19690	2
B60 vs OSE		YES
B61 vs OSE	19695	2
B61 vs OSE		YES
B62 vs OSE	19701	2
B62 vs OSE		YES

B63 vs OSE B63 vs OSE 19706	2	YES
B64 vs OSE B64 vs OSE 19713	2	YES
B70 vs OSE B70 vs OSE 19722	2	YES
B74 vs OSE B74 vs OSE 19727	2	YES
B77 vs OSE B77 vs OSE 19731	2	YES
B78 vs OSE B78 vs OSE 21103	2	YES
B79 vs OSE B79 vs OSE 19743	2	YES
B80 vs OSE B80 vs OSE 21088	2	YES
C114 vs OSE C114 vs OSE 21104	2	YES
C15 vs OSE C15 vs OSE 19734	2	YES
C16 vs OSE C16 vs OSE 19735	2	YES
C17 vs OSE C17 vs OSE 19736	2	YES
C1vs OSE C1vs OSE 19732	2	YES
C20 vs OSE C20 vs OSE 19737	2	YES
C41 vs OSE C41 vs OSE 19739	2	YES
C42 vs OSE C42 vs OSE 19740	2	YES
C49 vs OSE C49 vs OSE 19742	2	YES
C79 vs OSE C79 vs OSE 21367	2	YES
C87 vs OSE C87 vs OSE 19744	2	YES
C95 vs OSE C95 vs OSE 21369	2	YES
Overall Success		91.80%

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)